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ABSTRACT 
Diabetes is already one of the most common chronic diseases in the Dutch population and a 
substantial further increase in the number of people with diabetes is expected in the near 
future. A large part of the burden of diabetes can be ascribed to the cardiovascular 
complications of diabetes which affect quality of life, as well as life expectancy of the 
patients. In this thesis we explore the opportunities to reduce the future burden of diabetes 
and cardiovascular diabetes complications in the Dutch population, through prevention. 
These opportunities depend on the existence of modifiable risk factors for diabetes and the 
availability of interventions aimed at reducing the incidence of diabetes or diabetes 
complications. In this thesis we consider the role of weight change, alcohol consumption and 
smoking as risk factors for diabetes and the cost-effectiveness of preventive interventions in 
different target populations.   
Body Mass Index (BMI) is acknowledged as an important modifiable risk factor for diabetes 
but the role of weight change is not so clear. We showed that, conditional upon initial 
weight, people who gained weight, had an increased risk of diabetes, compared to persons 
with relatively stable weight. If adjusted for initial BMI, 5-years weight change was a 
significant risk factor for diabetes (OR 1.08, 95% CI: 1.04, 1.13 per kg weight change). There 
was no association between weight change and diabetes incidence, if the association was 
adjusted for attained BMI (OR 0.99, 95% CI 0.94, 1.04 per kg weight change). We concluded 
that weight change appears to have no effect on diabetes incidence, beyond its effect on 
attained BMI.    
In previous studies, smoking has been reported to increase diabetes risk, while for alcohol 
consumption the lowest risk for diabetes is generally observed for people who drink 
moderately. We assessed the associations between these, potentially modifiable, risk factors 
and diabetes incidence in a Dutch population. We found a u-shaped association between 
alcohol consumption and diabetes incidence in Dutch women, with the lowest risk for 
moderate drinkers (1 or 2 drinks per day). We found no evidence for a significant association 
between alcohol consumption and diabetes incidence in Dutch men. Smoking more than 10 
cigarettes per day tended to increase diabetes risk in both men and women, but the 
associations were not statistically significant.  
There is substantial evidence that lifestyle interventions focused at improved diet and 
physical exercise are cost-effective in persons at high risk of developing diabetes. However, 
the cost-effectiveness of these interventions in other target populations was relatively 
unknown. We explored the potential long-term health effects and cost-effectiveness of two 
types of lifestyle interventions: a community-based intervention, targeted at the general 
Dutch population, and an individual-based intervention, targeted at obese Dutch adults. The 
long-term effects of these interventions were simulated with a computer-based model: the 
Chronic Diseases Model (CDM). We showed that the 20-year cumulative incidence of 
diabetes could be reduced by 0.5-2.4% through large-scale implementation of a community-
based intervention, and by 0.4-1.6%, through an individual based intervention for obese 
adults. Both interventions were projected to reduce lifetime diabetes-related medical costs, 
but total health care costs increased. The cost-effectiveness ratios ranged from €3,100 to 
€3,900 per quality adjusted life year (QALY) for the community-based intervention, and from 
  
€3,900 to €5,500 per QALY for the individual-based intervention, which means that both 
interventions are cost-effective according to general standards. 
We also assessed the potential health effects and cost-effectiveness of seven selected lifestyle 
interventions for Dutch diabetes patients. Again, long-term effects were simulated with the 
CDM. There was a large variation in effectiveness between the seven interventions. The 
reductions in cumulative lifetime incidence of cardiovascular complications among 
participants ranged from 0.1% to 6.1%. The most effective intervention was a two year 
structured counseling program, aimed to increase physical activity in inactive diabetes 
patients. The intervention costs ranged from €124 to €584 per participant, and the cost-
effectiveness ratios ranged from €10,000 to €39,000 per QALY. The impact of uncertainty in 
intervention costs, intervention effects, and long-term maintenance of effects, were 
quantified with probabilistic sensitivity analyses. These analyses revealed, that four out of 
seven interventions had a high probability to be very cost-effective. 
Besides lifestyle, appropriate medication contributes to the prevention of complications in 
diabetes patients. Guidelines for cardiovascular management recommend lipid lowering 
treatment for nearly all patients with diabetes. However, in Dutch current practice (in 2007) 
‘only’ about 1 out of 3 patients received this treatment. We modeled the long-term effects on 
cardiovascular complications in the Dutch diabetes population, under the assumption that 
all patient would use lipid-lowering medication (statins). We showed that treatment for all 
patients (compared to current care) reduced the life-time cumulative incidence of 
cardiovascular complications in the Dutch diabetic population by approximately seven 
percent. With more realistic assumptions about effectiveness and participation, the 
cumulative incidence of cardiovascular complications decreased by approximately two 
percent. 
We conclude that lifestyle interventions can be cost-effective in divers target populations, 
including diabetes patients. Large-scale implementation of these interventions is justified, 
and required in order to reduce the future burden of diabetes. However, since the impact on 
population health, achieved through these interventions, is expected to be moderate, 
additional research should aim to improve currently available interventions. Simultaneously, 
opportunities for alternative approaches to the prevention of diabetes and its complications 
should be further explored.  
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GENERAL INTRODUCTION                                
During the last decades, the prevalence of diabetes has increased worldwide, and a further 
increase is expected for the future 1. In the Netherlands, the prevalence of diagnosed diabetes 
increased from just over 400,000 in 2000 to approximately 670,000 in 2007 2. Diabetes affected 
about 4% of the Dutch population in 2007, but is expected to affect about 8% in 2025 2. The 
enormous increase in diabetes prevalence is partly explained by demographic developments 
such as population growth, aging, and improved survival, as well as by improved early 
diagnoses. Another part results from unfavorable developments in lifestyle habits, such as a 
decrease in physical activity, poor diets, and an associated increase in the prevalence of 
obesity. The burden of diabetes is high due to the frequent, severe complications associated 
with diabetes, which strongly affect quality of life and life expectancy of the patients as well 
as the health care costs related to diabetes 3-9. To gather more insight in what can be done to 
minimize the future burden of diabetes in the Dutch population, the opportunities to prevent 
diabetes and its complications should be further explored. Therefore, extensive knowledge is 
required about modifiable risk factors for diabetes and its complications, and the 
(cost)effectiveness of available interventions. The focus in this thesis is on prevention of type 
2 diabetes and its cardiovascular complications, because 85%-90% of diabetes patients have 
type 2 diabetes and cardiovascular complications are the main cause of increased mortality 
among diabetes patients (see textbox).   
 
Diabetes prevention 
In this thesis, diabetes prevention refers to the prevention of diabetes in persons who do not 
yet have the disease (universal, selective or indicated prevention) or to the prevention of 
complications in diabetes patients (care-related prevention, see textbox for definitions). 
Opportunities for diabetes prevention depend on the existence of risk factors and the extent 
to which these risk factors can be modified. The existence of risk factors is generally explored 
in observational cohort studies, while intervention studies are required to examine if risk 
factors can be modified and if risk factor modification is actually followed by a lower 
incidence of diabetes or diabetes complications. Prevention can be considered successful if, 
on a population or group level, the number of new diabetes cases or complications is lower 
than would have been expected if preventive measures would not have been applied. In 
addition, prevention can be considered successful if diabetes or complications are delayed, 
or if (quality adjusted) life-expectancy improves. 
 
The next paragraphs provide a brief overview of the current knowledge of the opportunities 
to prevent diabetes and cardiovascular diabetes complications. Subsequently, the general 
aim and main research questions of this thesis will be defined and the content outlined. 
Background information about diabetes and its complications and the definitions of 
prevention as used in this thesis are given in the textbox on the next page. 
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Diabetes mellitus 
Diabetes mellitus is a chronic disease which is characterized by a disturbance in the metabolism of 
glucose. The body needs insulin, a hormone produced by the pancreas, to absorb glucose from the 
blood and to convert it into energy. Persons with diabetes have increased levels of glucose in their 
blood as a result of either an absolute (type 1 diabetes) or relative (type 2 diabetes) deficiency of 
insulin. The absolute insulin deficiency in type 1 diabetes results from an inability of the pancreas to 
produce sufficient insulin. Type 1 diabetes is generally diagnosed before the age of 30 years. The 
relative deficiency in type 2 diabetes results from an impaired ability of body tissues to respond 
properly to insulin in combination with insufficient compensatory insulin production. Type 2 diabetes 
is the most common type of diabetes, about 85-90% of persons with diabetes has type 2 diabetes. This 
type is generally first diagnosed in adults. Diabetes is diagnosed based on measurement of the level of 
blood glucose. This level can be determined irrespective of the time of the last meal (random glucose), 
after 8 hours fasting (fasting glucose) or two hours after an oral glucose tolerance test (2-hour glucose). 
According to Dutch guidelines, measurement of blood glucose should be performed once every three 
years in persons > 45 years at increased risk for diabetes or if a person presents with diabetes-related 
symptoms such as excessive thirst, frequent urination, unintentional weight loss, blurred vision or 
fatigue. Because these symptoms can be mild, vague or even absent, diabetes may initially be 
undiagnosed for several years.  
 
Impaired fasting glucose and impaired glucose tolerance  
Persons with high glucose levels just below the threshold for diabetes have ‘impaired fasting glucose’ 
(IFG) if only fasting levels are high or ‘impaired glucose tolerance’ if 2-hour glucose levels are (also) 
high. Persons with IFG or IGT have increased risks for diabetes. In the Dutch Hoorn study, the 6-year 
progression rate to diabetes was 9%, 33% and 65% for persons with IFG, IGT or both respectively 10. 
Due to their high risk, these persons constitute an important target group for preventive interventions.    
 
Diabetes complications 
Acute complications emerge if, at a certain moment, the level of blood glucose is extremely high 
(hyperglycemia) or too low (hypoglycemia). At the longer term, the continued high concentration of 
glucose in the blood causes damage to the blood vessels and the nerves, which may eventually lead to 
serious chronic complications. Complications that affect the eyes (retinopathy), kidneys (nephropathy) 
or nerves (neuropathy) are called the micro vascular complications. Coronary artery disease, 
peripheral arterial disease and stroke are known as the macro vascular or cardiovascular 
complications of diabetes. The risk to develop cardiovascular disease is about two times higher in 
persons with diabetes than in persons without diabetes 5, 6. Cardiovascular complications are the main 
cause of increased mortality among diabetes patients 5.  
 
Definitions of prevention as used in this thesis, based on definitions by CVZ 11: 
Universal prevention targets the general population without increased risk for diabetes and aims to 
reduce the risk to develop (risk factors) for diabetes. 
Selective prevention targets (high) risk groups and aims to reduce the risk to develop (risk factors) for 
diabetes in these specific groups by conducting specific local, regional or national prevention 
programs (includes screening).   
Indicated prevention targets individuals without diagnosed diabetes but with increased risk or 
symptoms of diabetes. Indicated prevention aims to reduce the risk of developing diabetes or further 
health damage by offering intervention or treatment. 
Care-related prevention targets individuals with diagnosed diabetes and is an essential and integral part 
of high quality care. It aims to reduce the health burden of diabetes, and to reduce the risk of 
developing diabetes complications.   
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Opportunities for the prevention of diabetes 
There are several potentially modifiable risk factors for diabetes. Observational studies have 
consistently shown strong associations between obesity measures and the incidence of 
diabetes 12-17. Body Mass Index (BMI) is often used as a measure of overweight in 
epidemiological research. With every one unit increase in BMI, corresponding to an increase 
in body weight of approximately 3kg in adults of average height, the risk to develop diabetes 
increases with about 20% 18. In addition, body fat situated around the waist increases 
diabetes risk 19. Physical activity and a healthy diet are important to control and maintain a 
healthy weight but they are also independent determinants of diabetes 12;15;20-23. Other 
potentially modifiable lifestyle factors that have been associated with diabetes are smoking, 
alcohol -, and coffee consumption 24-26.    
There is substantial evidence that lifestyle interventions, targeted at obesity, physical activity 
and a healthy diet, can improve body weight and cardiovascular risk factors in overweight 
and obese persons 27, and that these interventions can successfully reduce diabetes incidence 
in persons with IGT 28-34, even at longer term follow-up 35;36. Several studies have shown that  
these interventions are cost-effective compared to placebo or alternative (pharmacological) 
interventions 37-40. Since lifestyle interventions are safe and at least equally effective as most 
preventive pharmacological treatments 41-43, lifestyle modification should be the main, 
preferred (first) strategy in the prevention of diabetes.  
Although weight reduction appears to be the main determinant of the success of lifestyle 
interventions 44, the role of weight change as a risk factor for diabetes, independent from the 
level of body weight remains unclear 45;46. It is also not clear if additional lifestyle habits such 
as smoking or alcohol consumption need to be considered in the prevention of diabetes. 
Another issue that remains to be addressed is how lifestyle interventions may affect long-
term health outcomes such as cardiovascular disease incidence and quality adjusted life 
expectancy 36;47.  
In contrast to the convincing evidence for efficacy and cost-effectiveness of indicated 
prevention of diabetes for persons at high risk, universal and selective prevention of 
diabetes, as well as lifestyle counseling to patients at low risk, have been conducted with 
varying results 48-53 and information about the cost-effectiveness of these interventions is  
limited 54;55. Therefore, the cost-effectiveness of lifestyle interventions for persons at different 
levels of diabetes risk should be further explored.   
 
 
Opportunities for the prevention of cardiovascular diabetes complications 
Most risk factors for diabetes are also risk factors for cardiovascular disease (CVD). BMI 56;57, 
waist circumference 57, physical activity 58-61 and smoking 62-64 have all been associated with 
the incidence of CVD. It has been shown that about half of the excess risk for coronary heart 
disease related to overweight, is independent of blood pressure and the level of cholesterol 
65. The association between alcohol consumption and CVD seems to be J-shaped, with the 
lowest risk for persons with moderate alcohol consumption 66;67. Moderate alcohol 
consumption, compared to not drinking, is also associated with a lower incidence of CHD 
and reduced mortality in diabetic populations 68. Blood pressure, cholesterol- and blood 
glucose levels are all important risk factors for CVD and, together with age and smoking, 
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their contribution to CVD risk is quantified in several cardiovascular risk assessment scores 
69,70.   
Several trials in persons with diabetes have shown that CVD risk factors can be successfully 
modified through lifestyle interventions 71-74. However, these trials are generally too short to 
show reductions in the incidence of CVD. On the contrary, trials that applied medical 
treatments have shown substantial reductions in he incidence of CVD and there is some 
evidence for improved survival 75. Antihypertensive treatment and cholesterol lowering 
treatment can effectively reduce the incidence of CVD, both in persons with and without 
diabetes 76-78. Intensive glucose lowering treatment in diabetes patients is generally 
associated with a moderate reduction in major CVD complications 79, although very strict 
glucose lowering may not to be beneficial in specific populations 80. Antihypertensive, lipid-
lowering and glucose lowering treatments for diabetic patients (care-related prevention) 
appear to be cost-effective 54;81. 
Although self-management (including a healthy lifestyle) is considered to be an essential 
part of diabetes treatment, there is little information about which lifestyle modification 
strategies are the most effective. It is also unclear how short-term improvements in 
cardiovascular risk factors, achieved through lifestyle interventions, may translate into 
improved long-term outcomes for cardiovascular complications or survival. In addition, the 
cost-effectiveness of lifestyle interventions for diabetic patients is relatively unknown 82;83. 
With respect to pharmaceutical treatments, it is unknown to what extent, on a population 
level, improved adherence to treatment guidelines could improve long-term health outcomes 
of Dutch diabetic patients.  
 
Aim of this thesis 
The general aim of this thesis is to explore opportunities to reduce the future burden of 
diabetes and its cardiovascular complications in the Dutch population through prevention. 
Therefore the three main questions addressed in this thesis are:  
1) Are weight change, alcohol consumption and smoking associated with diabetes incidence 
in a Dutch population? 
2) To what extent can preventive lifestyle interventions reduce the future incidence of 
diabetes in the Netherlands and are these interventions cost-effective? 
3) To what extent can care-related preventive interventions reduce the future incidence of 
cardiovascular diabetes complications in the Netherlands and are these interventions cost-
effective? 
 
Methods 
Information from three related Dutch observational studies, the Monitoring Project on 
Cardiovascular Disease Risk Factors (MP-CVDRF study), the Monitoring project on Chronic 
Diseases Risk Factors (MORGEN study) and the Doetinchem Cohort Study are used to assess 
research question 1. Although questions 2 and 3 could, theoretically, be examined with large 
long-term intervention studies, this would require tremendous efforts, budgets and many 
years of patience. Therefore, a computer-based simulation model, the Dutch Chronic 
Diseases Model (CDM) 84 is used instead. A brief general description of the observational 
studies and the Chronic Diseases Model is provided below.  
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Monitoring Projects 
The MP-CVDRF study was conducted between 1987 and 2002 in order to monitor the 
prevalence of cardiovascular risk factors in the Dutch, general population. Participants were 
20-59 yrs old men and women selected from three Dutch towns: Doetinchem, Amsterdam 
and Maastricht. About 12,000 participants from each town visited the municipal health 
service where they filled out questionnaires and underwent a physical examination. The MP-
CVDRF study was followed by the MORGEN study, a quite similar but extended study 
conducted between 1993 and 1997. In Doetinchem only, a subset of participants from the 
MP-CVDRF study was re-invited to participate. These re-invited participants (N=7,769) were 
subsequently followed in the Doetinchem Cohort Study 85, a cohort with repeated 
measurements every five years. Repeated measurements are not available for MP-CVDRF 
participants from Amsterdam and Maastricht because MORGEN participants in these towns 
were selected from new random samples drawn from the general population. However, 
follow-up data is available for specific outcomes such as diabetes. 
 
The Chronic Diseases Model 
The CDM is a Markov-type state transition model, developed at the Dutch National Institute 
for Public Health and the Environment (RIVM) 84. The CDM comprises different lifestyle and 
biomedical risk factors and many chronic diseases including diabetes and CVD. By 
combining relevant data from different sources in a consistent way, the model can simulate 
developments over time of demography, risk factor prevalence, disease incidence and 
mortality in the Dutch population. Simulations can also be confined to the Dutch diabetic 
population. The model is well suited to explore the potential consequences of different kinds 
of interventions if implemented in the Dutch (diabetic) population.  
Due to the health care costs and utility weights incorporated in the CDM, the model can also 
be used to generate cost-effectiveness ratios of interventions. The cost-effectiveness analyses 
in the CDM are performed from a health care perspective; only health related effects, 
expressed in quality adjusted life years (QALYs) and costs incurred by the health care system 
are included. Health care costs are intervention costs and medical costs for the treatment of 
chronic diseases. The CDM includes costs for illnesses, such as dementia, which are 
unrelated to the risk factors targeted by the intervention, but for which expenditures may 
increase, especially if the intervention prolongs life 86. A preventive intervention with a CER 
below €20.000 per QALY is generally considered to be (very) cost-effective 87, 88.  
 
Outline of this thesis 
The first main question of this thesis ‘Are weight change, alcohol consumption and smoking 
associated with diabetes incidence in a Dutch population?’ is addressed in Chapters 2 and 3. 
Chapter 2 explores the role of weight change as a risk factor for diabetes incidence, 
independent from the level of attained BMI and Chapter 3 explores the (joint) associations 
between alcohol, smoking and diabetes incidence. Chapter 4 deals with the second main 
question: ‘To what extent can preventive lifestyle interventions reduce the future incidence 
of diabetes in the Netherlands and are these interventions cost-effective?’. It explores the 
potential health effects and the cost-effectiveness of large-scale implementation of two 
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lifestyle interventions aimed to prevent diabetes: a community-based intervention for the 
general population (universal prevention) and an intensive individual-based intervention for 
obese adults (indicated prevention). The final main question ‘To what extent can care-related 
preventive interventions reduce the future incidence of cardiovascular diabetes 
complications in the Netherlands and are these interventions cost-effective?’ is addressed in 
Chapters 5 and 6. Chapter 5 explores the (cost)effectiveness of seven lifestyle interventions 
for diabetic patients, if implemented in the Dutch population, as well as the impact of 
uncertainty in model input parameters on simulated outcomes. Chapter 6 quantifies the 
potential long-term health gains for the Dutch diabetic population, in terms of 
cardiovascular complications prevented and life years gained, if all patients would use lipid-
lowering medication. Chapter 7 provides a general overview and discussion with 
recommendations for health policy and future research as well as a brief general conclusion.   
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Weight change and incident diabetes: addressing an unresolved issue 
 
 
ABSTRACT 
 
The impact of weight change on diabetes incidence remains unclear. To clarify the role of 
weight change as a risk factor for diabetes, the authors assessed the association between 
weight change and diabetes incidence conditional upon either initial or attained BMI. 7,837 
Observations available from repeated measurements of 4,249 participants (men and women 
20-59 years) of the Dutch population based Doetinchem Cohort Study were used to analyze 
the association between 5-years weight change and diabetes incidence (n=124) in the 
subsequent 5 years. If adjusted for initial BMI, 5-years weight change was a significant risk 
factor for diabetes (OR 1.08, 95% CI: 1.04, 1.13 per kg weight change). However, there was no 
significant association between weight change and diabetes if the association was adjusted 
for attained BMI (OR 0.99, 95% CI: 0.94, 1.04 per kg weight change). Our results suggest that 
weight change is associated with diabetes incidence because, conditional upon initial BMI, 
weight change determines attained BMI. This implies that lifestyle interventions can 
contribute to diabetes prevention because they affect attained BMI. Weight change appears 
to have no effect on diabetes incidence beyond its effect on attained BMI.    
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BACKGROUND 
Obesity is acknowledged as an important risk factor for diabetes (1-8). The pooled ‘average’ 
relative risk for diabetes is approximately 1.18 per unit increase in body mass index (BMI) 
(4), but several studies have shown that the impact of BMI on diabetes incidence is larger for 
BMI measured more proximal to diabetes outcome, compared to earlier, remote measures (9-
13). Therefore, it is important that weight attained at the end of the weight change period is 
taken into account if the impact of weight change on diabetes incidence is assessed. We 
identified fifteen prospective observational studies that explored the association between 
weight change and incident diabetes (9-23, Table 1). It appeared that only two studies (11,18) 
took account of attained BMI, while two studies adjusted for ‘overall weight status’ (19) or 
‘average weight’ (22) during the weight change period. Most studies (12 out of 15) assessed 
the association with adjustment for initial BMI. Therefore, although many studies have 
found positive associations between weight change and diabetes, the impact of weight 
change on diabetes incidence, beyond its effect on attained weight, remains unclear.  
In an attempt to clarify this unresolved issue, this paper starts with discussing the 
implications of using different analytic approaches. Subsequently we will use Dutch data to 
analyze the association between weight change and diabetes with adjustment for either 
initial or attained BMI and discuss the implications of the different results.  
 
The methodological question of how to disentangle the impact of risk factor level versus risk 
factor change on disease incidence has been addressed by Hofman in 1983 (24). He pointed 
out that there are two different ways of looking at the impact of risk factor change on disease 
risk, that each way implies a specific data-analytic approach and that the obtained results 
have different implications. With respect to the impact of weight change on diabetes, the 
association can be explored from, what we will call, a ‘prospective’ or ‘retrospective’ point of 
view.  
With the prospective approach we can explore whether, at a certain level of BMI, future 
weight change is important. For the data-analysis this means that the effect of weight change 
is assessed, conditional upon initial BMI (Figure 1A). From Figure 1A it is easy to imagine 
that, conditional upon initial BMI, weight change determines attained BMI. Persons who 
loose weight will have lower attained levels of BMI and persons who gain weight will attain 
higher levels of BMI. Since both weight loss and a low attained BMI are expected to be 
associated with a lower risk for diabetes, the coefficient for weight change in this analysis 
could reflect a positive association with diabetes, ‘simply’ because weight change determines 
attained BMI. Results from this approach do not reveal whether weight change is a risk 
factor for diabetes, independent of the level of attained BMI. 
The retrospective approach explores whether, at a certain level of attained BMI, weight 
change history is important. In this analysis, the effect of weight change is assessed 
conditional upon attained BMI (Figure 1B). Figure 1B illustrates that, conditional upon 
attained weight, previous weight change determines initial BMI. Persons who lost weight 
started with higher initial levels of BMI and persons who gained weight started at lower 
levels. This means that the coefficient for weight change in this model reflects the joint 
presumably opposite (!) effects of weight change and initial BMI. A negative coefficient for 
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weight change in this model would imply that initial weight is more important than 
subsequent weight change while a positive coefficient would imply that weight change has a 
larger impact than initial weight and affects diabetes incidence beyond its effect on attained 
BMI.  
In the analyses in this paper we explore the association between weight change and incident 
diabetes conditional upon either initial or attained BMI. We hypothesize that, conditional 
upon initial BMI, weight change affects diabetes incidence by affecting attained BMI, but that 
weight change in itself has some additional effect.    
 
Table 1. Summary of previous observational studies that analyzed the association between weight 
change and incident diabetes. 
Publication a Cohort Weight 
measurement 
Incident 
diabetes at 
follow-up  
Results 
     
Waring  
2010 (19) 
1,476 
adults 28-
40 years at 
baseline in 
1948-1952 
Fram. 
Heart 
Study 
original 
cohort 
limited 
data-set 
 
Measured 
during 
biennial 
visits from 
age 40 to age 
50 
217 incident 
cases during 
35,359 person-
years of follow-
up after age 50 
(until 2003). 
Cases 
determined 
from non-
fasting glucose 
levels or 
medical 
treatment for 
diabetes   
Hazard ratio for diabetes incidence after 
age 50 in relation to weight change 
pattern from age 40 to age 50 compared 
to adults with stable weight (quintile 2 on 
weight change function) crude analyses: 
Loss (quintile 1): 1.2 (0.8-1.9) 
Gain (quintile 3 or 4): 1.1 (0.7-1.5)  
When adjusted for overall weight status 
and weight cycling (age 40-50) and 
confounders:  
Loss (quintile 1): 1.1 (0.7-1.8) 
Gain (quintile 3 or 4): 1.2 (0.8-1.7) 
Additional adjustment for recent weight 
does not influence these estimates.   
 
Mishra  
2007 (16) 
7,329 
women  
45-50 yrs 
in 1996 
Australian 
Long. 
Study on 
Women’s 
Health 
Self-reported 
in 1996, 1998, 
2001 and 
2004 
206 incident  
cases of self-
reported, 
physician 
diagnosed 
diabetes  
Odds ratio for diabetes incidence 1998-
2001 in relation to weight change 1996-
1998 or diabetes incidence 2001-2004 in 
relation to weight change 1998-2001 
compared to women with stable weight 
(1.5%). Adjusted for initial BMI in 1996: 
Loss (5%): 0.6 (0.2-1.4) 
Loss (2.5-5%): 1.3 (0.8-2.1) 
Loss (1.5-2.5%): 0.6 (0.3-1.2) 
Gain (1.5-2.5%): 1.2 (0.8-1.9) 
Gain (2.5-5%): 0.9 (0.6-1.4) 
Gain (5%): 1.5 (0.9-2.6) 
p for rend 0.08   
 
Schien-
kiewitz 2007 
(20) 
 
7,720 men 
and 10,371 
women 40-
65 years at 
baseline in 
1994-1998 
EPIC-
Potsdam 
study 
Retrospective 
self-reported 
weight at age 
25 and age 40 
Measured 
weight at 
baseline  
 
390 men and 
303 women 
with incident 
diabetes based 
on self-report 
and confirmed 
clinical 
diagnosis 
between  
Relative risk for diabetes between 
baseline (1994-1998) and 2005 in relation 
to weight change from age 25 to 40 and 
from age 40 to age 55 (estimated from 
baseline weight) per unit change in BMI, 
adjusted for initial weight at age 25 and 
included in one model. 
Men: 
BMI change 25-40: 1.3 (1.2-1.3)  
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Publication a Cohort Weight 
measurement 
Incident 
diabetes at 
follow-up  
Results 
baseline and 7-
year follow-up  
BMI change 40-55: 1.1 (1.1-1.2) 
Women: 
BMI change 25-40: 1.2 (1.2-1.3)  
BMI change 40-55: 1.1 (1.1-1.2) 
 
Oguma 
2005 (9) 
20,187 men 
mean age 
46 years at 
baseline in 
1962 or 
1966 
Measured at 
university 
entry (mean 
age 19) self-
reported at 
baseline  
1223 incident 
cases of self-
reported 
diabetes on one 
of the several 
follow-up 
questionnaires 
from baseline 
until 1998 
(mean duration 
27 years) 
Relative risk of incident diabetes from 
1962/1966 until 1998 by categories of per 
decade change in BMI between 
university entry and baseline (1962/1966) 
adjusted for initial BMI at university 
entry compared to men with stable 
weight (0.5 kg/m2 per decade): 
Loss 0.5: 0.9 (0.6-1.3) 
Gain 0.5-1.0: 1.3 (1.0-1.6) 
Gain 1.0-1.5: 2.1 (1.7-2.6) 
Gain 1.5-2.0: 2.7 (2.2-3.3) 
 
Gain 2.0-3.0: 4.7 (3.8-5.8) 
Gain 3.0: 7.0 (5.4-9.1) 
 
Wanne-
methee 
2005 (17) 
6,798 men 
40-59 at 
baseline 
(1978-
1980) 
British 
regional 
heart 
study 
Measured at 
baseline 
(1978-1980) 
and self-
reported at 5-
year follow-
up (1983-
1985) 
327 incident 
cases of self-
reported and 
confirmed 
diabetes during 
follow-up from 
baseline (1983-
1985) until 2000  
 
Relative risk of incident type 2 diabetes 
(1983/1985-2000) by categories of 5-year 
weight change (between 1978/1980 and 
1983/1985) adjusted for initial BMI in 
1978-1980 compared to men with stable 
weight (4%): 
Loss 4%: 0.6 (0.4-0.9) 
Gain 4-10%: 1.3 (1.0-1.6) 
Gain 10%: 1.8 (1.2-2.7) 
 
Black  
2005 (18) 
484 men 
‘healthy’ at 
final 
follow-up 
over-
sampling 
of obese 
men 
Measured at 
average age 
20,33,44 and 
51 year 
46 newly 
diagnosed 
diabetes cases 
determined 
with OGTT at 
the final follow-
up at average 
age 51 
 
Odds ratio for type 2 diabetes diagnosed 
at age 51 vs. NGT (n=316) per unit BMI 
increase adjusted for attained BMI:  
BMI change (age 44-51): 0.9 (0.7-1.0) 
BMI change (age 33-44): 0.9 (0.8-1.1) 
BMI change (age 20-33): 1.1 (1.0-1.3) 
Field  
2004 (22) 
 
46,634 
women  
25-43 years 
at baseline 
in 1989 
Biennial self-
reported 
weight from 
1989 to 1995 
‘recent 
weight 
change’: 
weight 
change in the 
4 years prior 
to inc. 
diabetes or 
end of 
418 incident 
cases of 
physician 
diagnosed 
diabetes during 
6-years follow-
up (1993-1999) 
 
Relative risk of incident diabetes (1993-
1999) by categories of weight change 
(1989-1993) and ‘recent weight change’ 
adjusted for average weight during the 
‘recent weight change’ period compared 
to women with ‘stable weight’(±5lb) 
included in one model:  
Weight gain 1989-1993 (5-14.9 lbs): 3.4 
Recent weight gain (5-14.9 lbs): 1.3    
Confidence limits and other estimates 
were not reported 
- 29 - 
Publication a Cohort Weight 
measurement 
Incident 
diabetes at 
follow-up  
Results 
follow-up.  
 
Koh-Banerjee  
2004 (10) 
22,171 men 
40-75 years 
at baseline 
in 1986 
Health 
prof. 
follow-up 
study 
Self-reported 
weight at age 
21, in 1986 
and biennial 
thereafter 
305 self-
reported and 
confirmed 
incident 
diabetes cases 
between 1996 
and 2000 
Relative risk of incident diabetes (1996-
2000) by categories of weight change 
from age 21 until 1996 adjusted for initial 
BMI at age 21 compared to men with 
stable weight (2kg):  
Loss (3kg): 0.4 (0.2-1.1) 
Gain (3-6kg): 1.8 (1.0-3.2) 
Gain (7-11kg): 2.1 (1.2-3.6) 
Gain (12-18kg): 3.0 (1.8-5.2) 
Gain (19kg): 8.8 (5.2-14.70) 
=7% (6-8) increase in risk /kg weight 
gain  
 
Relative risk of incident diabetes (1996-
2000) by categories of weight change 
(1986-1996) adjusted for initial BMI in 
1986 compared to men with stable weight 
(2kg):  
Loss (6kg): 0.5 (0.3-0.9) 
Loss (3-5kg): 1.0 (0.7-1.5) 
Gain (3-5kg): 1.4 (1.0-1.9) 
Gain (6-8kg): 1.6 (1.1-2.4) 
Gain (9kg): 2.1 (1.5-3.0) 
 
Will 
2002 (14) 
73,745 men 
and 70,278 
women 
with BMI> 
25 from 
the First 
Cancer 
Prevention 
Study  
> 30 years 
at baseline 
1959/1960  
Self-reported 
weight 
history: 
(intentional) 
weight gain 
or 
(intentional) 
weight loss 
before 
baseline. 
Duration of 
weight 
change 
period 
unclear 
 
Men 3857 and 
women 4290 
with incident 
diabetes 
determined 
from self-report 
or death 
certificates from 
baseline until 
1972. 
Incidence density ratio for incident 
diabetes during follow-up (1959/1960-
1972) for different classes of weight 
history at baseline, adjusted for initial, 
pre-baseline BMI, compared to those 
without weight change: 
Men: 
Unintentional gain: 1.3 (1.2-1.5) 
Unintentional loss: 0.9 (0.8-1.1) 
Intentional gain: 1.0 (0.7-1.5) 
Intentional loss: 0.8 (0.7-0.9)  
Women: 
Unintentional gain: 1.4 (1.3-1.5) 
Unintentional loss: 0.8 (0.7-0.9) 
Intentional gain: 1.2 (0.9-1.5) 
Intentional loss: 0.7 (0.7-0.8)  
Among those with intentional weight 
loss men decreased their rate of diabetes 
by 11% and women by 7% for every 20lb 
weight loss 
 
 
Resnick  
2000 (21) 
 
1,929 over-
weight 
adults 25-
74 years at 
 
Measured 
weight at 
baseline and 
10-years 
 
251 incident 
cases in the 10 
years follow-up 
after the weight 
 
Odds ratios for incident diabetes in the 10 
years following the 10-years weight 
change period per kg weight change per 
year adjusted for initial, baseline BMI. 
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Publication a Cohort Weight 
measurement 
Incident 
diabetes at 
follow-up  
Results 
baseline in 
1971-1975  
(NHEFS)  
 
follow-up 
examination 
change period. 
Ascertained 
from self-report, 
hospital records 
and death 
certificates.  
 
 Weight change (per kg/y): 1.5 (1.3-1.7)  
Brancati 
1999 (11) 
798 men  
(former) 
medical 
students 
Measured at 
average age 
20. Self-
reported at 
average age 
25, 35 and 45 
year 
35 self-reported, 
physician 
diagnosed 
incident 
diabetes cases 
during 1-30 
(mean 16 year) 
follow-up after 
age 50. 
Relative risk of incident diabetes during 
1-30 year follow-up after age 50 per unit 
BMI change between age 25 and 45 
adjusted for initial BMI at age 25: 
BMI change (age 25-45): 3.2 (1.4-7.4) 
Relative risk of incident diabetes during 
1-30 year follow-up after age 50 per unit 
BMI change between age 25 and 45, 
adjusted for age and attained BMI at age 
45: 
not significant (RR not reported) 
 
Wanna-
methee 
1999 (23) 
6,916 men  
40-59 years 
at baseline 
1978-1980 
(Q1) 
British 
Regional 
Heart 
Study 
 
Measured 
weight at 
baseline 
(1978-1980) 
and self-
reported 
weight 5 
years later 
(Q5) 
237 cases of self-
reported and 
confirmed 
diabetes during 
follow-up until 
1995  
Average follow-
up 12 years 
Relative risk for incident diabetes during 
12 years follow-up after Q5 by categories 
of 5-years weight change between Q1 and 
Q5 adjusted for initial weight at Q1 
compared to men with stable weight 
(±4%) 
Weight loss (>4%): 0.7 (0.5-1.1) 
Weight gain (4-10%): 1.2 (0.9-1.6) 
Weight gain (>10%): 1.6 (1.0-2.6) 
Test for trend p=0.0009 
 
Ford  
1997 (15) 
8,545 
adults  25 
years at 
baseline 
(1971-175) 
NHANES 
Measured at 
baseline 
(1971-1975) 
and at 
follow-up  
examination 
(1982-1984) 
487 self-
reported cases 
of incident 
diabetes from 
self-report or 
medical records  
during 10 
years follow-up 
(1982/1984-
1992)  
Hazard ratio for incident diabetes during 
10 years follow-up (1982/1984-1992) by 
categories of weight change between 
baseline (1971-1975) and follow-up (1982-
1984) adjusted for initial BMI at baseline 
compared to men with stable weight 
(5kg):  
Loss 11kg: 0.8 (0.5-1.4) 
Loss 5-11kg: 1.1 (0.7-1.8) 
Gain 5-8kg: 2.1 (1.4-3.2) 
Gain 8-11kg: 1.2 (0.8-1.9)  
Gain 11-20kg: 2.7 (1.8-3.9) 
Gain 20kg: 3.8 (2.0-7.2) 
4.5% increase in diabetes risk per 1kg 
weight gain (over 10 years) 
 
Colditz  
1995 (12) 
114,281 
women 30-
55 years at 
baseline in 
1976 
Nurses’ 
Self-reported 
at age 18 and 
in 1976 and 
1986.  
2204 self-
reported (and 
confirmed) 
incident 
diabetes cases 
on biennial 
Relative risk of incident diabetes (1976-
1990) by categories of weight change 
from age 18 until 1976, adjusted for initial 
BMI at age 18 compared to women with 
stable weight (5kg):  
Loss (11.0-19.9kg): 0.2 (0.1-0.4) 
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Publication a Cohort Weight 
measurement 
Incident 
diabetes at 
follow-up  
Results 
health 
study 
questionnaires 
during 14 years 
of follow-up  
(1976-1990)   
 
 
762 self-
reported (and 
confirmed) 
incident 
diabetes cases 
during 4 years 
of follow-up 
(1986-1990) 
Loss (5.0-10.9kg): 0.5 (0.4-0.8) 
Gain (5.0-7.9kg): 1.9 (1.5-2.3) 
Gain (8.0-10.9kg): 2.7 (2.1-3.3) 
Gain (11.0-19.9kg): 5.5 (4.7-6.3)  
Gain (20.0kg): 12.3 (10.9-13.8) 
 
Relative risk of incident diabetes (1986-
1990) by categories of weight change 
(1976-1986) adjusted for initial BMI in 
1976 compared to women with stable 
weight (3kg):  
Loss (5kg): 0.6 (0.4-1.0) 
Loss (3.0-4.9kg): 1.0 (0.6-1.5) 
Gain (3.0-4.9kg): 1.5 (1.1-2.0) 
Gain (10kg): 1.8 (1.4-2.3) 
 
Chan  
1994 (13) 
27,338 men 
40-75 years 
at baseline 
in 1986 
Health 
prof. 
follow-up 
study 
Self-reported 
at age 21, in 
1986 and 
biennial 
thereafter 
266 self-
reported and 
confirmed 
incident 
diabetes cases 
between 1987 
and 1992 
Relative risk of incident diabetes (1987-
1992) by categories of weight change 
from age 21 until 1987 adjusted for initial 
BMI at age 21 compared to men with 
stable weight (2kg):  
Loss (3kg): 0.3 (0.1-0.8) 
Gain (3-5kg): 0.9 (0.5-1.8) 
Gain (6-7kg): 1.9 (1.0-3.7) 
Gain (8-9kg): 3.5 (2.0-6.3) 
Gain (10-14kg): 3.4 (2.0-5.8) 
Gain (15kg): 8.9 (5.5-14.7) 
 
Relative risk of incident diabetes (1987-
1992) by categories of weight change 
from 1981-1986 adjusted for initial BMI in 
1981 compared to men with stable weight 
(4.5kg):  
Loss (4.5kg): 0.8 (0.5-1.2) 
Gain (4.5-13.6kg): 1.7 (1.2-2.3) 
Gain (13.6kg): 4.5 (2.4-8.2) 
 
 
a Prospective observational cohort studies, published after 1990, examining the association between 
weight change and incident diabetes in mainly Caucasian populations, identified through Pubmed 
search and reference tracking. 
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   A). Prospective approach 
Weight Gain 
 
    Initial BMI    Attained BMI      Diabetes Incidence 
    
Weight Loss   
  
   B). Retrospective approach 
Weight Loss 
 
    Initial BMI    Attained BMI        Diabetes Incidence 
 
   Weight Gain 
  
Figure 1: BMI, Body Mass Index; A) Prospective approach: Illustration of the data-analysis in which 
the association between Weight Change and Diabetes Incidence is assessed with adjustment for Initial 
BMI. The figure illustrates that, conditional upon Initial BMI, Weight Change determines Attained 
BMI. B) Retrospective approach: Illustration of the data-analysis in which the association between 
Weight Change and Diabetes Incidence is assessed with adjustment for Attained BMI. The figure 
illustrates that, conditional upon Attained BMI, previous Weight Change determines Initial BMI. 
MATERIALS AND METHODS 
Study population 
The Doetinchem Cohort Study is a prospective observational population-based Dutch study 
with four measurement rounds (at 5-year intervals) completed between 1987 and 2007. The 
first measurements took place between 1987 and 1991. In that period 12,405 inhabitants of 
Doetinchem between 20 and 59 years old were examined as part of the ‘Monitoring Project 
on Cardiovascular Disease Risk Factors’. From the participants of the first round (R1), a 
random sample of 7,769 was invited to participate in a second examination (R2: 1993-1997), 
and again five and ten years later for a third (R3: 1998-2002) and fourth examination (R4: 
2003-2007). Measurements included questionnaires and a physical examination. Details on 
sampling and data collection procedures are described elsewhere (25). The study was 
approved according to the guidelines of the Helsinki Declaration by the external Medical 
Ethics Committee of the Netherlands Organization of Applied Scientific Research Institute. 
All participants gave written informed consent. 
 
Assessment of weight and weight change  
Body weight and height were measured during each examination. Weight change was 
calculated between R1 and R2 and R2 and R3. Although the actual time between 
measurements was approximately six years between R1 and R2, ‘5-years weight change’ is 
used throughout this paper. To calculate 5-years weight change, weight change (absolute 
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change in kg, weight change relative to initial weight or absolute change in BMI) was 
divided by the actual time between measurements (in years) and multiplied by five. 5-Years 
weight change was modeled as a continuous risk factor (with weight loss having a negative 
value) and also considered in categories: ‘weight loss’ (> 2.0 kg), ‘stable weight’ (± 2.0 kg, = 
reference), ‘small weight gain’ (2.0-4.0 kg), ‘moderate weight gain’ (4.0-6.0 kg) and 
substantial weight gain (> 6.0 kg). These categories were based on a stable, sufficiently large 
reference group and a fair, relatively equal number of cases and observations in each of the 
remaining categories.     
 
Other variables 
Demographic and lifestyle characteristics were obtained from self-administered 
questionnaires filled out at home and checked during the examination visits. Biomedical 
outcomes were obtained from the physical examinations. Characteristics that were 
considered as potential confounders were age, gender, menopausal status (men, women 
with regular menstrual cycle or women without regular cycle), nationality (Dutch or other), 
prevalent cardiovascular disease (self-reported history of acute myocardial infarction or 
stroke) and education. Educational level was assessed as the highest level of completed 
education and classified into four categories: primary school or less, lower vocational or 
intermediate secondary education, intermediate vocational or higher secondary education, 
and higher vocational education or university. Lifestyle characteristics that were considered 
were leisure time physical activity (active or inactive), smoking (current, former or never), 
alcohol consumption (four categories) and coffee consumption (cups per day). Potential 
‘biomedical confounders’ were systolic blood pressure (SBP), diastolic blood pressure (DBP), 
hypertension (SBP≥140, DBP≥ 90 or antihypertensive medication), high-density lipoprotein 
(HDL) cholesterol, total cholesterol and cholesterol ratio (total/HDL cholesterol). In 
addition, 5-years changes in blood pressure and cholesterol levels were considered as 
confounders in the retrospective analyses.  
 
Outcome measurements 
Cases were defined based on self-reported diabetes (‘Do you have diabetes?’ yes/no) only. 
However, most of the self-reported cases have been verified against information from the 
general practitioner or pharmacist. Of the 99 (out of 124) self-reported cases that could be 
verified, 88 were confirmed cases with incident type 2 diabetes, 5 were confirmed non-type 2 
diabetics, 3 were prevalent type 2 diabetic cases and 3 were confirmed non-diabetics. 
‘Sensitivity’ analyses were performed with ‘confirmed incident type 2 diabetes’ cases only. In 
these latter analyses, all self-reported diabetic cases that were not ‘confirmed incident type 2’ 
were excluded.      
 
Statistical methods 
We used generalized estimating equation analyses (proc GENMOD in SAS with link=logit, 
D=binomial and correlation structure =exchangeable) to assess the association between 5-
years weight change and incident diabetes in the subsequent 5 years (Figure 2). Observations 
used in cluster 1 were initial BMI at R1, weight change between R1 and R2, attained BMI at 
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R2 and incident diabetes between R2 and R3. Observations used in cluster 2 were initial BMI 
at R2, weight change between R2 and R3, attained BMI at R3 and incident diabetes between 
R3 and R4. There was a significant, negative correlation between repeated weight change 
observations in cluster 1 and cluster 2 (r=-0.12) and we used the ‘repeated’ statement to 
control for this correlation.  
We applied a ‘prospective approach’, with baseline data from R1 and R2 to asses the 
association between weight change and diabetes, conditional upon initial BMI (Figure 2A). A 
‘retrospective approach’ with baseline data from R2 and R3 was used to assess the 
association between weight change and diabetes, conditional upon attained BMI (Figure 2B).  
 
 
    2A) 
 
 
 
 
 
 
 
 
 
 
      2B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. BMI, Body Mass Index; A) Prospective approach: Illustration of the data-analysis in which 
the association between Weight Change and Diabetes Incidence is assessed conditional upon Initial 
BMI and initial baseline characteristics. The figure illustrates how observations from four repeated 
measurements are combined and gives the number of participants (observations) and cases in each 
cluster. B) Retrospective approach: Illustration of the data-analysis in which the association between 
Weight Change and Diabetes Incidence is assessed conditional upon Attained BMI and attained 
baseline characteristics. The figure illustrates how the data from four repeated measurements are 
combined and gives the number of participants (observations) and cases in each cluster.  
 
R3 
R4 
R1 
R2 
R2 
R3 
5-year Weight Change  5-year Diabetes Incidence (n = 51) 
Cluster 1: n = 4,259  
Cluster 2: n = 3,578  
5-year Diabetes Incidence (n = 73) 
Initial BMI  
and baseline 
characteristics 
Attained BMI  
Attained BMI  
and baseline 
characteristics 
R3 
R2 
5-year Diabetes Incidence (n = 51) 
5-year Diabetes Incidence (n = 73) 
R4 
R3 Cluster 1: n = 4,259  
Cluster 2: n = 3,578  R2 
R1 
5-year Weight Change  
Initial BMI  
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Persons with prevalent diabetes at R1 or R2 were completely excluded, while observations 
from persons with incident diabetes at R3 were excluded in cluster 2. We excluded 
observations from pregnant women at R1 or R2 from cluster 1 and observations from women 
who were pregnant at R2 or R3 from cluster 2. Observations from persons with cancer (R1, 
R2 or R3) or (R2, R3 or R4) were excluded from cluster 1 and 2 respectively. To adjust for 
confounders, we explored which individual confounders caused a > 5% change in the odds 
ratio (OR) for diabetes for any of the four weight change categories if they were included in 
the age and gender adjusted models. Subsequently, these confounders were included 
simultaneously in fully adjusted models but removed if leaving them out caused a less than 
5% change. Initially ‘cluster’ was included in each model but finally removed since it did not 
confound nor modify the associations.  
RESULTS 
There were 7,837 observations available for the analyses; 4,259 participants had observations 
in cluster 1 and 3,578 of these participants had repeated observations in cluster 2 (Figure 2).  
Mean initial BMI was 24.8 kg/m2 (standard deviation (SD) 3.4). Mean 5-years weight change 
was a gain of 2.2 kg (SD 4.0) consistent with a 3.1% (SD 5.6) increase from initial weight. 
Among persons who gained weight (74% of the observations) mean 5-years weight gain was 
3.9 kg (SD 3.1). Among persons in the substantial weight gain category, median weight gain 
was 8.0 kg (range 6-29 kg). Persons who lost weight (26% of the observations) lost 2.4 kg (SD 
2.4) on average. Among persons in the weight loss category median weight loss was 3.5 kg 
(range 2-24 kg). The negative correlation between initial BMI and weight change was weak 
(r=-0.06) but significant. The positive correlation between weight change and attained BMI 
(r=0.35) was much stronger. Mean attained BMI was 25.6 kg/m2 (SD 3.6).  
During follow-up, 124 persons developed diabetes. The risk to develop diabetes within 5 
years was 1.6% (Table 2). After adjustment for age and gender, initial BMI, 5-years weight 
change and attained BMI were all ‘crudely’ associated with diabetes incidence. The adjusted 
OR was 1.24, 95% confidence interval (CI): 1.20, 1.29 per kg/m2 for initial BMI and 1.23, 95% 
CI: 1.19, 1.27 per kg/m2 for attained BMI. The adjusted OR for 5-years weight change as a 
continuous variable was 1.08, 95% CI: 1.03, 1.14 per kg change.  
 
Prospective approach 
The crude association between weight change and diabetes remained essentially unchanged 
after adjustment for initial BMI and baseline characteristics (Table 3). The fully adjusted OR 
for 5-years weight change was 1.08, 95% CI: 1.04, 1.13 per kg change, 1.08, 95% CI 1.04, 1.12 
per % change from initial weight and 1.27, 95% CI: 1.12, 1.44 per unit change in BMI. Persons 
with substantial weight gain had more than doubled risk for diabetes compared to persons 
with stable weight: adjusted OR 2.4, 95% CI: 1.4, 4.0.   
It appears that the odds ratio for diabetes associated with 5-years weight change (OR 1.27, 
95% CI: 1.12, 1.44 per unit of BMI) is not larger than the odds ratio for diabetes associated 
with a one unit difference in attained BMI (OR 1.23, 95% CI: 1.19, 1.27). This suggests that the 
association between weight change and diabetes might be explained by differences in the 
attained level of BMI (see also Figure 1A).  
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Table 2. Absolute and Relative Risks (Odds Ratios) for 5-Years Diabetes Incidence According to 
Baseline Characteristics and Weight Variables, Doetinchem Cohort Study, the Netherlands, 1987-2007.  
 Observations a Cases b Cumulative 
diabetes 
incidence (%) 
Odds ratio c  
 
95% CI 
      
All 7837  124 1.6   
  Men 3831 71 1.9 1.0 ref  
  Women 4006 53 1.3 0.7  0.5, 1.1 
Age d      
  age 25-49   4634 34 0.7 1.0 ref  
  age 50-70 3203 90 2.8 3.9  2.6, 5.8 
Initial BMI unit      
   BMI< 25 4476 17 0.4 1.0   
   BMI 25-30 2837 66 2.3 4.4  2.5, 7.6 
   BMI>30 520 41 7.9 15.7  8.7, 28.3 
5-years weight change      
   gain > 6.0 kg 1139 29 2.6 2.8  1.7, 4.5 
   gain 4.0 - 6.0 kg 1141 20 1.8 1.6  0.9, 2.7 
   gain 2.0 - 4.0 kg 1663 19 1.1 0.9  0.5, 1.6 
   stable ± 2.0 kg 2986 42 1.4 1.0   
   loss > 2.0 kg 895 14 1.6 1.0  0.6, 1.9 
Attained BMI unit      
   BMI< 25 3665 11 0.3 1.0   
   BMI 25-30 3324 57 1.7 4.2  2.2, 8.1 
   BMI>30 838 56 6.7 17.3  8.9, 33.5 
a 3578 of 4259 participants contributed observations to both clusters (Figure 2)  
b Incident cases (self-reported diabetes) in cluster 1 or cluster 2 (Figure 2) 
c Adjusted for age, age*age and gender 
d Attained age (after the 5-years weight change period, Figure 2) 
 
 
Table 3. Prospective Approach: Adjusted Odds Ratio’s for Diabetes Incidence in the 5 Years Following 
the Weight Change Period, According to 5-Years Weight Change, Adjusted for Initial BMI 
 Model 1 Model 2 
 OR 95% CI OR 95% CI 
     
5-years weight change (per kg) a 1.07  1.02, 1.11 1.08  1.04, 1.13 
5-years weight change (per %) a 1.06  1.02, 1.10 1.08  1.04, 1.12 
5-years change in BMI (per unit) a 1.21  1.07, 1.36 1.27  1.12, 1.44 
5-years weight change class a     
  weight gain > 6.0 kg 2.0  1.2, 3.4 2.4  1.4, 4.0 
  weight gain 4.0 - 6.0 kg 1.3  0.8, 2.3 1.3  0.8, 2.3 
  weight gain 2.0 - 4.0 kg 0.9  0.5, 1.5 0.9  0.5, 1.6 
  stable weight ± 2.0 kg 1.0  1.0  
  weight loss > 2.0 kg 0.8  0.4, 1.4 0.7  0.4, 1.3 
a Each measure of weight change (per kg increase, per % increase from initial weight, per BMI unit or 
in weight change classes) is analyzed in a separate model 
Model 1: adjusted for age, age*age, gender, and initial BMI 
Model 2: adjusted for age, age*age, gender, initial BMI, initial hypertension and initial total/HDL 
cholesterol ratio 
 
The impact of weight change (and attained BMI) on diabetes incidence was slightly modified 
by initial BMI (P = 0.12, for interaction). The adjusted OR for diabetes for persons with initial 
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BMI <30 was 1.38, 95% CI: 1.15, 1.65 per one unit change in BMI and 1.32, 95% CI: 1.22, 1.42, 
for a one unit difference in attained BMI. For persons with initial obesity the corresponding 
ORs were 1.14, 95% CI: 0.98, 1.34 and 1.11, 95% CI: 1.02, 1.20, respectively.   
 
Retrospective approach  
The crude association between 5-years weight change and diabetes disappeared completely 
after adjustment for attained BMI (Table 4). The fully adjusted OR for 5-years weight change 
was 0.99, 95% CI: 0.94, 1.04 per kg weight change, 0.99, 95% CI: 0.95, 1.03 per % change from 
initial weight and 0.97, 95% CI: 0.84, 1.12 per unit change in BMI. This association was not 
modified by the level of attained BMI: the association was similar for persons with attained 
BMI lower than 30 and persons with attained BMI higher than 30.  
 
Sensitivity analyses 
The results remained essentially similar when the analyses were based on cases with 
confirmed incident type 2 diabetes only: fully adjusted odds ratios were 1.12, 95% CI: 1.07, 
1.17 per kg weight change in the prospective approach and 1.02, 95% CI: 0.96, 1.08 per kg 
change in the retrospective approach.  
 
Table 4. Retrospective Approach: Adjusted Odds Ratio’s for Diabetes Incidence in the 5 Years 
Following the Weight Change Period, According to 5-Years Weight Change, Adjusted for Attained 
BMI 
a Each measure of weight change (per kg increase, per % increase from initial weight, per BMI unit or 
in weight change classes) is analyzed in a separate model 
Model 1: adjusted for age, age*age, gender, and attained BMI 
Model 2: adjusted for age, age*age, gender, attained BMI, attained diastolic blood pressure and 5-
years change in total/HDL cholesterol ratio 
 
DISCUSSION 
Our study shows that short-term weight change is associated with diabetes incidence in 
crude analyses as well as after adjustment for initial BMI. However, weight change is not 
associated with diabetes incidence if attained BMI is taken into account. Taken together, our 
results seem to imply that weight change does not affect diabetes incidence beyond its effect 
on attained BMI.  
A literature search yielded fifteen previous observational studies in which the association 
between weight change and diabetes was explicitly addressed (9-23, table 1). There were 
 Model 1 Model 2 
 OR 95% CI OR 95% CI 
     
5-years weight change (per kg) a 1.00  0.95, 1.05 0.99  0.94, 1.04  
5-years weight change (per %) a 1.00   0.96, 1.04 0.99  0.95, 1.03 
5-years change in BMI (per unit) a 1.00  0.87, 1.14 0.97  0.84, 1.12 
5-years weight change class a     
  weight gain > 6.0 kg 1.1  0.7, 1.9 1.0  0.6, 1.7 
  weight gain 4.0 - 6.0 kg 0.9  0.5, 1.5 0.8  0.5, 1.4 
  weight gain 2.0 - 4.0 kg 0.7  0.4, 1.3 0.7  0.4, 1.2 
  stable weight ± 2.0 kg 1.0  1.0  
  weight loss > 2.0 kg 1.1  0.6, 2.0  1.1 0.6, 2.1 
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large differences between these studies with respect to the duration of the weight change 
period (ranging from two to more then 20 years) as well as the duration of follow-up that 
ranged from 0 to more than 20 years. Eleven studies compared diabetes risk for different 
categories of weight change compared to a ‘stable’ reference group. Nine studies (also) 
assessed a continuous association between weight change and diabetes. Weight change was 
generally assessed as absolute change in kg or units BMI.  
Most studies assessed the association between weight change and diabetes with adjustment 
for initial BMI and most of these studies reported positive associations. For example, Colditz 
et al. (12) showed that weight gain from young adulthood until early midlife increased 
diabetes risk among women in the Nurses’ Health Study and stressed the importance of 
maintaining a constant weight throughout adult life. Oguma et al. (9) reported very similar 
findings for men and concluded that avoidance of weight gain is important even among 
those who are initially lean. Mishra et al. (16) did not find a continuous effect of short-term 
weight change on diabetes incidence after adjustment for initial BMI, but women with a high 
gain had a higher risk for diabetes than women with stable weight.  
Only four studies examined the association between weight change and diabetes while 
taking account of attained (11,18) or ‘average’ weight (19,22). In one other study (23), 
attained BMI was used as stratification variable to assess the impact of duration of 
overweight and obesity on diabetes risk. Brancati et al. (11) reported that weight change 
between age 25 and 45 was crudely associated with diabetes incidence after age 50, but not 
after adjustment for attained weight at age 45. This suggests that long-term weight change 
does not affect diabetes incidence beyond its effect on attained BMI. However, Black et al. 
(18) found that the risk of diabetes at age 51 increased by weight gain from age 20 to age 31 
but not by weight gain from age 33 to 44 or by recent weight gain from age 44 to 51, 
suggesting that the impact of weight change might differ between specific stages in life. In 
the study by Waring at al. (19), weight change between age 40 and 50 was not associated 
with diabetes incidence after age 50 in crude analyses, maybe due to the long duration of 
follow-up in this study (average 24 years), and this negative result remained after adjustment 
for either ‘overall weight status’ during the weight change period, or ‘recent’ weight. In the 
study by Field et al. (22), the impact of weight gain between 1989 and 1993 appeared to have 
a larger impact on diabetes incidence in the subsequent 6 years than ‘recent’ weight gain in 
the four years period prior to the development of diabetes, after adjustment for average 
weight during this latter period. Again, the findings suggest that the impact of weight 
change might be different during different periods of life.    
 
We explored the impact of weight change on diabetes incidence from two different points of 
view. The results from the prospective analyses showed that substantial weight gain is 
associated with a higher risk for diabetes; persons who gain more than 6 kg over 5 years 
have more than doubled risk to develop diabetes in the subsequent five years compared to 
persons with stable weight. The significant, continuous association between weight change 
and diabetes also suggests that weight loss is associated with a lower risk for diabetes, and 
underscores the potential benefits of weight loss interventions. Weight loss over five years 
was also associated with a lower risk to develop diabetes in men in the British regional heart 
- 39 - 
study (17), but there was no evidence for weight loss to be associated with a lower risk for 
major cardiovascular disease (CVD) events. On the other hand, men who gained weight (> 
10% in five years) had a higher risk for diabetes as well as for CVD. Based on these results it 
seems justified to conclude that weight loss appears beneficial in order to prevent diabetes, 
but at least (substantial) weight gain should be avoided.  
The results from our retrospective analyses suggest that recent weight change history is not 
an independent risk factor for diabetes. This finding could be of interest for clinicians, who 
have to decide upon possible treatments, for epidemiologists who are engaged in risk 
prediction or for those who are interested in the causation of diabetes. We showed in our 
introduction (Figure 1b) that the results from a ‘retrospective analysis’ are difficult to 
interpret and that potential effects of initial BMI and weight change can not be separated. 
However, together with our results from the prospective approach, we showed that the 
impact of weight change on diabetes incidence can be explained through its effect on 
attained BMI. Our results imply that weight change history is not an independent risk factor 
for diabetes and not an important additional factor to consider in clinical or epidemiological 
prediction models (26-28). However, since only a few former studies have applied this 
‘retrospective approach’, further research is required to explore the impact of short-term 
weight change, long-term weight change and weight change at different stages of life.  
 
The Doetinchem Cohort Study is a population based study with repeated measurements for 
over four thousand Dutch men and women of different ages. The comprehensiveness of the 
study enabled us to adjust for many lifestyle variables such as physical activity, alcohol and 
smoking, as well as for biomedical factors such as blood pressure and cholesterol. Due to the 
physical examinations in each round, all our analyses were based on measured weight 
variables, in contrast to many other studies that have to rely on self-reported weight. 
There were also some limitations. First, identification of cases was based on self-reported 
diabetes and we might have missed persons with undiagnosed diabetes. This potential 
misclassification could have caused an underestimation of the associations that were found. 
Self-reported diabetes in our study appeared to be quite accurate and our results remained 
essentially similar when the analyses were restricted to diabetic cases with confirmed 
incident type 2 diabetes. Second, we do not know the reasons for weight loss. (Intentional) 
weight loss could be advised by a physician to persons with unfavorable risk profiles and 
unintentional weight loss might be caused by pre-clinical disease. Although both reasons 
could cause weight loss to be associated with a higher risk for diabetes (14,17), our results 
suggest that weight loss is associated with a lower risk of diabetes. Finally, information 
about weight cycling during the 5-year periods was not available. However, although weight 
cycling appeared associated with diabetes incidence in both the Framingham Heart Study 
(19) and the Nurses’ Health study II (22), the associations between weight cycling and 
diabetes disappeared in both studies after adjustment for respectively ‘overall weight status’ 
(19) or attained BMI (22). 
 
In conclusion, weight change is associated with diabetes incidence because, conditional on 
initial BMI, weight change determines attained BMI. This implies that lifestyle interventions 
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can contribute to diabetes prevention because these interventions can influence attained BMI. 
Weight change history appears to have no effect on diabetes incidence beyond its effect on 
attained BMI.     
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Alcohol use, cigarette smoking and the incidence of type 2 diabetes: 
findings from a prospective cohort study in the Netherlands 
 
 
 
ABSTRACT 
 
Background: The potential roles of alcohol consumption and smoking in diabetes prevention 
are not entirely clear. Furthermore, only few studies explored the interaction between 
alcohol and smoking with respect to diabetes risk.   
Methods: A prospective cohort study was conducted among 20 119 Dutch adults, aged 20-59 
years at baseline, followed for 7.8 years on average. Adjusted hazard ratios (HR) were 
determined to quantify the associations between alcohol use, cigarette smoking and self-
reported diabetes incidence.  
Results: During 156 387 person-years 308 persons developed type 2 diabetes. A significant 
U-shaped association between alcohol consumption and diabetes incidence was observed in 
women. Compared to moderate drinkers, adjusted hazard ratios were 2.54 (1.26-5.13) for 
abstainers, 2.16 (1.09-4.31) for occasional drinkers, 1.69 (0.83-3.45) for light drinkers and 1.93 
(0.73-5.10) for heavy drinkers. No significant association between alcohol consumption and 
diabetes risk was found in men. Compared to never smoking, current smoking of at least ten 
cigarettes per day tended to increase diabetes risk in both men and women. Interaction 
between smoking and alcohol consumption with respect to diabetes risk was found for men. 
Alcohol consumption tended to decrease diabetes risk only among former smokers. Current 
smoking increased diabetes risk among drinkers only.   
Conclusions: In order to prevent diabetes, women who drink moderately and safely may not 
need to change their drinking habits, but smoking should be discouraged. In males, 
interaction between lifestyle risk factors, their mechanisms and potential implications for 
diabetes prevention should be further explored.  
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BACKGROUND 
The prevalence of diabetes is growing steadily and is expected to have doubled by the year 
2030 (1). Type 2 diabetes accounts for the majority of cases and is, besides hereditary factors, 
strongly associated with lifestyle-aspects such as being overweight and physically inactive 
(2). These lifestyle factors have become the main subject of prevention programs. However, 
other risk factors may also play a role, such as the consumption of alcohol and cigarette 
smoking, both modifiable aspects of behavior and potentially of added value in preventing 
diabetes. 
Moderate alcohol consumption has been found to reduce diabetes risk in most (3-15), but not 
all studies (16). Two meta-analyses reported a U-shaped relationship where both low and 
high alcohol intake were associated with a higher diabetes risk compared to moderate 
alcohol intake (11,12). However, inconsistent results have been found with respect to high 
alcohol intake, both for men and for women (6,7,9,10,13,15,17).  
Smoking has been reported to increase diabetes risk by almost all previous studies, but a lack 
of association has also been observed (16,29). Most studies found higher diabetes risks for 
heavy smokers as compared to light smokers or an increase in diabetes risk with the amount 
smoked (19,22,30). In general, results for men and women are not substantially different 
(19,20). The relative risk for active smokers to develop diabetes compared with nonsmokers 
is approximately 1.4, as estimated in a recent meta-analysis (31). 
Although “unhealthy habits” such as smoking and drinking tend to cluster, few studies have 
explored the joint relationship of alcohol and smoking with diabetes. One study reported the 
absence of interaction between alcohol intake and cigarette smoking with respect to diabetes 
risk in women (7). In the British Regional Heart Study, the protective effect of alcohol was 
more prominent in smoking men compared to non-smoking men (6).  
The aim of this study is to further examine the relationship between alcohol, smoking and 
diabetes, in a large Dutch population based cohort. In addition, the joint effect of alcohol and 
smoking on the incidence of type 2 diabetes will be explored. 
 
RESEARCH DESIGN AND METHODS  
Participants 
Since 1987 two consecutive monitoring studies have been conducted to evaluate the health 
situation and occurrence of risk factors in the Netherlands: the Monitoring Project on 
Cardiovascular Disease Risk Factors and the Monitoring Project on Chronic Diseases Risk 
Factors (MORGEN-project). Prospective data was gathered on men and women aged 20 to 59 
in the towns Doetinchem and Maastricht, in three rounds conducted between 1987 and 2002, 
as was described previously by van Dam and Feskens (32). Participants visited the municipal 
health service where they answered a questionnaire and underwent a physical examination. 
In Doetinchem baseline data were retrieved in the first round (1987 to 1991), while diabetes 
status was retrieved from the latest follow-up survey available (1993 to 1997 or 1998 to 2002). 
In Maastricht, cross-sectional samples were drawn in the first and second round, while 
diabetes status was assessed with a short questionnaire that was sent to all participants in 
1998. All participants gave written informed consent and approval was obtained from the 
local ethics committee. 
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Persons with self reported diabetes at baseline were excluded (n=241), as were pregnant 
women (n=193), subjects with a history of cardiovascular disease (n=418) and subjects with a 
nationality other than Dutch (n=748). Persons with missing values on any of the diabetes risk 
factors were also excluded (n=160). Finally, we excluded persons with missing diabetes 
status at follow-up (n=43) or who were considered probable type 1 diabetics, based on self-
reported diabetes diagnosed before age 40 and treated with insulin within six months of 
diagnosis (n=17). The final study population totaled 20 119 persons (9236 men and 10 883 
women), with a total follow-up of 156 387 person-years. 
 
Assessment of variables and outcome 
To assess alcohol habits, subjects were asked whether they consumed alcohol at the time and 
the amount of consumed glasses per week. The variable was divided into four categories 
based on the Dutch Institute for Health Promotion and Prevention of Diseases’ guidelines on 
safe alcohol use; 1. never drinkers, 2. former drinkers, 3. occasional drinkers: less than 1 
consumption per week, 2. light drinkers: 0 to 1.5 drinks/day (men) and 0 to 1.0 (women), 3. 
moderate drinkers: 1.5 to 3.0 drinks/day (men) and 1.0 to 2.0 (women) and 4. heavy 
drinkers: 3 or more drinks/day (men) and 2 or more (women). One standard drink contains 
10 gram of alcohol on average. People were asked whether they currently smoked cigarettes 
and if so, the average number of cigarettes each day. Cigarette smoking was categorized into 
three levels: never, former or current smoker. In addition current smokers were classified 
into three categories (<10, 10 to 19 or ≥20 cigarettes/day). 
Height and weight were measured and used to calculate BMI as weight in kilograms divided 
by the height in squared meters. 
In contrast to all other variables used, the questions and response options for physical 
activity during leisure time differed between both monitoring projects. The variable was 
dichotomized into active or inactive. Active was defined as at least 4 hours of activity per 
week, with undefined intensity, in the Monitoring Project on Cardiovascular Disease Risk 
Factors, while active was defined as at least three hours of activity per week, with at least 
moderate intensity, in the Monitoring Project on Chronic Diseases Risk Factors. The different 
definitions were chosen in such a way that the proportion of people who were classified as 
active was more or less similar for both projects in consecutive years. Socio-economic status 
was classified into lower, intermediate and higher socio-economic status based on highest 
level of education and current employment. Questionnaires were also used to gather 
information on family history of diabetes in a first-degree relative (yes, no or unknown) and 
coffee consumption.  
To assess diabetes status at baseline and follow-up subjects were asked whether they had 
ever been diagnosed with diabetes (yes or no) and if so, at what age. Also, treatment 
modality was asked for (diet, oral medication, insulin injections or none at all) and 
specifically the use of insulin in the first six months after diagnosis. Since subjects also 
reported the year of diagnosis, time between baseline and diagnosis of diabetes or time 
between baseline and end of follow-up for non-cases could be calculated (in years). 
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Statistical analysis 
All analyses were conducted with SPSS version 12.0 (SPSS Inc., Chicago, Illinois). To assess 
the statistical significance of the differences between men and women with and without 
diabetes, t-tests and chi-square analyses were used. To verify whether relative risks were 
constant over time, Kaplan Meier survival curves were generated. After that, multivariate 
analyses using Cox’s proportional-hazards were carried out. For alcohol moderate drinkers 
were the referent group, for smoking the never smokers were referent, because they were 
expected to have the lowest diabetes risk. Former drinkers were excluded from the analyses 
for alcohol.  
Analyses were carried out in 4 steps. Model 1 adjusted for age and age squared. In model 2 
the modifiable aspects of lifestyle (consumption of coffee, physical activity, alcohol and 
smoking) and familial diabetes were added. BMI and BMI squared were added in model 3 
and socio-economic status was added in model 4. 95% Confidence intervals were calculated, 
the significance level was set at p<0.05 (two sided). Indications for interaction were assessed 
with the age adjusted model (model 1). Stratified analyses were conducted if the p value for 
the interaction term was lower than 0.10.  
 
RESULTS 
Baseline characteristics 
Of 20 119 subjects, 308 developed diabetes (1.5%), during an average follow-up of 7.8 years; 
168 men (1.7%) and 140 women (1.2%, table 1). Subjects that developed diabetes were more 
likely to be older and male and to have a higher BMI than subjects that did not. Also, they 
were more likely to be inactive, have a lower socio-economic status and to have a first degree 
relative with diabetes. Alcohol habits differed substantially between sexes, while smoking 
patterns for men and women were very similar.  
 
Alcohol and type 2 diabetes 
There was some indication for interaction between alcohol and gender with respect to 
diabetes risk (p for interaction 0.06) and thus analyses were conducted for men and women 
separately (table 2).  
In men, non drinkers (ex-drinkers excluded) had the highest diabetes risk but no significant 
associations between alcohol consumption and diabetes risk were observed.    
In women the risk pattern for diabetes was U-shaped. Not drinking or occasional drinking 
were significant risk factors when compared to moderate drinking, with fully adjusted 
hazard ratios of 2.54 (1.26-5.13) and 2.16 (1.09-4.31) respectively. The HRs for light and heavy 
drinking compared to moderate drinking were 1.69 (0.83-3.45) and 1.93 (0.73-5.10) 
respectively.  
 
Smoking and type 2 diabetes 
There was some interaction between smoking and gender with respect to diabetes risk (p for 
interaction 0.07) and therefore gender specific analyses were conducted.   
In men, former smoking and smoking of at least ten cigarettes per day tended to increase 
diabetes risk, although not significant (table 3). Also in women, smoking of at least ten 
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cigarettes per day increased diabetes risk with a significantly increased risk in women 
smoking 10 to 19 cigarettes per day, HR 1.66 (1.04-2.66). There was no evidence for an 
increased diabetes risk for female ex-smokers.  
After adjustment for confounders, no significant dose-response associations between 
smoking and diabetes risk were observed within current smokers.  
 
Table 1. Baseline characteristics by gender and diabetes status 
Variable Men Women 
 Diabetes p  Diabetes p  
 Yes 
(n=168) 
No 
(n=9068)  
 Yes 
(n=140)  
No  
(n=10 743)  
 
Mean±SD for age (years) 48.5±7.3 40.9±10.4 <0.01 48.7±8.0 40.7±10.7 <0.01 
Mean±SD for BMI (kg/m2) 29.4±3.9 25.3±3.2 <0.01 29.9±5.1 24.4±3.8 <0.01 
Mean±SD coffee (cups/day) 5.5±3.3 5.4±3.0 0.60 4.8±3.0 4.5±2.8 0.30 
Alcohol, n(%)‡    0.14   <0.01 
  Former drinker 3 (1.8) 128 (1.4)  3 (2.1) 95 (0.9)  
  Non drinker 13 (7.7) 408 (4.5)  42 (30.0) 1846 (17.2)  
  Occasional drinker 15 (8.9) 1186 (13.1)  46 (32.9) 3420 (31.8)  
  Light 73 (43.5) 3583 (39.5)  32 (22.9) 3006 (28.0)  
  Moderate 39 (23.2) 2243 (24.7)  10 (7.1) 1708 (15.9)  
  Heavy 25 (14.9) 1520 (16.8)  7 (5.0) 668 (6.2)  
Smoking, n(%)   <0.01   0.19 
  Never 34 (20.2) 2821 (31.1)  66 (47.1) 4318 (40.2)  
  Former 81 (48.2) 3095 (34.1)  22 (15.7) 2484 (23.1)  
  <10/day 5 (3.0) 691 (7.6)  10 (7.1) 990 (9.2)  
  10-19/day 19 (11.3) 1238 (13.7)  26 (18.6) 1710 (15.9)  
  ≥20/day  28 (16.7) 1222 (13.5)  16 (11.4) 1234 (11.5)  
Family history dm, n(%)   <0.01   <0.01 
  Positive 63 (37.5) 1411 (15.6)  63 (45.0) 1950 (18.2)  
  Negative 87 (51.8) 6985 (77.0)  59 (42.1) 8039 (74.8)  
  Unknown 18 (10.7) 672 (7.4)  18 (12.9) 754 (7.0)  
SES, n(%)   <0.01   <0.01 
  Lower 111 (66.1) 4712 (52.0)  119 (85.0) 6878 (64.0)  
  Intermediate 29 (17.3) 2274 (25.1)  14 (10.0) 2208 (20.6)  
  Higher 26 (15.5) 2066 (22.8)  7 (5.0) 1624 (15.1)  
Physically inactive, n(%) 70 (41.7) 2728 (30.1) <0.01 62 (44.3) 3829 (35.6) 0.03 
SD standard deviation, SES socio-economic status. ‡ Occasional < 1 drink/week, light > 1 drink/week 
– 1.5 drinks/day (men), > 1 drink/week – 1.0 drinks/day (women), moderate 1.5 – 3.0 drinks/day 
(men), 1.0 – 2.0 drinks/day (women), heavy ≥3.0 drinks/day (men), ≥2.0 drinks/day (women).  
 
Alcohol and smoking combined 
Alcohol consumption was dichotomized into more or less than one consumption per week 
(non drinkers and occasional drinkers combined) to assess a possible clustering of lifestyle 
habits and to assess whether there is interaction between alcohol consumption and smoking 
status with respect to diabetes risk.  
Alcohol consumption and smoking habits appeared to cluster. Among never smoking men, 
25% drink less than one alcohol consumption per week, as compared to only 15% in current 
smokers and 14% in former smokers. The corresponding figures for women are 59% versus 
45% and 41%. Correspondingly, among men and women who drink less than one alcohol 
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consumption per week, 44% and 48% are never smokers compared to 28% and 33% among 
men and women drinking more than one consumption per week.  
There was some interaction between alcohol consumption and smoking with respect to 
diabetes risk in men (p=0.06), but not in women (p=0.69). The hazard ratio’s for diabetes for 
drinking more versus less than one consumption per week in men were 1.89 (0.68-5.24), 0.60 
(0.35-1.04) and 1.65 (0.70-3.93) among current, former and never smokers, respectively. The 
hazard ratios for smoking more than 10 cigarettes per day versus never-smoking were 0.71 
(0.17-2.90) and 1.44 (0.87-2.37) among men who consume less or more than one alcohol 
consumption per week, respectively. For men, new categories based on both alcohol 
consumption and smoking status were constructed with never smokers who consumed more 
than one alcohol consumption per week as the referent category. Former smokers who 
consumed less than one alcohol consumption per week had the highest diabetes risk: HR 
1.91 (1.03-3.53, table 4).  
 
Table 2. Hazard ratios (95% CI) for type 2 diabetes by alcohol categories in different models† 
Alcohol categories‡  
 Non 
drinkers 
Occasional Light Moderate Heavy p§ 
Men       
cases / py 13 / 3242 15 / 9166 73 / 29 403 39 / 17 897 25 / 11 788  
Model 1 1.83  
(0.98-3.43) 
0.79 
(0.43-1.43) 
1.16  
(0.78-1.70) 
1.0 (ref.) 0.97  
(0.59-1.61) 
0.36 
Model 2 1.50  
(0.78-2.89) 
0.79  
(0.44-1.44) 
1.17  
(0.79-1.72) 
1.0 (ref.) 0.92  
(0.56-1.53) 
0.60 
Model 3 1.38  
(0.72-2.67) 
0.93  
(0.51-1.69) 
1.25 
(0.84-1.84) 
1.0 (ref.) 0.95  
(0.58-1.58) 
0.35 
Model 4 1.38  
(0.71-2.68) 
0.94 
(0.51-1.70) 
1.23  
(0.83-1.82) 
1.0 (ref.) 0.92  
(0.55-1.53) 
0.32 
Women       
cases / py 45 / 14 484 46 / 26 360 32 / 23 939 10 / 13 224 7 / 5080  
Model 1 3.61  
(1.81-7.21) 
2.78  
(1.40-5.52) 
1.92  
(0.94-3.90) 
1.0 (ref.) 1.79  
(0.68-4.71) 
<0.01 
Model 2 3.27  
(1.63-6.57) 
2.62  
(1.32-5.22) 
1.88  
(0.92-3.84) 
1.0 (ref.) 1.75 
(0.66-4.61) 
<0.01 
Model 3 2.58  
(1.28-5.19) 
2.19  
(1.10-4.37) 
1.71  
(0.84-3.49) 
1.0 (ref.) 1.94 
(0.73-5.12) 
0.05 
Model 4 2.54  
(1.26-5.13) 
2.16  
(1.09-4.31) 
1.69  
(0.83-3.45) 
1.0 (ref.) 1.93 
(0.73-5.10) 
0.05 
† Model 1 adjusted for age, model 2 adjusted for model 1 + coffee, physical activity, smoking and 
familial diabetes, model 3 adjusted for model 2 + BMI, model 4 adjusted for model 3 + socio-economic 
status. ‡ Occasional < 1 drink/week, light > 1 drink/week – 1.5 drinks/day (men), > 1 drink/week – 
1.0 drinks/day (women), moderate 1.5 – 3.0 drinks/day (men), 1.0 – 2.0 drinks/day (women), heavy 
≥3.0 drinks/day (men), ≥2.0 drinks/day (women). § p-value for exponential trend (drinks/day 
squared); py: person years 
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Table 3. Hazard ratios (95% CI) for type 2 diabetes by smoking categories for different models† 
Smoking categories p # 
 Never Former <10/day 10-19/day ≥20/day  
Men       
cases /py  34 / 22 246 81 / 24 866 5 / 5 284 19 / 10 121 28 / 9 987  
Model 1 1.0 (ref.) 1.34  
(0.89-2.00) 
0.53  
(0.21-1.34) 
1.05 
(0.60-1.84) 
1.32 
(0.80-2.18) 
0.05 
Model 2 1.0 (ref.) 1.37  
(0.91-2.06) 
0.57  
(0.22-1.45) 
1.04  
(0.59-1.84) 
1.24 
(0.73-2.13) 
0.06 
Model 3 1.0 (ref.) 1.40  
(0.93-2.10) 
0.59  
(0.23-1.51) 
1.39  
(0.79-2.46) 
1.40  
(0.82-2.38) 
0.10 
Model 4 1.0 (ref.) 1.37 
(0.91-2.06) 
0.59  
(0.23-1.51) 
1.43 
(0.80-2.53) 
1.44  
(0.84-2.45) 
0.10 
Women       
cases /py  66 / 34 039 22 / 19 001 10 / 7 573 26 / 13 599 16 / 9 634  
Model 1 1.0 (ref.) 0.68  
(0.42-1.11) 
0.83  
(0.43-1.62) 
1.20  
(0.76-1.90) 
1.00  
(0.58-1.74) 
0.75 
Model 2 1.0 (ref.) 0.82  
(0.50-1.34) 
0.96  
(0.49-1.88) 
1.31  
(0.82-2.11) 
1.13  
(0.63-2.01) 
0.99 
Model 3 1.0 (ref.) 0.83  
(0.51-1.35) 
1.08  
(0.55-2.12) 
1.66  
(1.04-2.66) 
1.39  
(0.78-2.46) 
0.96 
Model 4 1.0 (ref.) 0.84  
(0.51-1.37) 
1.08  
(0.55-2.12) 
1.64  
(1.02-2.64) 
1.39  
(0.78-2.46) 
0.96 
† Model 1 adjusted for age, model 2 adjusted for model 1 + coffee, physical activity, alcohol 
consumption and familial diabetes, model 3 adjusted for model 2 + BMI, model 4 adjusted for model 3 
+ socio-economic status. # p for linear trend within current smokers: py: person years  
 
 
Table 4. Hazard ratios (95% CI) for the joint effect of alcohol and smoking on diabetes incidence 
among men* 
 
Smoking categories Alcohol categories 
  
Less than one alcohol 
consumption per week † 
 
At least one consumption per 
week  
Never   
Cases / person-years 7 / 5 454 27 / 20 438 
Hazard ratio  0.72 (0.31-1.66) 1.0 (ref.) 
Former   
Cases / person-years 17 / 3 365 61 / 21 084 
Hazard ratio  1.91 (1.03-3.53) 1.11 (0.70-1.76) 
Current   
Cases / person-years 4 / 3 594 49 / 21 391 
Hazard ratio  0.64 (0.22-1.86) 1.23 (0.76-1.98) 
* adjusted for age, coffee, physical activity, familial diabetes, BMI and SES (model 4).  
† non drinkers and occasional drinkers combined, ex-drinkers excluded.  
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CONCLUSIONS 
We evaluated the associations between alcohol consumption, smoking and the incidence of 
type 2 diabetes in a Dutch population. For women the relationship between alcohol and 
diabetes risk was U-shaped with the lowest risk for women consuming one to two drinks per 
day. In men, no significant association between alcohol consumption and diabetes risk was 
observed. Current smoking of at least 10 cigarettes per day tended to increase the risk of 
diabetes in both men and women, but a clear dose-response association was not found.   
All analyses were adjusted for confounders in a stepwise manner, in order to observe the 
additional effect of adjusting for each factor. In women, adding BMI to the model attenuated 
the increased risk for non-, and occasional drinkers, but did not alter statistical significance. 
Additional adjustment for BMI increased the hazard ratios for diabetes for moderate and 
heavy smokers. The effect of additional adjustment for SES was ignorable.  
 
Our results for alcohol consumption are partly consistent with previous findings. In 2005 
Koppes et al. conducted a meta-analysis on the association between alcohol consumption 
and incidence of type 2 diabetes and concluded that moderate alcohol consumption reduces 
diabetes risk by ~30%, in an U-shaped manner (12). The systematic review by Howard et al. 
also reported a U-shaped relationship, with moderate alcohol consumption reducing 
diabetes risk by 33 – 56% (13). Both studies present their results for men and women 
combined. The U-shaped association has also been found for women specifically (3). 
Carlsson et al. reported results for men and women more similar to ours; abstaining 
increased the risk in both sexes and heavy alcohol intake increased the risk in women, but 
not in men (10). 
Our finding for an increased diabetes risk among current smokers (although not significant) 
is concordant with findings from most previous studies (30). We did not find a significant 
dose-response association between smoking and diabetes risk, in contrast to some other 
studies that did report such association (22,24,25).   
In men there appeared to be some interaction between alcohol and smoking status. Alcohol 
consumption reduced diabetes risk only among former smokers, while current smoking 
appeared to be a risk factor only for men drinking more than one alcohol consumption per 
week. However, the number of diabetes cases in some subgroups was very low and 
confidence intervals very wide. Overall, non-drinking, former smokers had the highest risk 
which may point at a ‘sick quitter effect’, where men stop drinking and smoking because of 
disease related complaints. However, former drinkers were already excluded from the 
analyses, as were men with a cardiovascular history at baseline, making it less likely that 
such an effect was present.  
With respect to a possible interaction, Wannamethee et al. (6) found a more prominent risk 
reduction of light and moderate alcohol consumption (compared to non or occasional 
drinking) in currently smoking men as compared to non-smoking men. As Wannamethee 
included former smokers in the non smoking group, these result seem inconsistent with our 
findings. In 2003, the same researchers found no significant interaction, between smoking 
and drinking in younger women (7), which is consistent with our results.  
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Several potential limitations of our study need to be addressed. Like all epidemiological 
research into behavior and diabetes our study knew two major difficulties: obtaining 
accurate information on exposure and identifying all cases of diabetes. In this study, 
information on alcohol and smoking habits was based on subjects’ self-report and was not 
validated. The reported amounts of alcohol and cigarettes were most probably 
underreported; the observed associations could in reality belong to a higher consumed 
amount of alcohol or number of cigarettes smoked.  
Diabetes status was also self-reported and since many patients are unaware of the disease, 
this too was likely to have been underreported. However, assuming that the observed 
associations between alcohol and smoking and the incidence of diabetes are true, 
underreporting of diabetes would have attenuated the association. Authors who investigated 
the validity of self-reported diabetes report high levels of agreement between self-reported 
diabetes and medical records with κ-values for agreement varying from 0.67 (33), to 0.76 (34) 
and up to 0.84 (35). This suggests that the use of self-reported diabetes as an endpoint is 
justified. In order to evaluate the effect of potentially having included subjects with only 
impaired glucose tolerance, we repeated the analyses, restricted to diabetes subjects who 
used diabetes medication and the results remained essentially the same. 
 
In conclusion, the results of this study support the evidence that alcohol and type 2 diabetes 
are related in a non-linear, U-shaped pattern in women, in which moderate alcohol use 
generates the lowest risk. It also supports previous findings that moderate and heavy 
smoking increase the risk of type 2 diabetes in both men and women. These findings suggest 
that, with respect to diabetes prevention, women who drink moderately and safely may not 
need to change their drinking habits, and should be encouraged to stop smoking. Our results 
also suggest that the association between alcohol consumption and diabetes risk in men may 
be modified by smoking habits (and vice versa). However, it seems preliminary to infer any 
subgroup recommendations such as for example discouraging moderate alcohol 
consumption in currently smoking or never smoking men. At least in males, further studies 
should explore the possible interaction between alcohol and smoking with respect to 
diabetes risk, what mechanisms are involved and what the potential consequences for 
diabetes prevention could be.  
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Lifestyle interventions are cost-effective in people with different levels of diabetes 
risk: results from a modeling study 
 
 
 
ABSTRACT 
 
Objective: The current study explores the long-term health benefits and cost-effectiveness of 
both a community-based lifestyle program for the general population (community 
intervention) and an intensive lifestyle intervention for obese adults, implemented in a 
health care setting (health care intervention).  
Research design and methods: Short-term intervention effects on Body Mass Index and 
physical activity were estimated from the international literature. The RIVM Chronic 
Diseases Model was used to project lifetime health effects and effects on health care costs for 
minimum and maximum estimates of short-term intervention effects. Cost-effectiveness was 
evaluated from a health care perspective and included intervention costs and related and 
unrelated medical costs. Effects and costs were discounted at 1.5% and 4.0% annually. 
Results: One new case of diabetes per 20 years was prevented for every 7 to 30 participants 
in the health care intervention and for every 300 to 1500 adults in the community 
intervention. Intervention costs needed to prevent one new case of diabetes (per 20 years) 
were lower for the community intervention (€2000 to €9000) than for the health care 
intervention (€5000 to €21,000). The cost-effectiveness ratios were €3100 to €3900 per quality-
adjusted life-year (QALY) for the community intervention and €3900 to €5500 per QALY for 
the health care intervention.  
Conclusions: Health care interventions for high-risk groups and community-based lifestyle 
interventions targeted at the general population (low risk) are both cost-effective ways of 
curbing the growing burden of diabetes.  
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BACKGROUND 
Risk factors for developing type 2 diabetes include a high body weight, physical inactivity, 
and smoking, while moderate consumption of alcohol or coffee appears to be protective (1-
9). The most serious of these factors is being overweight. With every one-unit increase in 
body mass index (BMI), the risk of developing type 2 diabetes increases by approximately 
10% to 30% (10). There is substantial evidence that lifestyle interventions focused at diet and 
physical exercise can reduce diabetes incidence in persons at high risk of developing diabetes 
(11-14). Although the direct effect of lifestyle interventions on diabetes incidence in other 
target populations is relatively unknown, it is suggested that a relatively small shift of the 
entire general population towards more healthy behavior could lead to a reduction in the 
incidence of diabetes (15).  
Modeling can be used to assess the potential long-term impact of lifestyle programs on 
future health and health care costs. Such information is interesting to policy makers who 
have to decide on optimal allocation of limited budgets. Models have been used to 
demonstrate that intensive lifestyle modification programs are cost-effective for persons at 
high risk of developing diabetes (16,17). However the cost-effectiveness of such interventions 
for persons at lower risk of developing diabetes is relatively unknown (15,16,18-20). Only a 
few lifestyle intervention studies have directly assessed the incidence of diabetes in persons 
without a high risk of developing this disease (18,21). However, effects on the most 
important diabetes risk factors, BMI and physical inactivity, have been evaluated for 
different kinds of lifestyle interventions, in different target populations. The long-term 
impact of lifestyle interventions can be modeled through modifying risk factor levels, with 
the advantage that effects of risk factor modification on all cause mortality and diseases other 
than type 2 diabetes can be taken into account (22).  
Therefore, the aim of this study is to explore and compare the cost-effectiveness of lifestyle 
interventions for persons at different levels of diabetes risk, using the RIVM Chronic 
Diseases Model (CDM). The CDM is a Markov type, dynamic population model which 
describes transitions between risk factors, chronic diseases and mortality (23). This allows the 
effects of risk factor modification on mortality and the incidence and prevalence of several 
diseases. A second aim is to explore the potential health benefits for large-scale 
implementation of lifestyle interventions in the Netherlands. 
 
RESEARCH DESIGN AND METHODS 
A large amount of data is available about the long-term effects of two types of interventions, 
namely community-based lifestyle programs and intensive lifestyle programs for high risk 
groups (24-27). Typically, community programs comprise mass media campaigns, and a 
range of activities in various settings aimed at changing risk factor behavior in the general 
population. Lifestyle interventions for high-risk groups are typically implemented in a health 
care setting and comprise dietary advice, exercise programs and/or behavior modification 
therapy for individuals or groups. The current study explores the lifetime health effects and 
cost-effectiveness of a once-only implementation of the following interventions: 
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 1. A community-based program with a duration of 5 years, focusing on nutrition and 
exercise and targeted at the general population; further referred to as ‘community 
intervention’.  
2. An intensive lifestyle intervention with a duration of 3 years, focusing on diet and exercise, 
for adults with moderate risks of developing diabetes (obese adults 30-70 years), 
implemented in a health care setting; referred to as ‘health care intervention’.  
 
Short-term effects on BMI and physical (in)activity are estimated from published studies, 
which are representative for the aforementioned interventions. In general, community 
programs have modest effects on body weight and physical inactivity (25,28-32), while on 
average, the effects of health care interventions are larger (11,13,26,33). In the current study, 
potential intervention effects are expressed within a range that reflects the diversity of 
positive intervention effects that we found in the international literature.  
 
Effects of the community intervention are defined as: 
Minimum effect: Average BMI decreases by 0.05 kg/m2 and physical (in)activity is 
unchanged.  
Maximum effect: Average BMI decreases by 0.25 kg/m2 and 15% of inactive persons 
increase their level of physical activity (to moderately active).  
Effects are assumed for adults 20─80 years. 
 
Effects of the ‘health care intervention’ are defined as: 
Minimum effect: Average BMI decreases by 0.3 kg/m2 and 50% of inactive persons increase 
their level of physical activity (to moderately active).  
Maximum effect: Average BMI decreases by 1.5 kg/m2, 75% of inactive persons become 
moderately active and 20% of moderately active persons increase their level of physical 
activity (to active).  
 
In the current study, intervention costs are based on two Dutch projects. The community-
based program entitled ‘Hartslag Limburg’ (Heart Health Limburg) aimed at decreasing the 
prevalence of cardiovascular diseases in the general population (34). Total intervention costs 
for activities focusing on nutrition and physical activity for 5 years were approximately €4.50 
per inhabitant (or €6 per 20+ adult) in the target area (35).  
The “Study on Lifestyle intervention and Impaired glucose tolerance Maastricht (SLIM)” is 
an intensive lifestyle intervention that aims to improve lifestyle in overweight subjects with 
impaired glucose tolerance by means of a 3-year dietary advice and an exercise program 
(36,37). The cost calculations for this intervention are briefly outlined in Appendix A. The 
costs for large-scale implementation are estimated at approximately €700 per participant, 
based on the assumption that 50% of the participants will participate in the exercise 
program.  
Health effects, intervention costs and effects on health care costs are assumed to be 
proportional to the number of intervention participants (which implies that the cost-
effectiveness ratios are independent on the reach of the interventions).  
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For each intervention, the CDM computes lifetime health effects, effects on health care costs, 
and costs per QALY resulting from the minimum and maximum estimated intervention 
effect. In the model each intervention is compared to a reference scenario which describes 
developments in the Dutch population when no interventions are applied.  
 
The RIVM Chronic Diseases Model (CDM) 
The CDM is a Markov-type, multistate transition model, developed at the Dutch National 
Institute for Public Health and the Environment (RIVM) (38-42). An extensive description of 
the CDM structure and the relevant input data used is given in Appendix B. The model was 
updated for diabetes in 2005 (43). In short, the model describes the development over time of 
demography, risk factor prevalence, disease incidence and mortality in the Dutch 
population. In the CDM, BMI and physical activity are each modeled in three classes: normal 
weight (BMI <25, class 1), overweight (BMI 25-30, class 2) and obesity (BMI ≥30, class 3), 
active (30 minutes of activity of moderate intensity on at least 5 days of the week, class 1), 
moderately active (30 minutes of activity of moderate intensity on 1-4 days of the week, class 
2) and inactive (30 minutes of activity of moderate intensity on less than 1 day a week, class 
3). BMI and physical activity are linked to all cause mortality, diabetes, cardiovascular 
diseases, musculoskeletal disorders and cancers through relative risks on disease incidence 
(43,44). Relative risks are based on international literature, while incidence, prevalence, 
transition rates and mortality rates in the model apply to the Dutch population. All data are 
age- and sex specific. Health care costs are based on the Costs of Illness study in the 
Netherlands (45,46). The Global and Dutch Burden of Disease studies are used to compute 
health effects in terms of quality-adjusted life-years (QALYs) (46-50). Recently the RIVM 
model was extended with a module for cost-effectiveness analyses (46). The cohort in the 
start year of the simulation resembles the total Dutch population at the end of 2004 (n=16.3 
million). Newborns or migrants are not included in the analysis. The time step used for 
modeling is 1 year. A lifetime horizon (70 years) is applied.  
 
Translation of intervention effects into model parameters 
The intervention effects on BMI and physical activity were translated into altered prevalence 
rates in each risk factor class in the model. For example, we assumed that all adults in the 
Netherlands had been reached by the community intervention. At the end of year 5, the 
prevalence of normal weight (BMI class 1) in the ‘community scenario’ (maximum effect) 
was 2.4%-points higher compared to the reference scenario (52.4% versus 50%). The 
differences in BMI classes 1 to 3 and physical activity classes 1 to 3 (in %-points) were: +2.4, -
1.1, -1.3, no change, +1.2 and -1.2, respectively. For the health care intervention, we assumed 
that 200,000 obese adults participated. In the “maximum effect scenario”, differences 
between the intervention and reference scenario after 3 years in BMI classes 1 to 3 and 
physical activity classes 1 to 3 (in %-points) were: no change, +1.7, -1.7, +0.2, +0.1 and -0.3, 
respectively. After the interventions, yearly age- and gender specific transition probabilities 
between risk factor classes (for example the chance to gain weight with ageing) were equal 
for the intervention and reference scenarios. As a result of extinction of the intervention 
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‘cohorts’, the differences between intervention and reference scenarios gradually declined to 
zero.  
 
Cost-effectiveness analysis 
The cost-effectiveness analysis was performed from a health care perspective, meaning that 
only health-related effects and costs incurred by the health care system were included. A 
distinction was made between related and unrelated medical costs. Related medical costs are 
intervention costs and (prevented) medical costs for diseases linked to BMI or physical 
activity within the CDM. Unrelated medical costs are costs for illnesses, for example 
dementia, that may develop in life years gained as a result of the intervention. Costs and 
effects were discounted by 4% and 1.5% per year according to recent Dutch guidelines (51). 
A cost-effectiveness ratio below €20,000 per QALY gained was considered cost-effective 
(52,53).  
 
Outcome measures 
Intervention effects in terms of life-years and QALYs per person were estimated by dividing 
the total gain in life-years or QALYs resulting from the interventions (minimum and 
maximum estimate) by the number of assumed intervention participants in each intervention 
(12 million for the community intervention and 200,000 for the health care intervention). The 
same applied to effects on health care costs per person. The number needed to treat (NNT) to 
prevent one new case of diabetes or cardiovascular disease (in 20 years) was calculated by 
dividing the number of intervention participants by the cumulative number of incident cases 
prevented in 20 years. Cost-effectiveness ratios were determined for intervention costs per 
prevented diabetes case (in 20 years), intervention costs per QALY gained (lifetime), related 
costs per QALY gained (lifetime) and total costs per QALY gained (lifetime).  
 
Sensitivity analysis 
Analyses were performed in which intervention costs and discount rates were varied. Costs 
for the interventions were varied between €4 and €8 per adult for the community 
intervention and between €400, €1000 and €2000 (comparable to the intervention costs found 
in the DPP (54) per participant for the health care intervention. Both costs and effects were 
discounted by 0% or 4% per year. Discount rates of 3% on both costs and effects were 
calculated to enhance comparability with a former study (16).  
 
RESULTS 
Health effects 
Outcomes for both interventions compared to the reference scenario (no intervention) are 
displayed in Table 1. On average health benefits per participant are larger for the health care 
intervention compared to the community intervention: 1.17 versus 0.04 QALYs based on the 
maximum estimated intervention effects. This can be interpreted as an average individual 
gain of 15 days versus 14 months of living in good health. The number needed to treat 
(NNT) is lower for the health care intervention: 7 to 30 obese adults should participate in a 
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health care intervention to prevent 1 new case of diabetes in 20 years, while a community 
program should reach 300 to 1500 adults to obtain the same result.  
 
Table 1. Effects on health, health care costs and cost-effectiveness of lifestyle interventions 
Outcome Community 
intervention 
Health care 
intervention 
Health effects   
Life years * 0.007 to 0.043 
2 to 16 days 
0.32 to 1.35 
4 to 16 months 
QALYs * 0.006 to 0.039 
2 to 15 days 
0.27 to 1.17 
3 to 14 months  
NNT to prevent 1 case of diabetes in 20 years 1500 to 300  30 to 7  
NNT to prevent 1 case of CVD in 20 years † 3700 to 400 60 to 18 
Costs ‡   
Intervention costs 5.55 675 
∆ Lifetime related medical costs -10 to -70  -500 to -1700 
∆ Lifetime unrelated medical costs 30 to 180 1300 to 5600 
∆ Lifetime total medical costs  20 to 110 800 to 3900 
Cost-effectiveness   
Intervention costs per QALY 900 to 140  2500 to 600  
Related costs per QALY § -500 to -1500 800 to -900  
Total costs per QALY ║ 3900 to 3100 5500 to 3900  
All ranges correspond to result when “minimum intervention effect” is assumed to result when 
“maximum intervention effect” is assumed; * effect per intervention participant; life-years and QALYs 
discounted by 1.5% per year; NNT: number needed to treat; † CVD: cardiovascular disease; ‡ costs per 
adult or intervention participant in 2005 in Euros, discounted by 4% per year; § intervention costs and 
lifetime related medical costs; ║ intervention costs and lifetime total medical costs 
 
Costs 
Both interventions reduce cumulative lifetime medical costs for diabetes, cardiovascular 
diseases and other intervention-related diseases (related costs, Table 1). Unrelated and total 
medical costs increase because people live longer as a result of the interventions. For 
participants in the health care intervention, lifetime-related medical costs per person may be 
reduced by up to €1700. On the other hand, unrelated health care costs increase by €5600. 
Average lifetime total health care costs therefore increase by €3900 for participants in the 
health care intervention.  
 
Cost-effectiveness 
Intervention costs needed to prevent disease are lower for the community intervention; 
€1800 to €9000 (300 to 1500 *€6) to prevent one new case of diabetes in 20 years versus €4900 
to €21,000 (7 to 30* €700) for the health care intervention (intervention costs not discounted). 
Related costs per QALY in the community intervention are negative because over a patient’s 
lifetime, savings in related health care costs are larger than initial intervention costs. Whether 
the high costs of health care intervention are counterbalanced by savings in related health 
care costs depends on the intervention effect achieved. Cost-effectiveness ratios in which 
unrelated medical costs are accounted for are €3100 to €3900 per QALY for the community 
intervention and €3900 to €5500 for the health care intervention.  
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Sensitivity analyses 
The results of the sensitivity analyses on QALYs and cost-effectiveness ratios are given in 
Table 2. Discounting health effects by 4% (versus 1.5% in the base-case analyses) reduces 
health benefits by approximately 50%. For both interventions, all cost-effectiveness ratios 
remain below €20,000 per QALY.  
 
Table 2. Quality-adjusted life-years (QALYs) and cost-effectiveness of both interventions; sensitivity 
analyses 
 QALYs  Related costs (€) / 
QALY 
Total costs (€) / 
QALY 
Community intervention    
Base-case analysis * 0.006 to 0.04 -500 to -1500 3900 to 3100 
Intervention costs 4 /adult  -800 to -1600  3600 to 3100 
Intervention costs 8 /adult  -200 to -1500 4200 to 3200 
D.R. 0% costs and effects † 0.01 to 0.06 -1300 to -2300  10,000 to 9400 
D.R. 3% costs and effects 0.004 to 0.03 -1100 to -2700  7700 to 6500  
D.R. 4% costs and effects 0.003 to 0.02 -1000 to -2800  7200 to 5800  
Health care intervention    
Base-case analysis ‡ 0.27 to 1.17 800 to -900  5500 to 3900  
Intervention costs 400 pp  -200 to -1100 4500 to 3600  
Intervention costs 1000 pp  1900 to -600  6600 to 4100  
Intervention costs 2000 pp  5400 to 200 10,100 to 4900 
DR 0% costs and effects 0.41 to 1.75 -300 to -1300 12,000 to 11,200  
DR 3% costs and effects 0.19 to 0.82 800 to -1600 10,000 to 7800  
DR 4% costs and effects 0.15 to 0.66 1500 to -1600 10,000 to 6900  
All ranges correspond to result when “minimum intervention effect” is assumed to result when 
“maximum intervention effect” is assumed; * intervention costs €6 per adult and discount rates 4% for 
costs and 1.5% for effects; † DR: discount rates; ‡ intervention costs €700 per participant and discount 
rates 4% for costs and 1.5% for effects  
 
Large-scale implementation in the Netherlands 
The Netherlands has approximately 12 million adults aged 20-80 years and 1 million obese 
adults aged 30-70 years. Potential effects of large-scale implementation of the lifestyle 
intervention in the Netherlands are illustrated in Table 3. Theoretically, a community 
intervention reaching all adults might prevent 2.4% of the new diabetes cases in 20 years. A 
health care intervention including 200,000 (20%) of the obese adults in the Netherlands may 
reduce 20-year diabetes incidence by 1.6% but intervention costs are high.  
 
CONCLUSIONS 
By modeling the effect of risk factor modification on long-term disease incidence, mortality 
and health care costs we demonstrated that lifestyle interventions can be cost-effective in 
persons with low or moderate risks of developing diabetes.  
Community-based lifestyle interventions have been conducted with varying results (25,31). 
In general, effects on weight are modest. The largest effect on weight, the maximum effect of 
the community intervention in our study (-0.25 kg/m2) was based on this, was found in the 
Stanford Five City Project (28). This study found that after 5 years, weight increase was 0.7 
kg less in intervention communities compared to control regions. Most community-based
- 66 - 
Table 3. Effects of large-scale implementation of lifestyle interventions in the Netherlands 
 Reach of the intervention 
low estimate 
Reach of the intervention 
high estimate 
Community intervention   
# adults reached 2.4 million (20%) 12 million (100%) 
∆ Life-years  16,000 to 104,000 81,000 to 522,000 
∆ QALYs  15,000 to 95,000 76,000 to 477,000 
prevented DM in 20 years 1600 to 8600 (0.1% to 0.5%) 8000 to 43,000 (0.4% to 2.4%) 
prevented CVD in 20 years 600 to 6200 (0.0% to 0.1%)  3000 to 31,000 (0.1% to 0.7%) 
intervention costs €13 million  €66 million 
∆ related medical costs savings: 20 to 160 million savings: 100 to 800 million 
∆ total medical costs 40 to 280 million 200 to 1400 million 
Health care intervention   
# obese participants 50,000 (5%) 200,000 (20%) 
∆ Life-years  16,000 to 68,000 64,000 to 271,000 
∆ QALYs  14,000 to 59,000 56,000 to 234,000 
prevented DM in 20 years 1500 to 7000 (0.1% to 0.4%) 6000 to 28,000 (0.3% to 1.6%) 
prevented CVD in 20 years 1000 to 2800 (0.0% to 0.1%) 4000 to 11,000 (0.1% to 0.3%) 
intervention costs €34 million €135 million 
∆ related medical costs savings 20 to 70 million  savings 100 to 300 million 
∆ total medical costs 40 to 200 million 200 to 800 million 
All ranges correspond to result when “minimum intervention effect” is assumed to result when 
“maximum intervention effect” is assumed; discount rates 4% for costs and 1.5% for effects; DM: 
Diabetes Mellitus; CVD: cardiovascular disease 
 
programs fail to achieve substantial effects on physical activity, but the prevalence of 
physical inactivity may be reduced. In contrast, effects of ‘health care interventions’ on mean 
body weight can be substantial, especially within the first year (21). A recent review revealed 
that a weight loss of 5% can be achieved within 1 year (27). However, the effect tends to 
decrease at longer term follow-up (11-13,21,26,33,55). After three years, as we simulated in 
our study, the maximum effect is about 4.5 kg (or 1.5 kg/m2) (11,13). With regard to physical 
activity, intensive programs have been shown to improve maximum oxygen uptake (13), 
increase time spent on physical activities (11,12) and reduce physical inactivity (12). As 
intervention effects differ considerably between studies, we explored the cost-effectiveness 
for a range of potential intervention effects. Despite methodological differences, average 
individual health benefits for participants in the health care intervention in our study were in 
the same order of magnitude as those projected for participants in the Diabetes Prevention 
Program (0.19 to 0.82 QALYs versus 0.56 in the DPP, all discounted at 3% (11). Both studies 
concluded that intensive lifestyle interventions for persons at increased risk for diabetes are 
cost-effective. 
The literature on cost-effectiveness of interventions aimed at primary prevention of diabetes 
is scarce (20). Only one earlier study assessed the cost-effectiveness of a community-based 
program aimed at diabetes prevention (56). Several preventive interventions for different 
target groups were compared in this study. In general, the cost-effectiveness of (theoretical) 
interventions was more favorable in IGT groups compared to “mixed populations”. 
However, lifestyle interventions appeared to be highly cost-effective in all target groups and 
were more effective than surgery for the severely obese. Lifestyle interventions have also 
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been shown to be more cost-effective than metformin treatment for the primary prevention 
of diabetes (57).  
With respect to the potential impact of community-based lifestyle programs, a recent study 
showed that, theoretically, diabetes incidence could fall by 20% if the entire (UK) population 
were able to meet one more of the five predefined “diabetes healthy behavior prevention 
goals” related to BMI, diet and physical activity (15). BMI and physical activity had the 
largest impact on diabetes incidence and the authors suggested that even small shifts of the 
entire population towards more healthy behavior (through population-level interventions) 
would reduce diabetes incidence. Based on more realistic assumptions about potential effects 
on just BMI and physical inactivity, the community program in our study would prevent 
between 0.4% and 2.4% of the diabetes incidence in 20 years, if the entire Dutch population 
were to be reached by the intervention. Although the average lifetime health benefits per 
person were relatively low (a gain of a few days in good health), health benefits may be 
substantial for persons whose risk factor levels are actually changed.  
Several comments need to be made with respect to the generalizability of the results 
obtained from our study. First, cost-effectiveness of lifestyle interventions differs between 
countries due to country-specific intervention- and health care costs (17). Although the per 
person intervention costs of the health care intervention in our study (€700) were much 
lower then the intervention costs calculated for the US Diabetes Prevention Program 
(approximately €2000 if screening costs for IGT are not considered), they compare well to the 
costs of other lifestyle interventions within health care as reported in a recent review (27). 
Costs of diabetes care in the Netherlands appear to be relatively low compared to other 
(European) countries (58). Second, the potential impact of large-scale implementation of 
interventions depends on risk factor distributions. For example, one out of four US adults is 
considered obese, and so there is a large potential target population for health care 
interventions. Third, the efficiency of lifestyle interventions may also differ due to country-
specific risk factor prevalence; a community-based program aimed at increasing physical 
activity might be more cost-effective in for example the US, where the prevalence of physical 
inactivity is three times as high as the Netherlands (59).  
In conclusion, both an intensive lifestyle intervention implemented in a health care setting 
and targeted at persons at increased risk of developing diabetes as well as a community-
based lifestyle intervention for the general population are effective in reducing diabetes 
incidence. Although the average lifetime health benefit per person for the community 
intervention is relatively low, health gains on a population level may be substantial when the 
intervention is implemented on a large scale. Both kinds of lifestyle interventions are cost-
effective ways to curb the growing burden of diabetes.  
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Appendix Chapter 4 
 
A. Calculation of costs of the SLIM-intervention (health care intervention) 
 
Short description of the SLIM-project  
SLIM is the abbreviation of ‘Study on lifestyle-intervention and impaired glucose tolerance  
Maastricht’ (1,2). The intervention consisted of counseling sessions with a nutritional component, 
based on conventional dietary guidelines, and information about the benefits of being physically 
active (according to the standard of at least half an hour a day on 5 days in the week). In overweight 
persons the intervention consisted of individual dietary counseling aiming at weight loss. In addition 
to the counseling sessions, participants were encouraged to participate in an organized fitness 
program. This program consisted of a combination of increasing strength and aerobic training.  
 
Assessment of costs  
Fixed costs, for example the training of personnel, and costs for developing and starting up the 
intervention were not included. Only the costs for executing the intervention (real resource use) were 
considered. The first step was to identify the different costs parts of the intervention, e.g. primarily 
material and personnel. Thereafter the consumption frequency and duration of these costs parts were 
assessed. For instance, the frequency and average length of a counseling session. The usage is 
multiplied by the costs per unit.  
 
Costs for personnel  
Personnel costs were calculated by using the method as described in the Dutch guidelines for cost 
calculations within pharmaco-economic research (3). Firstly, the monthly mean gross salary per 
professional category was determined by using the middle number plus 1 within the specific salary 
scale. A surcharge of 35% was calculated for holiday allowance, social security etc. Thereafter, a 
surcharge of 35% was calculated for institutional overhead costs. A further surcharge of 10% was 
calculated for housing costs. Finally the amount of working hours in one year was calculated, 1540 for 
a 36-hour working week and 1632 for a 38-hour working week. The unit cost per hour was calculated 
assuming a productivity of 70 percent.  
  
The cost calculation of the SLIM intervention is shown in Table 1:  
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Table 1. Costs of the SLIM intervention 
Intervention 
component 
content 
 
 
units per person costs per 
unit  
costs per 
person 
Nutrition Year 1    
 4 individual sessions 
with a dietician 
4*45 = 180 min € 0.84 /min € 151 
 1 group session with a 
dietician 
90 min / 15 persons =  
6 min / person 
€ 0.84 /min € 5 
 1 handbook nutrition 1 € 13 € 13 
 Year 2 and 3     
 3 individual sessions 
with a dietician 
3*45 = 180 min € 0.84 /min € 114 
 1 group session with a 
dietician 
90 min / 15 persons =  
6 min / person 
€ 0.84 /min € 5 
 Total nutrition   € 407 (A) 
Exercise Year 1    
 1 individual advice by a 
researcher 
45 min € 1.02 € 46 (B) 
 Fitness program  52*60 min / 15 
persons = 208 min / 
person 
€ 0.70 € 146 
 Year 2 and 3    
 Fitness program  52*60 min / 15 
persons = 208 min / 
person 
€ 0.70 € 146 
 Total exercise   € 484 (C) 
 
Total for participants of the fitness program A+C        891 
 for non participants  A+B  453 
 (rounded) average costs used for the analyses*  700 
 
*Based on the intervention results it was known that 50% of the participants participated in the fitness 
program. This participation rate can be anticipated in planning large-scale implementation of the 
program.  
 
 
 
 
 1.  Mensink M, Feskens EJM, Saris WHM, Bruin TWAd, Blaak EE: Study on Lifestyle Intervention 
and Impaired Glucose Tolerance Maastricht (SLIM): preliminary results after one year. Int J Obes 
Relat Metab Disord 27:377-384, 2003 
 2.  Mensink M, Blaak EE, Corpeleijn E, Saris WH, de Bruin TW, Feskens EJ: Lifestyle intervention 
according to general recommendations improves glucose tolerance. Obes Res 11:1588-1596, 2003 
 3.  Oostenbrink JB, Koopmanschap MA, Rutten FFH: Handleiding voor kostenonderzoek. Methoden 
voor economische evaluaties in de gezondheidszorg [Guideline for cost research. Methods for 
economic evaluations in the health care]. Amstelveen: College voor zorgverzekeringen 2000 
- 74 - 
B: Description of the Chronic Diseases Model (CDM) and relevant input data with respect 
to diabetes prevention 
 
Introduction 
The RIVM Chronic Disease Model is a multistate Markov-type simulation model. It describes how 
morbidity and mortality rates for several chronic diseases change over time in the Dutch population 
as a result of changes in epidemiological risk factors (1,2). In general, the state transition model is a 
suitable and accepted model to describe demographic / epidemiological processes (3). Disease experts 
and modelers have cooperated in building and testing of the CDM. Several studies with different 
applications of the model have already been published (4-7). The model states defined are classes for 
the risk factors (i.e. normal weight: BMI<25; overweight: BMI 25-30; obesity: BMI  30) and states for 
the diseases included in the model (diabetes; yes or no). In the starting year of the simulation period 
all persons are distributed over these states. Then for each 1-year simulation step persons move from 
one state to another. These transitions are governed by so-called transition rates. E.g., class transition 
rates between the BMI states ‘normal weight’ and ‘overweight’ govern the change of the BMI 
distribution in the population, incidence rates between the states ‘without diabetes’ and ‘with 
diabetes’ govern the disease prevalence rates, and mortality rates from the state ‘alive’ to ‘deceased’ 
govern the surviving population numbers. The transition rate is assumed independent from the 
preceding states and depends only on the present state defined by risk factor class, disease state, sex 
and age. All dependencies in the Chronic Diseases Model relevant to diabetes prevention are 
illustrated in figure 1.    
 
The disease incidence rates depend on the risk factor class, using relative risk values. E.g., 
‘overweight’ persons have higher diabetes risks than persons with ‘normal weight’. For non diseased, 
the mortality rates depend on risk factor class, e.g., obese persons have higher mortality risks than 
persons with a normal weight. The mortality rates also depend on the disease states, but are 
conditional hereon independent on the risk factor values. E.g., the excess mortality risks of people 
with diabetes compared to people without diabetes are equal for all weight states. 
 
As depicted in figure 1, interventions that affect BMI directly influence the incidence of diabetes, 
cardiovascular diseases, musculoskeletal disorders, (six forms of) cancer and total mortality (see tables 
4 and 5 for relative risks). Physical activity is related to diabetes, coronary heart disease, (two forms of) 
cancer and total mortality (tables 4 and 6). Diabetes is related to increased incidence of cardiovascular 
disease (table 7). All patients have higher mortality risks as compared to disease free persons.  
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Figure 1. Dependency relations between risk factors, diabetes mellitus, cardiovascular diseases, other 
(related) diseases and mortality 
 
Data on risk factors were obtained from representative national or regional surveys, disease incidence 
and prevalence data were obtained from national registries in general practice (nearly all non-
institutionalized people in the Netherlands are registered by a general practitioner) and cancer 
registries. Relative risks were obtained from international epidemiological literature. Sources and 
references for input data are given in table 1. The higher mortality risks of patients compared to 
disease-free persons were calculated from published relative survival proportions for types of cancer, 
and from incidence and prevalence figures for other chronic diseases, using an Incidence, Prevalence, 
Mortality (IPM) model (8). All input data were specified by gender and age (2). 
 
We assumed that all risk factors that are distinguished are independently distributed, e.g. we assumed 
that the distribution of physical inactivity is independent from BMI. All disease incidence risks were 
made dependent on these risk factors by multiplying the baseline risk with relative risk values 
specified by risk factor class. Adjusted relative risks were used (i.e. the relative risk for physical 
inactivity on diabetes was adjusted for BMI). Moreover, we assumed for some disease pairs 
independent effects of one disease on the other. E.g., people with diabetes have higher risks of 
myocardial infarction compared to people without diabetes, independently from overweight and the 
other risk factors.  
 
Diabetes
CHDBMI 
All cause mortality Physical 
activity 
CHF
CVA
Cancers 
Musculoskeletal disorders
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Data used 
 
 
Table 1. Input data for the model and the sources. 
Input data Source 
Population numbers Statistics Netherlands 
Total mortality in population Statistics Netherlands 
Prevalence rates of risk factors 
           - body weight and physical activity 
National representative data sources  
- lifestyle monitoring surveys from Statistics 
Netherlands 
Transition rates for risk factors  
(e.g. body weight increases when ageing) 
Derived from prevalence rates (9)  
Disease incidence and prevalence rates General practice registrations, cancer 
registration (8)  
Relative risks 
- risk factor / disease combinations 
- risk factor / mortality combinations 
- disease / disease combinations 
Literature reviews (2,10) 
Weights for quality of life (DALYs) Burden of Disease Studies (11-14)  
Costs of diseases Dutch Costs of illness study (15,16) 
 
 
 
Table 2. Incidence and prevalence rates for diabetes and health care costs for diabetes treatment for 
men (M) and women (F) in the Netherlands. 
Age incidence 
per 1000 per year 
prevalence % costs in 2004 €   
per patient per year (15) 
 M F M F M /F 
20-25 0.5 0.5 0.3 0.3 1840 
25-30 0.6 0.8 0.3 0.4 1700 
30-35 1.2 0.7 0.6 0.6 1580 
35-40 1.4 1.6 1.0 0.7 1480 
40-45 2.7 2.1 1.2 1.1 1400 
45-50 5.1 2.7 2.1 1.9 1330 
50-55 9.0 4.3 4.4 2.9 1290 
55-60 9.2 7.9 7.0 4.7 1280 
60-65 13.1 12.2 9.4 7.4 1290 
65-70 13.6 13.0 11.4 11.1 1320 
70-75 18.8 16.1 13.0 12.8 1390 
75-80 12.4 17.0 14.8 15.0 1480 
80-85 12.3 14.2 14.4 15.7 1600 
85+ 15.4 12.9 13.0 15.9 1750 
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Table 3. Prevalence rates (%) for overweight and activity for men (M) and women (F) in the 
Netherlands. 
Age Overweight (%) Activity (%) 
 
 Normal Overweight Obesity Norm 
active 
Medium 
active 
Inactive 
 M F M F M F M F M F M F 
20-25 79 80 18 16 3 4 46 42 42 43 12 15 
25-30 59 70 32 21 8 9 49 49 42 44 9 7 
30-35 55 64 35 25 10 12 48 52 44 43 8 5 
35-40 51 62 38 25 11 14 48 55 43 40 9 5 
40-45 44 58 43 28 13 14 47 56 44 37 9 7 
45-50 39 56 46 32 15 13 45 55 45 37 10 8 
50-55 34 44 48 38 18 18 43 55 45 37 12 8 
55-60 36 43 45 37 19 20 65 67 27 25 8 8 
60-65 37 44 49 39 14 18 75 72 18 19 7 9 
65-70 41 38 45 43 14 19 75 69 16 20 9 11 
70-75 37 35 50 45 14 21 71 59 16 24 13 17 
75-80 48 40 41 43 11 17 65 46 16 26 19 28 
80-85 53 44 38 39 9 17 54 31 21 25 25 44 
85+ 55 53 39 36 6 11 40 16 27 21 33 63 
Statistics Netherlands: Overweight 2000-2002 (adjusted for self reporting); Activity 2001-2003  
 
 
Table 4. Relative risks for diabetes mellitus for men (M) and women (F) for overweight and activity (2) 
 Overweight Activity 
 
 Normal Overweight Obesity Norm active Medium Inactive 
 M F M F M F M F M F M F 
20-25 1.0 1.0 4.9 3.7 21.1 23.7 1.0 1.0 1.1 1.2 1.5 1.4 
25-30 1.0 1.0 3.7 3.7 17.4 19.3 1.0 1.0 1.1 1.2 1.5 1.4 
30-35 1.0 1.0 3.6 3.3 16.2 13.3 1.0 1.0 1.1 1.2 1.5 1.4 
35-40 1.0 1.0 3.2 3.1 15.6 13.8 1.0 1.0 1.1 1.2 1.5 1.4 
40-45 1.0 1.0 2.8 2.9 11.8 12.3 1.0 1.0 1.1 1.2 1.5 1.4 
45-50 1.0 1.0 2.6 2.6 9.7 9.5 1.0 1.0 1.1 1.2 1.5 1.4 
50-55 1.0 1.0 2.4 2.5 7.8 8.8 1.0 1.0 1.1 1.2 1.5 1.4 
55-60 1.0 1.0 2.2 2.3 5.9 7.0 1.0 1.0 1.1 1.2 1.5 1.4 
60-65 1.0 1.0 1.9 2.0 4.6 5.2 1.0 1.0 1.1 1.2 1.5 1.4 
65-70 1.0 1.0 1.8 1.9 3.1 3.8 1.0 1.0 1.1 1.2 1.5 1.4 
70-75 1.0 1.0 1.6 1.6 2.5 2.9 1.0 1.0 1.1 1.2 1.5 1.4 
75-80 1.0 1.0 1.4 1.4 1.9 2.1 1.0 1.0 1.1 1.2 1.5 1.4 
80-85 1.0 1.0 1.2 1.2 1.5 1.6 1.0 1.0 1.1 1.2 1.5 1.4 
85+ 1.0 1.0 1.1 1.1 1.1 1.2 1.0 1.0 1.1 1.2 1.5 1.4 
 
- 78 - 
Table 5. Relative risks for mortality and diseases (other than diabetes) for overweight and obesity, as 
compared to normal body weight (reference class; RR=1.0). The relative risks are ranges, because of 
variation by age. In general, the risks decline in older ages (10). 
        Risk factor class  Overweight Obesity 
 
 M F M F 
Total mortality 1.0-1.2 1.0-1.2 1.2 -1.9 1.2- 2.1 
Coronary heart disease  1.0-1.4 1.0-1.5 1.0 -2.2 1.0-2.5 
Heart failure 1.2 1.2 1.4 -1.5 1.5 
Cerebro vascular disease 1.0-1.1 1.0-1.2 1.0 -1.4 1.0 -1.4 
Artrosis – knee 1.1-2.3 1.1-2.3 1.2 -6.4 1.2 -6.4 
Artrosis – hip 1.2-1.3 1.2-1.3 1.5 -1.6 1.5 -1.6 
Low back pain 1.0 -1.2 1.0 -1.2 1.1 -1.6 1.1 -1.6 
Cancer – rectum 1.1 1.1 1.2 -1.3 1.3 
Cancer – colon 1.2 1.2 1.4 -1.6 1.5 -1.7 
Cancer – breast - 1.1 -1.2 - 1.0 -1.7 
Cancer – prostate 1.0 -1.1 - 1.1 -1.3 - 
Cancer – kidney 1.0 -1.8 1.0 -1.8 1.0 -3.6 1.0 -3.6 
Cancer – cervical - 1.6 - 2.5 
 
 
 
Table 6. Relative risks for mortality and diseases other than diabetes for medium activity and 
inactivity as compared to norm activity (reference category; RR=1.0) (10).  
Class of activity Medium active Inactive 
 
Age category < 60 yrs  60 yrs < 60 yrs  60 yrs 
 M F M F M F M F 
Total mortality 1.1 1.1 1.1 1.1 1.4 1.4 1.4 1.4 
Coronary heart disease  1.2 1.2 1.2 1.2 1.8 1.8 2.0 2.0 
Cerebro vascular disease 1.2 1.2 1.3 1.3 2.0 2.0 2.2 2.2 
Colon cancer 1.1 1.7 1.1 1.7 1.1 1.7 1.1 1.7 
Breast cancer - 1.1 - 1.1 - 1.3 - 1.3 
 
 
 
Table 7. Relative risks for cardiovascular diseases for people with diabetes as compared to people 
without diabetes (reference category; RR=1.0). The relative risks are ranges, because of variation by 
age. In general, the risks decline in older ages (2).   
 M F 
Chronic heart failure 1.1 - 10.0 1.1 - 10.0 
Coronary heart disease  1.5 - 2.1 1.8 - 3.2 
Cerebro vascular disease 1.0 - 3.1 1.0 - 3.1 
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Table 8. DALY weights derived in the Global Burden of Disease 1990 study for relevant diseases. 
Some DALY weights are expressed in ranges because of variation by age (11).   
 M F 
Diabetes 0.03 0.03 
Acute myocardial infarction 0.40 0.40 
Other coronary heart disease  0.17 0.17 
Heart failure 0.17 0.17 
Cerebrovascular disease 0.26 0.26 
Artrosis hip / knee 0.16 0.16 
Low back pain 0.07 0.07 
Cancer – rectum / colon 0.24-0.25 0.24-0.25 
Cancer – breast 0.09-0.11 0.09-0.11 
Cancer – prostate 0.14-0.15 - 
Cancer – kidney 0.19-0.27 0.28-0.44 
Cancer – cervical - 0.09-0.14 
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Cost-effectiveness of lifestyle modification in diabetes patients  
 
 
 
ABSTRACT 
 
Objective - To explore the potential long-term health and economic consequences of lifestyle 
interventions for diabetes patients.  
Research Design and Methods - A literature search was performed to identify interventions 
for diabetes patients in which lifestyle issues were addressed. We selected recent (2003-2008), 
randomized controlled trials with a minimum follow-up of 12 months. The long-term 
outcomes for these interventions, if implemented in the Dutch diabetes population, were 
simulated with a computer-based model. Costs and effects were discounted at respectively 
4% and 1.5% annually. A life-long time horizon was applied. Probabilistic sensitivity 
analyses were carried out, taking account of variability in intervention costs and (long-term) 
treatment effects.  
Results - Seven trials with 147 to 5,145 participants, met our pre-defined criteria. All 
interventions improved cardiovascular risk factors at  one year follow-up and were 
projected to reduce cardiovascular morbidity over lifetime. The interventions resulted in an 
average gain of 0.01 to 0.14 quality adjusted life-years (QALYs) per participant. Health 
benefits were generally achieved at reasonable costs (≤ €50,000/QALY). A self-management 
education program (X-PERT) and physical activity counseling achieved the best results with 
≥ 0.10 QALYs gained and ≥ 99% probability to be very cost-effective (≤ €20.000/QALY).  
Conclusions - Implementation of lifestyle interventions would probably yield important 
health benefits at reasonable costs. However, essential evidence for long-term maintenance 
of health benefits was limited. Future research should focus on long-term effectiveness and 
should compare multiple treatment strategies to determine incremental costs and benefits of 
one over the other.  
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BACKGROUND 
Compared to lifestyle interventions for persons at high risk for diabetes, the long-term health 
and economic consequences of lifestyle interventions for diabetes patients are relatively 
unknown (1). This is noteworthy, since diabetes patients have a high risk for (cardiovascular) 
complications and therefore, improving lifestyle is also worthwhile in this population. 
Furthermore, optimal management of lifestyle issues, often addressed within the context of 
self-management programs, is increasingly acknowledged as an essential part of diabetes 
treatment, and incorporated in most national standards of care (2). Additional knowledge 
about long-term effects of these interventions is required to be able to identify the most 
successful strategies. Since the common aim of self-management, education, diets, lifestyle- 
and exercise interventions is to reduce cardiovascular risk through lifestyle modification, we 
will refer to all of them as lifestyle interventions.  
Trials are generally too short to capture the long-term benefits of an intervention, and 
epidemiological modeling can be used to fill this gap. By combining available evidence from 
different sources, modeling enables predictions of future outcomes and can be regarded as a 
valuable tool in addition to long-term trials. However, there is an important difference 
between modeling pharmaceutical and lifestyle interventions. With pharmaceutical 
interventions, the assumption is that if you keep taking the drug, you keep getting the 
benefits. If you stop taking the drug, you lose the benefits but the costs of the intervention 
cease. With lifestyle interventions, the costs are up front costs and long-term outcomes are 
substantially affected by the extent to which health benefits are sustained after the 
intervention has stopped. Therefore, modeling lifestyle interventions requires explicit 
assumptions about how lifestyle changes are sustained over time (3;4).  
The aim of our study is to explore the long-term outcomes of lifestyle interventions for 
diabetes patients. We use a computer-based simulation model to project long-term health 
benefits and cost-effectiveness, assuming implementation in the Dutch diabetes population.   
 
RESEARCH DESIGN AND METHODS 
Selection of trials  
A literature search was performed to identify randomized controlled trials of patient-
centered interventions, in persons with type 2 diabetes, in which lifestyle issues (at least 
nutrition and/or exercise) were addressed. Inclusion criteria were: recent publication (2003-
2008), large trial (n >150), a minimum follow-up of 12 months, mainly Caucasian population, 
risk factor outcomes reported (weight, BMI, physical activity, smoking, diet, glycemic 
control, lipids and/or blood pressure) and sufficient information to be able to calculate 
intervention costs. In addition we searched for studies that provided quantitative 
information about long-term maintenance of health benefits achieved through lifestyle 
interventions. Selection criteria for these studies as well as the methods for determining long-
term maintenance estimates are described in the online Appendix.   
 
Model input 
Intervention effect was defined as a significant change in risk factor outcome for intervention 
participants compared to controls, at the latest follow-up. Long-term maintenance for each 
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risk factor was defined as the proportion of the intervention effect that could be expected to 
sustain over lifetime. For each risk factor, intervention effect was multiplied with long-term 
maintenance to estimate the average intervention effect over lifetime. Calculations of 
intervention costs were based on publications and additional information provided by 
authors. We assumed that the interventions would be implemented as described, but with a 
minimum of two patient contacts during the first two years (to enhance long-term 
maintenance). We accounted for additional intervention costs if these requirements were not 
met in the original intervention.  
 
The Chronic Diseases Model 
The CDM is a Markov type simulation model, developed at the Dutch National Institute for 
Public Health and the Environment (RIVM). The model simulates developments for the 
Dutch diabetes population and is well suited to explore long-term consequences of lifestyle 
changes. The model combines epidemiological data to quantify the associations between 
multiple risk factors and chronic diseases, such as cardiovascular diseases and cancers 
(Appendix, Figure A1 and Table A1). The model does not include micro vascular 
complications. Starting from base-line distributions over risk factor classes and diseases, one-
year state transitions determine future developments. State transition probability values 
depend on a persons risk level, determined by age, gender, risk factor class and prevalent 
disease. Estimates of the strengths of the associations between risk factors and diseases are 
based on international, observational studies. The CDM has previously been used to evaluate 
long-term outcomes for diabetes prevention and diabetes treatment and to explore the 
impact of lifestyle risk factors on healthy life expectancy and life-time medical costs (5-8).  
 
Long-term health benefits 
We explored the long-term health benefits of the interventions by comparing simulated 
outcomes for a reference cohort and an intervention cohort. Both cohorts represented Dutch 
diabetes patients eligible for each specific intervention. The intervention cohort differed from 
the reference cohort (usual care) by an altered risk factor distribution at the start of the 
simulation, based upon the trials results. For example, participants in the ICAN trial lost 2.4 
kg of baseline weight compared to a weight gain of 0.6 kg in controls; a difference of 3 kg, or 
2.8% of baseline weight ( BMI). The long-term maintenance estimate for BMI was 35% (see 
results) and consequently, ICAN participants were assumed to have an average 
2.8%*35%=1.0% lower BMI over lifetime, compared to patients receiving usual care. We used 
a large Dutch diabetes data-base to determine how this difference affected BMI risk factor 
class distributions at the start of the simulation.  
Once the simulation had started, the same state-specific transition probabilities were applied 
to both reference and intervention cohorts. Cumulative life-time incidence of cardiovascular 
disease (CVD = AMI + CHD + CHF + stroke) and (quality adjusted) life years, were 
simulated for these cohorts as well as for 60-year old participants. 
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Cost-effectiveness 
Economic analyses were performed from a health care perspective. Participants were eligible 
Dutch diabetes patients. Intervention costs were determined by multiplying resource use 
with Dutch unit costs in 2007. The incremental effects on the costs of care were calculated 
from the model simulations as follows: All model states in the CDM were associated with 
health care costs, depending on age, gender and disease state. These costs represent total 
medical costs, including costs for ‘unrelated’ diseases such as dementia and mental illness 
(9). For each intervention net present values of incremental costs were calculated by 
summing the discounted costs over all simulation years and taking the difference with the 
reference scenario (usual care). Cost-effectiveness ratios (CER) were calculated as (Δ 
intervention costs + Δ lifetime medical costs) / Δ quality adjusted life-years (QALYs) for each 
intervention. In the base-case analyses, clinical benefits and costs were discounted at 1.5% 
and 4% annually, in accordance with Dutch guidelines. The simulations were run for closed 
cohorts, with a lifelong time horizon. 
 
Sensitivity analyses 
One way sensitivity analyses were performed to explore the impact of discount rates, time 
horizon and additional long-term intervention costs on the cost-effectiveness of the 
interventions. Probabilistic sensitivity analyses were performed, taking account of 
uncertainty in intervention effects, long-term maintenance and intervention costs. For each 
intervention 200 random, independent drawings were taken from the distributions for effect, 
maintenance and costs. Intervention effect and maintenance estimates were multiplied to 
generate ‘long-term effect’ estimates. We took into account that changes in lifestyle risk 
factors may be correlated. For example, participants with the largest increase in physical 
activity may also achieve the largest weight loss (10-12). Since quantitative information about 
all possible combinations of risk factor outcomes is limited (and sometimes inconsistent) we 
assumed respectively 0% and 100% correlation between the long-term effect estimates of all 
risk factors affected. To do so, the ‘long-term effect estimates’ for each risk factor were 
ordered, before they were combined. Consequently, a low (high) effect estimate for one risk 
factor was combined with low (high) estimates for all other risk factors affected. For 
intervention costs we considered variation in total contact time of the interventions and we 
varied the number of participants in group activities.  
 
RESULTS 
Selected trials  
Seven trials fulfilled all pre-defined criteria. The interventions differed by scope, focus, 
content, intensity and target population. Intervention duration ranged from six hours to 24 
months. The included trials were:  
 DESMOND: a 6-hour self-management education program for newly diagnosed patients 
(n=824) evaluated at 12 months (13) 
 Beyond Good Intentions (BGI): a 12-week self-management course for screen-detected 
patients (n=196) evaluated at 12 months (14) 
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 Look AHEAD: a one-year intensive lifestyle intervention for overweight patients 
(n=5145) evaluated at 12 months (15) 
 Mediterranean lifestyle program (MLP): a 6-month lifestyle program for 
postmenopausal women with diabetes (n=279) followed by two different maintenance 
programs, evaluated at 24 months (16) 
 X-PERT: a 6-week, structured self-management education program for diabetes patients 
(n=314) evaluated at 14 months (17) 
 Improving Control with Activity and Nutrition (ICAN): a one-year moderate intensity 
lifestyle intervention for overweight patients (n=147) evaluated at 12 months (18) 
 Counseling for physical activity (CPA): a two-year structured counseling intervention to 
promote physical activity (n=340) evaluated at 24 months (10) 
The selected trials, calculations of intervention costs and characteristics of the simulated 
cohorts are described in Appendix, Tables A2 to A5.  
 
Model input 
Significant reductions in risk factors were obtained in all trials (Table 1). Based on the long-
term results from five other trials (see Appendix) we assumed that on average, respectively 
85%, 55% and 35% of the initial effects for HbA1c, physical activity and BMI (and all other risk 
factors) could be sustained over life-time. We assumed slightly better maintenance for MLP 
and CPA, since ‘initial effects’ in these trials were measured at 24 months follow-up. Total 
intervention costs, incurred over two years, ranged from €124 to €584 per participant (Table 
1).  
 
Table 1. Model input: intervention costs and intervention effects   
Total per 
participant 
costs for the 
interventions * 
BMI % 
decrease 
HbA1c 
decrease 
Physical 
activity 
increase 
SBP 
decrease 
Smokers 
% who 
quit 
Fruit / 
vegetables 
increase 
Saturated 
fat % 
decrease 
DESMOND 1.1 0.3 ns % active: 0 mmHg 15 NA NA 
€ 206   -1 ns ns    
BGI 2.6 0 ns NA 6 mmHg NA NA NA 
€ 248        
Look AHEAD 7.9 0.5 NA ‡ 4 mmHg NA NA NA 
€ 503        
MLP  2.5 ns † 0.1 ns 45 MET 1 mmHg NA 0.1 portion 2% 
€ 584   min/wk ns  (80g) fruit  
X-PERT 2.0 0.7 20  3 mmHg NA 1 portion 0.4% ns 
€ 124   min/wk ns  (80g) each  
ICAN  2.8 0.2 ns NA NA NA NA NA 
€ 373        
CPA  3.4 0.5 24 MET NA NA NA NA 
€ 345   h/wk     
ns: not significant; NA: not available 
* Details are provided in Table A2 in the online appendix  
† This was the only non significant effect that was included in the simulations.   
‡ Significant increase in fitness  
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Long-term health benefits 
The interventions were projected to reduce lifetime cumulative incidence of cardiovascular 
complications by 1 to 54 per 1000 participants (Table 2). In other words, the number needed to 
treat to prevent one new cardiovascular complication over lifetime was 19 to 1000. The 
relative reduction in expected lifetime CVD incidence ranged from 0.1 to 6.1%. The 
interventions increased life expectancy by 0.02 to 0.34 years and (discounted) QALYs by 0.01 
to 0.14. For 60-year old participants (Appendix, Table A6) life-expectancy increased by 0.02 to 
0.42 years and (discounted) QALYs by 0.01 to 0.18. The physical activity intervention (CPA) 
had the largest simulated health gains. This intervention increased life expectancy of 60-year 
old participants by 0.42 years, while average time spent with CVD complications decreased 
by 0.06 and 0.07 years for stroke and CHD respectively (data not shown).  
 
Table 2. Clinical benefits and health care costs for intervention participants compared to usual care 
 Incident CVD 
prevented * 
Life years gained 
per participant 
QALYs gained 
per participant † 
Increase in total 
health care costs € 
per participant ‡ 
DESMOND 1 of 761 (0.1%) 0.02 0.01 63 
BGI 12 of 835 (1.4%) 0.09 0.04 215 
Look AHEAD 33 of 828 (4.0%) 0.18 0.08 475 
MLP 7 of 776 (0.9%) 0.05 0.02 125 
X-PERT 38 of 768 (5.0%) 0.21  0.09  718 
ICAN 2 of 888 (0.2%) 0.02 0.01 30 
CPA 54 of 881 (6.1%) 0.34 0.14 1128 
* absolute reduction in cumulative lifetime incidence of new CVD complications per 1000 participants, 
expected cumulative number of new CVD complications without intervention (per 1000 patients in 
the reference cohort) and between brackets, relative reduction achieved through the intervention  
† discounted with 1.5% annually; ‡ discounted with 4% annually 
 
Cost-effectiveness 
Despite prevented costs for complications, all interventions were projected to increase health 
care costs over lifetime, due to increased survival (Table 2). The base-case CERs ranged from 
10,000 to 39,000 €/QALY (Table 3). Four interventions (BGI, X-PERT, Look AHEAD and 
CPA) had average CER below €20,000/QALY even with equal discounting of costs and 
effects, a 20-year time-horizon or additional lifetime intervention costs. In the probabilistic 
sensitivity analyses (for which details are provided in Appendix Tables A7 to A9), these 
interventions had > 85% probability to remain below €20,000/QALY (Table 3).  
As expected, assuming 100% correlation between risk factor outcomes increased the 
variability of the simulated outcomes (Appendix, Table A10). For example for Look AHEAD, 
QALYs increased by 0.03-0.12 if outcomes were assumed to be independent and by 0.01-0.15 
with 100% correlation. Similarly, the variability in simulated health care costs and CERs was 
higher if outcomes were assumed to be correlated (data not shown). The cost-effectiveness 
acceptability curves for the interventions, assuming correlated outcomes, are displayed in 
Figure 1.      
In the base-case analyses, immediate cost-savings through reduced medication use (reported 
for X-PERT, Look AHEAD and ICAN) were not taken into account and additional analyses 
were performed to explore the potential impact of these additional intervention benefits 
- 89 - 
0
20
40
60
80
100
5000 15000 25000 35000 45000 55000 65000
Value of ceiling ratio (€/QALY)
Pr
ob
ab
ili
ty
 c
os
t-e
ffe
ct
iv
e 
(%
)
DESMOND BGI
Look AHEAD MLP
X-PERT ICAN
CPA
(Table 3). Although economic outcomes for the three interventions improved, the main 
results as summarized above were not substantially changed.  
 
Table 3. Results for cost-effectiveness (€/QALY): base-case and sensitivity analyses 
 lifetime 
DC 1.5-4 
base-case 
lifetime 
DC 0-0 
lifetime 
DC 3-3 
20 years 
DC 1.5-4 
additional 
costs * 
% below 
€20.000 
DESMOND 32,000 35,000 43,000 39,000 62,000 5.0†/ 9.0 ‡ 
BGI 12,000 18,000 17,000 9000 19,000 91.5/86.0 
Look AHEAD 12,000 19,000 18,000 11,000 16,000 98.5/90.5 
MLP 33,000 35,000 43,000 38,000 46,000 1.0/ 2.5 
X-PERT 10,000 17,000 15,000 8000 13,000 100/100 
ICAN 39,000 38,000 52,000 52,000 68,000 4.0/NA 
CPA 10,000 18,000 15,000 8000 12,000 100/ 99.5 
Look AHEAD §  11,000 18,000 16,000 9000 15,000 99.5/95 
X-PERT §  9000 16,000 13,000 6000 12,000 100/100 
ICAN §  30,000 30,000 39,000 38,000 59,000 16.0/ NA 
DC: annual discount rates for effects and costs  
NA: not available, just one risk factor affected 
* assuming one additional 30 minutes individual contact (€27) per year for the remaining lifetime, 
starting from year three 
 † independent intervention effects for affected risk factors  
‡ dependent intervention effects for affected risk factors (100% correlation)  
§ assuming an average €100 per patient reduction in life-time health care costs due to reduced 
medication use 
 
 
Figure 1. Cost-effectiveness acceptability curves for each intervention 
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CONCLUSIONS 
We showed that it is feasible to simulate long-term outcomes for different kinds of lifestyle 
interventions for diabetes patients. However, due to limited information about long-term 
maintenance of health benefits, there was substantial variability (uncertainty) in the expected 
long-term outcomes for each intervention. Large differences in health outcomes were also 
observed between interventions (0.01 to 0.14 QALYs gained). However, despite this 
variability, health gains were generally achieved at reasonable costs (≤ €50,000/QALY). Self-
management education (X-PERT) and physical activity counseling (CPA) achieved the most 
promising results with ≥ 0.10 QALYs gained per person and a very high probability to be 
cost-effective.  
Overall, the results of the selected trials were consistent with results from several meta-
analyses that generally showed 0.3-0.8% improvements in HbA1c and modest (1.5 kg) 
reductions in weight achieved through non-pharmacological diabetes interventions (2;19;20). 
However, we want to highlight some interesting results. First, substantial weight loss was 
achieved in the Look AHEAD trial. This intervention focused on weight loss, mainly through 
caloric restriction, and included meal replacement products and weight loss medication (12). 
Although substantial short-term weight loss with caloric restriction has been reported 
previously (21), long-term results of Look AHEAD must be awaited to see whether these 
weight losses are sustained long-term. Second, the major increase in voluntary physical 
activity in the CPA trial (23 MET hours per week, corresponding to one addition hour of 
brisk walking per day) was much larger than the average 20 to 60 minutes of additional 
physical activity per week generally seen in other studies (22). Although the CPA intervention 
combined multiple evidence-based treatment strategies to enhance physical activity, it 
remains to be seen whether its findings can be replicated in other settings. Finally, three trials 
reported a decrease in medication use which is an important, relatively new finding, since 
health care utilization outcomes were not assessed in any of 21 diabetes self-management 
trials included in a previous review (23).   
Our study has several important strengths. The large number of participants in each of the 
studies indicates that implementation in regular care is probably feasible. To ensure that 
health benefits were sustained for a reasonable period of time, we only used intervention 
effects that were measured at least 12 months after the start of the intervention. In addition, 
we required interventions to be continued (with at least two counseling sessions) in the 
second year. Long-term maintenance estimates were based on the best evidence available, 
and the impact of uncertainty in these estimates was explored in extensive sensitivity 
analyses. Finally, since changes in various lifestyle habits may go together we considered the 
impact of correlated outcomes (10;11).  
Some methodological issues should be considered. Our simulations were based upon 
randomized trial results and it may be difficult to replicate these findings in daily practice. 
On the other hand, there are some reasons to believe that our health benefits might be 
underestimated. First, only risk factors included in the model could be used and 
consequently reported improvements in waist circumference, diastolic blood pressure, 
lipids, fitness and psycho-social outcomes were not taken into account. Second, our model 
does not include micro vascular complications. Although long-term health outcomes and 
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health care costs are mainly determined by macro vascular diabetes complications, excluding 
micro vascular disease results in an under-estimation of health benefits, especially in case of 
improved glycemic control. Finally, enhanced standard care was provided to controls in 
three trials (13;15;17) and for these interventions we may have underestimated the effects in 
relation to the assumed resources used. On the other hand, large variation also exists in the 
extent to which lifestyle issues are currently addressed in Dutch usual care.  
Since promotion of a healthy lifestyle is already acknowledged as an essential part of 
diabetes treatment the question is no longer if lifestyle issues should be addressed, but how 
to find the most (cost)effective strategies for specific groups of patients. For example, Look 
AHEAD and ICAN were both directed at overweight diabetes patients. Although Look 
AHEAD seemed to dominate ICAN (larger health benefits and lower CER), these trials used 
different inclusion criteria and outcome measures and therefore, results could not be 
properly compared. In addition, favorable efficacy and cost-effectiveness are not sufficient 
and potential Reach, Effectiveness, Adoption, Implementation and Maintenance issues (RE-
AIM) of interventions should also be addressed (24). Since numerous factors influence the 
effectiveness of lifestyle interventions, standardized descriptions of intervention components 
are required to identify successful strategies and to enhance replication and implementation 
in regular care (23;25).  
We showed that lifestyle interventions can probably improve long-term health of diabetes 
patients at reasonable costs. Future research should focus on long-term maintenance of 
health benefits achieved through lifestyle interventions and should directly compare 
multiple treatment strategies to determine incremental costs and benefits of one over the 
other. Since the potential benefits of successful lifestyle interventions are huge, we should be 
investing much more in gathering this valuable information.  
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Appendix Chapter 5  
 
Estimating long-term maintenance  
 
Selection of trials 
To determine long-term maintenance of treatment effect we searched for studies that met the 
following criteria: 
 controlled lifestyle intervention trial with at least 100 participants (intervention (I) + controls (C))  
 with either impaired glucose tolerance or diabetes 
 at least three measurements of BMI, HbA1c, physical activity, smoking, SBP or nutrition 
 t1=baseline measurement  
 t2= measurement after active / intensive intervention phase  
 t3= measurement after maintenance / less intensive / follow-up phase 
 t1-t2 and t2-t3 at least 12 months 
 significant intervention effect between t1 and t2   
 
Maintenance (%) was defined as: (Δ t3-t1 (I) - Δ t3-t1(C)) / (Δ t2-t1 (I) - Δ t2-t1(C)) 
For example: 
BMI (kg/m2) t1 t2 t3 t2-t1 t3-t1 
I 30.0 28.5 29.5 -1.5 -0.5 
C 30.5 30.5 31.0 0 +0.5 
Δ    1.5 1.0 
maintenance=1.0/1.5=67% 
 
Results 
Five trials (six publication) met our criteria:  
 Diabetes Prevention Program (DPP) 1 
 Diabetes Prevention Study (DPS) 2,3 
 China Da Qing Diabetes Prevention Study 4  
 An educational intervention for diabetes patients 5 
 A one-month residential lifestyle intervention 6 
 
The results of these trials are plotted in figures 1 (BMI), 2 (glycemic control) and 3 (physical activity). 
We fitted a trend line by using the logarithmic equation (y=clnx+b) for each intervention. Lifetime 
average maintenance was estimated from the figures as the average of the trials at six years of follow-
up (the average expected lifetime of participants in the trials was almost 15 years). Estimated long-
term maintenance was 35% for BMI, 85% for glyceamic control and 55% for physical activity.  
Only two studies provided information for systolic blood pressure with respectively >100% sustained 
after two years 7 and 35% sustained after four years 6. We found ≤ one study with information about 
maintenance for other risk factors. For these risk factors (SBP, nutrition and smoking) we assumed 
that maintenance would be similar to maintenance for BMI (35%). The assumed distributions for long-
term maintenance are given in Table A8 in this appendix. 
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Figure 1. Long-term maintenance for BMI
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Figure 2. Long-term maintenance for glycemic control
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Figure 3. Long-term maintenance for physical activity
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Figure A1. Schematic representation of the Dutch Chronic Diseases Model 
 
          potential transitions                       states influence transition rates 
BMI: Body Mass Index (kg/m2); HbA1c: glycemic control (%); SBP: systolic blood pressure (mmHg); TC: total cholesterol (mmol/l); 
fruit (g); vegs: vegetables (g); sat fat: saturated fat (%)   
CHD: coronary heart disease (angina pectoris); AMI: acute myocardial infarction; CHF: chronic heart failure   
Cancer: 15 subtypes; other diseases: asthma, COPD, dementia, musculoskeletal disorders (5 types)  
Disease state = (history) of disease (event), recurrent events not possible  
Model starts with Dutch (diabetes) population specified by age gender, risk factor distribution and disease prevalence 
Model simulates yearly transitions and tracks population numbers in each state for each risk factors and disease, not for joint states 
Qalys and health care costs are calculated; Closed cohort simulation until extinction 
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Table A1. Associations between risk factors, diseases and mortality in the Chronic Diseases Model 
 Diseases       
Risk factor Stroke CHD AMI CHF Cancer(s)  Other Mortality 
BMI X X X X X X X 
HbA1c X X X     
Physical 
activity 
X X X  X  X 
Smoking X X X X X X X 
SBP X X X X   X 
Total 
cholesterol 
 X X    X 
Fruit X X X  X   
Vegetables  X X  X   
Saturated fat  X X     
Stroke  X X X   X 
CHD   X X   X 
AMI    X   X 
CHF       X 
Cancers       X 
Others        
BMI: Body Mass Index; HbA1c: glycemic control; SBP: systolic blood pressure (mmHg)   
CHD: coronary heart disease (angina pectoris); AMI: acute myocardial infarction; CHF: chronic heart 
failure   
Cancers: 15 subtypes; Other: asthma, COPD, dementia, musculoskeletal disorders (5 types)  
Patients in unfavorable risk factor classes (for example BMI 25-30 or BMI>30) have higher relative 
risks for all X-marked outcomes compared to patients in the reference class (BMI<25).  
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Table A2. Characteristics and results of the selected trials  
Reference Study characteristics Intervention  
Control 
Outcome  Comments 
 
Davies 2008 8 
DESMOND 
program 
 
 
Multi-center RCT (UK) 
824 newly diagnosed 
diabetes patients 
mean age 60 range 28-87 
mean weight 91.8 (19.2)  
mean Hba1c 8.3 (2.2) 
 
 
6 hour structured group 
education  
based on psychological 
theories of learning  
 
enhanced usual care 
 
 
Treatment differences at 12 months: 
weight reduction: 1.0 (0.1-1.9) kg 
% smokers  
from 14% to 11% (intervention group) stable 
(16%) in controls 
 
10-year CVD risk  
from 19% to 11% (intervention group) from 
18% to 14% in controls 
 
greater improvements in CHD risk 
score, depression score and 
knowledge.  
no effect on HbA1c (nor with 
adjustment for oral medication) or 
quality of life 
response 12-monts questionnaire 
75% 
 
large improvements in HbA1c in 
both groups, financial rewards for 
good CVD control in UK, difficult to 
have additional improvements in 
newly diagnosed  
 
Thoolen 2007 9 
Beyond Good 
Intentions (BGI) 
 
 
 
 
 
 
 
RCT (Netherlands) 
196 screen-detected diabetes 
patients from the Dutch arm 
of the ADDITION study,  
mean age 62 range 50-70   
mean BMI 29.6 
mean HbA1c 6.2 
 
12 week self-management 
course 
based on theories of proactive 
coping and self-regulation 
individual and group 
meetings  
 
enhanced usual care 
Intervention effect-size at 12 months:  
BMI decrease: 0.8 kg/m2 
SBP decrease: 6 mmHg 
  
no effect on HbA1c 
Pi-Sunyer 2007 10 
Look-AHEAD 
 
 
 
 
 
 
 
 
 
 
 
 
Multi-center RCT (USA) 
5145 overweight diabetes 
patients  
(±35% from ethnic / racial 
minority groups)  
mean age 59 range 45-74 
mean BMI  
36.3 (6.2) women  
35.3 (5.7) men 
mean HbA1c 7.3  
 
ongoing intensive lifestyle 
intervention (planned 
duration 4 years / follow-up 
11 years): prescribed diets 
(caloric restriction, liquid meal 
replacement and structured 
meal plans) and  
home-based exercise  
group and individual 
meetings  
main focus: weight loss 
 
enhanced usual care  
Change from baseline at 12 months for 
intervention participants versus controls:  
BMI decrease:  
8.6% (6.9) versus 0.7% (4.8) 
% achieving weight loss > 7%:  
55% versus 7% 
A1c decrease:  
0.64 (0.02) versus 0.14 (0.02) 
SBP decrease:  
6.8 (0.4) versus 2.8 (0.3)  
 
significant improvements in waist, 
fasting glucose, diastolic blood 
pressure, HDL, triglycerides, 
albumine to creatine ratio, fitness 
and % with metabolic syndrome 
reduced diabetic, antihypertensive 
and lipid-lowering medicine use 
97% attended 1-year examination 
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Reference Study characteristics Intervention  
Control 
Outcome  Comments 
 
Toobert 2007 11 
Mediterranean 
lifestyle program  
 
 
RCT (USA) 
279 postmenopausal women 
with diabetes 
mean age 60.7 (7.8) 
mean BMI: 35.6 (8.8) 
mean HbA1c 7.4 (1.3)  
 
6 months of group education 
focused on Mediterranean 
diet, exercise and stress 
management  
18 months maintenance 
condition 
using social-cognitive 
strategies and peer support 
(social support, stress 
management, graded goals, 
self-monitoring, rewards, 
videotapes)  
 
usual care 
  
 
Change from baseline at 24 months for 
intervention participants versus controls:  
reduction in % calories from saturated fat:  
3% versus 1% (24 months sign) 
Change in physical activity in MET 
min/week:  
44 versus -1 (24 months sign) 
Change in BMI:  
-0.55 versus +0.39 (6 months, sign)   
-0.32 versus +0.56 (24 months not sign) 
Decrease in HB:  
0.37 versus 0.01 (6 months, sign)   
0.34 versus 0.27 (24 months not sign) 
Increase in fruit intake 
0.36 versus 0.25 (24 months sign) 
 
 
improved problem solving and self-
efficacy   
no difference in maintenance of 
treatment effects between two 
strategies used between 6 and 24 
months 
no effect on medication 
Deakin 2006 12 
Diabetes X-PERT 
program 
 
RCT (UK)  
314 diabetes patients 
mean age 61.3 (9.7) 
mean BMI 30.8 (5.3) 
mean Hba1c 7.7 (1.6) 
6-week group-based self-
management education based 
on theoretical models of 
empowerment and discovery 
learning  
 
enhanced usual care 
 
Post-intervention difference between groups 
at 14 months / effect-size: 
BMI decrease: 0.4 (-1.0-1.7) / 0.6 
HbA1c decrease: 0.7 (0.3-1.0) / 0.7 
 
improvements in waist, physical 
activity, knowledge, diet, total 
cholesterol and less medication 
 
Wolf 2004 13 
ICAN  
 
RCT (USA) 
147 diabetes patients  
mean age 53.4 (8.0) 
BMI>27  
mean BMI 37.5 (6.4) 
mean Hba1c 7.5 (1.5) 
one year lifestyle intervention 
case-management approach to 
lifestyle change 
 
usual care 
 
Intervention effect-size at 12 months:  
weight: 3.0 (0.6-5.4) (5.0 at 8 months but 
weight regain in last 4 months) 
HbA1c difference at 4 months (0.6%) but not 
significant at 12 months (0.2%) (adjusted for 
change in medication) 
medication: -0.8/day 
 
Improved waist 
Change in weight did not predict 
change in HbA1c 
improved quality of life (7 of 9 SF-36 
domains) 
26% of intervention group dropped 
out  
 
Di Loretto 2003 14 RCT (Italy) 
one outpatient diabetes 
center 
340 diabetes patients 
mean age 62 (SE 0.7) 
mean BMI 29.3 (SE 0.2) 
mean Hb 7.6 (SE 0.1) 
Brief, two year structured 
counseling recommending 
physical activity 
 
usual care 
 
Intervention effect-size at 24 months:  
BMI decrease: 1.0 (0.7-1.3) 
HbA1c decrease: 0.5 (0.37-0.63)  
physical activity increase: 
23 (21-25) METs*h/week 
equal diets for both groups 
drop out 3/182  
intervention based on SG report 
recommendations 
ΔLA correlates with ΔBMI r=0.55 
ΔLA correlates with ΔHB r=0.63 
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Table A3. Intervention costs  
Intervention Intervention components  Calculations Total 
costs 
DESMOND 8    
intervention 1* 6-hour group session with 2 dietitians 
with 5 participants 
3 * 30 min with individual counseling with dietician † 
 
6*60* € 0.88 *2 /5 
3*30* € 0.88 
 
 
€ 206 
control practices resourced to enable equivalent contact-time 
with healthcare professionals 
  
 
BGI 9    
intervention 2 one-hour individual session with nurse 
4 two-hour group session with nurse  
with 6-8 participants 
3 * 30 min with individual counseling with dietician † 
2*60* € 0.90   
 
4*2*60* € 0.90 /7 
3*30* € 0.88 
 
  
 
€ 248 
control self-management brochure € 3.20 € 3 
LookAHEAD 10    
intervention 1 one-hour group session with ‘interventionist’ with 
15 participants 
12 20-30 min individual sessions with ‘interventionist’ 
30 group sessions (60-75 minutes) with 
‘interventionist’ with 10-20 participants 
orlistat: 20% of participants, average use 16.8 weeks  
brochure 
2 * 30 min with individual counseling with dietician † 
 
60* € 0.88 /15 
12*25* € 0.88 
 
30*67.5* € 0.88 /15 
0.2*€18*16.8 
€ 3.20 
2*30* € 0.88 
 
 
 
 
 
 
 
€ 503 
control 1 one-hour group session with interventionist * with 
15 participants 
3 group sessions (60-90 minutes) with interventionist 
with 15 participants 
brochure 
 
60* € 0.88 /15 
 
3*75* € 0.88 / 15 
€ 3.20 
 
 
 
 
€ 20 
MLP 11    
intervention 1 20-hour (2.5 days) group sessions with professional 
and assistant 
23 4-hour group meetings:   
   1-hour with physical activity leader + assistant  
   1-hour with stress management leader 
   1-hour potluck dinner with meeting leader 
   1-hour with 3 professional leaders and 3 assistants  
39 or 4 (mean 21.5) 4-hour group meetings 
20*60*  
(€ 0.88 + € 
0.66)/40 
23*€ 483/ 40 
60* (€ 0.90+€ 0.66)  
60* € 0.90  
60* € 0.90  
60*3*((€ 0.90+€ 
0.66)  
21.5*€ 483 / 40 
 
 
 
 
 
 
 
€ 584 
control -    
X-PERT 12    
intervention 6 two-hour group sessions with dietitian with 16 
participants 
manual 
3 * 30 min with individual counseling with dietician † 
 
6*2*60* € 0.88 /16 
€ 5.10 
3*30* € 0.88 
 
 
 
€ 124 
control 1 individual 30-minutes session with dietitian 
1 individual 15-minutes session with nurse 
1 individual 15-minutes session with GP 
manual 
30* € 0.88 
15* € 0.90 
15* € 2.13 
€ 5.10 
 
 
 
€ 77 
ICAN 13    
intervention 6 individual sessions with dietitian (totaling 4 hour) 
6 one-hour small group sessions with dietitian 
monthly phone contacts 
written information 
2 * 30 min with individual counseling with dietician † 
4*60* € 0.88 
6*60* € 0.88/6 
12*5* € 0.88 
€ 3,20 
 
 
 
 
€373 
control written information € 3,20 € 3 
CPA 14    
intervention 1 30-min sessions with physician 
7 15-min sessions with physician 
30* € 2.13 
7*15* € 2.13 
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Intervention Intervention components  Calculations Total 
costs 
1 15-30 min telephone call  
brochures and diary 
22* € 2.13 
3* € 3.20 
 
€345 
control brochures and diary 3* € 3.20  €10 
* dietician, psychologist, exercise specialist 
† these counseling sessions were added to the original intervention as described in order to have the 
required minimum of two annual contacts during the first two years  
 
 
Table A4. Baseline characteristics of Dutch diabetes patients (30-75 years) 
 Diabetes cohort 
N 398 016 
Men (%) 53 
BMI 25 - 30 kg/m2 (%)  41 
BMI  30 kg/m2 (%) 40 
Current smokers (%) 25 
Former smokers (%) 48 
Moderately active (%) 27 
Inactive (%) 14 
Total cholesterol  6.5 mmol/l (%) 37 
Systolic blood pressure  140 mmHg (%) 67 
Coronary Heart Disease (%) 21 
Stroke (%) 4 
Hemoglobin A1c 7-8.5% (%) 45 
Hemoglobin A1c  8.5% (%) 15 
 
 
Table A5. Eligible patients for each intervention  
Intervention Characteristics of the cohorts used for the simulations 
DESMOND Dutch diabetes population, 30-85 years. 
BGI Dutch diabetes population, 50-70 years. HbA1c < 7% 
Look AHEAD Dutch diabetes population, 45-75 years. BMI > 25 kg/m2 and SBP < 160 mmHg 
MLP Dutch diabetes population, 45-75 years. Women 
X-PERT Dutch diabetes population, 30-85 years. 
ICAN Dutch diabetes population, 35-75 years. BMI > 25 
CPA Dutch diabetes population, 40-80 years. Inactive (28%) or moderately active 
(72%) 
 
 
Table A6. Clinical benefits, health care costs and cost-effectiveness ratio’s for 60-year old 
participants  
 Incident CVD  
prevented * 
Life years 
gained per 
participant 
QALYs gained 
per participant † 
Increase in total 
health care costs 
per participant ‡ 
CER  
DESMOND 2 / 918 0.03 of 16.6 0.01 67 24,000 
BGI 12 / 855 0.09 of 16.8 0.04 209 12,000 
LOOK A. 35 / 885 0.20 of 16.8 0.09 485 11,000 
MLP 7 / 841 0.05 of 16.8 0.02 126 29,000 
X-PERT 46 / 923 0.25 of 16.5 0.11 723 8000 
ICAN 2 / 930 0.02 of 16.4 0.01 27 39,000 
CPA 64 / 1007 0.42 of 15.9 0.18 1107 8000 
* prevented per 1000 participants over lifetime; † discounted with 1.5% annually; ‡ discounted 
with 4% annually 
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Intervention effect 
 
Table A7. Distributions of intervention effects used for PSA 
 BMI  
% decrease 
HbA1c 
decrease 
Physical 
activity 
SBP  
decrease 
Smokers 
who quit 
(%) 
Fruit  
and vegs 
Sat fat 
% decrease 
DESMOND N(1.1,0.45)    N(15, 7)   
BGI N(2.6,0.8)   N(6,2.5)    
L. AHEAD N(7.9,0.17) N(0.5,0.028)  N(4, 0.5)    
MLP 
 
N(2.6,1.5)  N(45,7) 
Met*min/w
k 
  N(0.1,0.05) 
fruit 
N (2.0,0.4) 
X-PERT 
 
N(2,0.75) 
 
N(0.7,0.18) 
 
N(20,10)  
min/week 
  N(1,0.25) 
fruit / vegs 
 
ICAN N(2.8,1.1)       
CPA N(3.4,0.53) N(0.5,0.065) N(23,2) 
Met*h/wk 
    
N: Normal distribution; wk: week; vegs: vegetables 
 
Long-term maintenance 
 
Table A8. Distribution of long-term maintenance of intervention effects used for PSA  
Risk factor  Average proportion of effect 
maintained over lifetime 
Distribution References on which 
the estimated effect is 
based 
BMI and other risk  
factors 
35  
45 MLP/CPA 
B(3.5, 6.5)   
B(4.5, 5.5) MLP/CPA 
1,3,6 
Physical activity 
 
55  
65 MLP/CPA  
N(55, 20) 
N(65, 20) MLP/CPA 
1-3,6  
HbA1c  85 
85 CPA 
N(85, 30) 
N(85, 25) CPA 
1,2,4-6 
B: beta distribution (used to avoid negative maintenance); N: Normal distribution 
 
 
 
 
 
 
 
 
 
 
Beta-distribution B(3.5,6.5) (with 10.000 drawings) used to reflect (uncertainty in) long-term 
maintenance for BMI, SBP, nutrition and smoking   
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Intervention costs 
 
Table A9. Distributions for intervention costs used for PSA 
 Individual 
contact time  
Contact time in 
groups 
Number of 
participants in 
groups 
Other variable 
costs 
DESMOND  N(360,80) N(5,1)  
BGI N(120,15) N(480,60) N(7,1)  
LOOK AHEAD N(300,38) N(2085,261) N(15,2.5) N(23, 10)* 
MLP 
 
 N(11760,1470)† 
N(5340,668) ‡ 
N(35,5)  
X-PERT  N(720,90) N(16,3)  
ICAN N (240,30) N(360,45) N(6,1) N(60,15)§ 
CPA N(135,17)   N(22,5) § 
* use of weight loss medication (average number of days with orlistat per participant) 
† total contact time with one professional + one assistant 
‡ total contact time with one professional 
§ telephone time  
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Lipid lowering treatment for all could substantially reduce the burden of 
macro vascular complications of diabetes patients in the Netherlands  
 
 
 
ABSTRACT 
 
Background We aimed to quantify the potential health benefits of increased use of 
lipid lowering treatment (LLT), according to current guidelines, for the Dutch diabetes 
population.  
Design Simulation study. 
Methods We compared the long-term health outcomes for a scenario in which all 
diabetes patients received LLT to those in a ‘current practice’ scenario, in which 28% 
received LLT. The model reflected the Dutch diabetes population 40 to 80 years of age, 
in 2003. Sensitivity analyses were performed, using more conservative assumptions.  
Results Over the lifetime, LLT for all diabetes patients reduced the expected 
cumulative incidences of coronary heart disease (CHD) and stroke by respectively six 
and nine percent. Average life expectancy of Dutch diabetes patients would increase by 
0.33 years, ranging from 0.14 years for patients aged 70-79 years, to 0.84 years for 
patients aged 40-49 years at the start of the simulation. Life-long treatment for patients 
aged 50-59 contributed most to the life-years gained (55,000 out of 146,000). With 
reduced effectiveness of LLT and fewer patients starting LLT, the cumulative 
incidences of both CHD and stroke would decrease by approximately two percent. The 
number needed to treat (NNT) in order to prevent one incident case of cardiovascular 
disease over lifetime was 20 for CHD and 44 for stroke.   
Conclusions This simulation study shows that increased use of LLT can substantially 
reduce the expected future burden of CHD and stroke in the Dutch diabetes 
population.  
 
- 108 - 
BACKGROUND 
What would the health impact be for a population if lipid lowering treatment (LLT) 
was actually prescribed to all diabetes patients? This is an interesting question as most 
of the recent guidelines recommend LLT for virtually all persons with diabetes [1;2], 
while prescription rates in daily practice are still far below that target.  
There is a wealth of evidence that persons with diabetes are at increased risk for 
cardiovascular disease (CVD) while excess mortality in diabetes patients is mainly due 
to CVD [3:4]. Consequently, cardiovascular prevention should be undertaken more 
rigorously in diabetes patients than in the general population. Several studies have 
shown that LLT can substantially reduce the occurrence of major cardiovascular events 
in persons with diabetes [5-9]. The proportional reductions in CVD incidence due to 
LLT are almost similar for persons with and without diabetes, with or without 
coronary disease, and independent of the baseline level of cholesterol [5;6;9]. 
Furthermore, in persons with diabetes, relative treatment benefits appear to be 
independent of diabetes duration and glycemic control [9].  
However, the long-term health benefits that could be gained on a population level 
when all diabetes patients would be treated according to recent guidelines, are 
unknown. So far, all reports of observed health outcomes are from clinical trials, 
conducted in selected populations with a follow-up duration of at most five years [5]. 
Previous modeling studies were confined to newly diagnosed patients and patients 
with dyslipidemia [10;11].     
In this study we assess the potential long-term health benefits of lipid-lowering 
treatment, for the Dutch diabetes population.  
 
METHODS 
The Chronic Diseases Model 
The Chronic Diseases Model (CDM) is a Markov type state transition model [12;13]. In 
this study, the CDM simulation starts with a cohort resembling the Dutch diabetes 
population. The states specified in the CDM are risk factor classes, presence or absence 
of chronic diseases and vital status. The current state determines the probability to 
change to another state in the next one year time-step. The risk factors included in the 
simulations in this study are total cholesterol (TC), body mass index (BMI), systolic 
blood pressure (SBP), and glycemic control (HbA1c). The cardiovascular complications 
of diabetes modeled are coronary heart disease (CHD) and stroke.  
With every time-step, patients have a risk to change risk factor class, disease state or to 
die. The probability to develop CHD or stroke depends on age, gender and risk factor 
class. For example, the risk for stroke is higher for higher levels of SBP. Subsequently, 
the probability to die is higher for patients with CHD or stroke than for patients 
without cardiovascular complications. In addition, stroke increases the risk for CHD 
independently from all risk factors.   
We used a closed cohort approach, meaning that persons leave the cohort due to 
mortality, but there are no new persons entering the cohort. With every time-step the 
simulated cohort becomes smaller, until finally all persons have died.   
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The CDM has been used previously to evaluate cost-effectiveness of diabetes 
prevention and smoking cessation [12;14] to explore the impact of lifestyle risk factors 
on healthy life expectancy [15] and life-time health care costs [16], and to estimate the 
future burden of stroke and COPD [17;18].  
 
Input data 
Age-specific prevalence rates for diabetes derive from Dutch general practitioners’ 
registrations [13]. The risks for CHD and stroke in the diabetes group are calculated 
from two different input parameters: 1) age-specific CHD and stroke incidence rates in 
the general population (from general practitioners registrations) and 2) relative risks 
for CHD and stroke for persons with diabetes compared to persons without diabetes. 
A similar approach is used to calculate age-specific mortality rates for persons with 
diabetes. Distributions of cholesterol levels derive from Dutch health monitoring 
studies conducted between 1998-2001 [19-21] The strengths of the associations (relative 
risks) between risk factors and diseases (CHD and stroke) are based on international 
observational studies, and we assume that these associations are similar in persons 
with and without diabetes. All data in the CDM are age and sex-specific. 
 
Treatment effect 
In the CDM, total cholesterol (TC) is modeled in four classes, with cut-off points at 5.0, 
6.5 and 8.0 mmol/L. In the model, these classes are linked to coronary heart disease 
(CHD) through relative risks of disease incidence [13]. The level of TC has no effect on 
the incidence of stroke [22]. To simulate the effect of LLT, each cholesterol class is 
stratified by treatment status (treated or untreated). Estimates for cardiovascular risk 
reductions for treated patients as compared to untreated patients derive from a meta-
analysis of statin treatment [6]. We used the following estimates, independent of the 
pre-treatment level of TC: a 26% risk reduction for CHD incidence in persons younger 
than 65 years, and a 19% risk reduction for persons over 65. For stroke, a 17% risk 
reduction for all ages. These estimates correspond to treatment effects obtained with an 
average LDL reduction of 1.0 mmol/L [6].  
 
Current practice scenario 
At the start of the simulation (2003), the cohort comprised 445,200 diabetes patients 
aged 40-80 years, with a mean age of 65 years. The prevalence of known CHD was 24% 
and that of stroke 5%. In this cohort, 86% had TC levels >5.0 mmol/L and 28% (123,600 
patients) were treated with lipid-lowering medication. We assumed that treated 
patients continued treatment for the rest of their lives. Similarly, we assumed that 
untreated patients remained untreated, while TC levels stayed stable (no transitions 
between cholesterol classes).  
 
Guideline scenario 
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In this scenario we assumed treatment for all patients, while keeping all other risk 
factors unchanged. This means that we assumed life-time treatment for an additional 
321,600 patients.   
 
Sensitivity analysis 
The effect of LLT may be lower in daily practice than in well-controlled trials. 
Furthermore, some patients may refuse treatment or discontinue within a few years. 
Therefore, we defined and run the following alternative scenarios (AS): 
AS 1. the relative risk reductions for CHD and stroke, due to LLT, were set equal to the 
lower boundaries of the confidence intervals as reported by Baigent et al. [6]: 21% for 
persons under 65 years and 12% for persons over 65 for CHD; 12% for stroke  
AS 2. reduced effect (AS 1) + the assumption that additional treatment is confined to 
50% of currently untreated patients  
AS 3. reduced effect (AS 1) + additional treatment is confined to 50% of currently 
untreated patients with TC >5.0 mmol/L 
AS 4. reduced effect (AS 1) + additional treatment is confined to 50% of currently 
untreated patients with TC >5.0 mmol/L and age  70 years. 
 
RESULTS 
CHD and stroke incidence 
Cumulative CHD and stroke incidence were consistently lower in the guideline 
scenario than in the current practice scenario, although the proportional reductions 
declined with increased treatment duration (table 1). With life-long treatment, 
cumulative numbers of incident cases of CHD and stroke were 16,100 (5.6%) 
respectively 7,300 (8.8%) lower in the guideline scenario. Life-long treatment started at 
age 50-59 years contributed most to the reduction in CHD (5,247 cases, table 2) and 
treatment started at age 60-69 years contributed most to the reduction in strokes (2,304 
cases).  
 
Table 1. Expected health outcomes for the ‘current practice’ and ‘guideline’ scenario, for the 
total diabetes cohort 
  Current practice 
scenario 
Guideline 
scenario 
Difference 
n (%) 
Number Needed 
to Treat 
n 445,200 445,200   
n with LLT(%) 123,600 (27.8) 445,200 (100) 321,600 (72.2)  
5-year incidence (n)     
  CHD 95,461 86,520 -8,941 (9.4) 36 
  Stroke 27,173 23,917 -3,256 (12.0) 99 
10-year incidence (n)     
  CHD 160,168 146,556 -13,612 (8.5) 24 
  Stroke 45,696 40,569 -5,128 (11.2) 63 
Lifetime incidence (n)     
  CHD  284,344 268,294 -16,050 (5.6) 20 
  Stroke 82,097 74,840 -7,258 (8.8) 44 
Life years 6.42 million 6.57 million 146,200 (2.3)  
Life expectancy (yrs) 14.42 14.75 + 0.33 (2.3)  
LLT, Lipid Lowering Treatment: CHD, Coronary Heart Disease 
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Life years and life expectancy 
The guideline scenario resulted in 146,200 life years gained, meaning that LE increased 
by 0.33 years (146,200/445,200) in the total diabetes cohort and by 0.45 years 
(146,200/321,600) in additionally treated patients (table 1). The largest contribution to 
the life years gained derived from life-long treatment for all patients aged 50-59 years 
at the start of the simulation. Increase in average LE ranged from 0.14 years in patients 
aged 70 to 79 years to 0.84 years in patients aged 40-49 years (table 2).  
 
Numbers needed to treat 
The NNT in order to prevent one incident case of CHD or stroke declined with 
increased treatment duration (table 1). The NNT for CHD declined from 36 to prevent 
one event in five years to 20 to prevent one event over the life-time. The corresponding 
numbers needed to treat for stroke were 99 and 44, respectively.  
 
Table 2. Expected health outcomes for the ‘current practice’ and ‘guideline’ scenario 
age group  Current practice 
scenario 
Guideline 
scenario 
Difference n (% ) 
40-49 years     
   With LLT n (%) 8,148 (20.2) 40,280 (100) 32,132 (79.8) 
   CHD / NNT a 34,045 31,713   2,332 (6.8) / 14 
   Stroke / NNT b 9,906 9,119 787 (7.9) / 41 
   Life years (millions) 1.073  1.107 0.034 (3.1) 
   Life expectancy (years) 26.67 27.51 0.84 (3.1) 
50-59 years     
      With LLT n (%) 31,541 (29.8) 106,015 (100) 74,474 (70.2) 
   CHD / NNT a 85,057 79,809 5,247 (6.2) / 14 
   Stroke / NNT b 24,192 22,325 1,867 (7.7) / 40 
   Life years (millions)  2.049 2.104 0.055 (2.7) 
   Life expectancy (years) 19.34 19.86 0.52 (2.7) 
60-69 years     
   With LLT n (%) 47,106 (32.7) 143,978 (100) 96,872 (67.3) 
   CHD / NNT a 92,876 88,065 4,811 (5.2) / 20 
   Stroke / NNT b 26,316 24,012 2,304 (8.8) / 42 
   Life years (millions) 2.010 2.046 0.036 (1.8) 
   Life expectancy (years) 13.95 14.21 0.25 (1.8) 
70-79 years     
   With LLT n (%) 35,172 (24.6) 143,157 (100) 107,985 (75.4) 
   CHD / NNT a 68,305 64,848 3,457 (5.1) / 31 
   Stroke / NNT b 20,390 18,243 2,147 (10.5) / 50 
   Life years (million) 1.220 1.240 0.020 (1.6) 
   Life expectancy (years) 8.52 8.66 0.14 (1.6) 
LLT, Lipid Lowering Treatment: CHD, Coronary Heart Disease : a Life-time cumulative 
incidence of coronary heart disease and number needed to treat to prevent one incident case of 
CHD over lifetime. b Life-time cumulative incidence of stroke and number needed to treat to 
prevent one incident case of stroke over lifetime. 
 
Sensitivity analysis  
With more conservative estimates for treatment effect and additional treatment 
confined to 50% of untreated patients with TC>5.0 mmol/L (AS 3), the proportional 
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reductions in CHD and stroke incidence declined to respectively 1.6% and 2.6%. Life 
years gained declined from 146,200 to 45,200 (table 3).     
 
Table 3: Results for the sensitivity analysis: proportional reductions in life-time cumulative 
incidence of coronary heart disease and stroke and total life years gained  
 Additionally 
treated patients (n) 
 CHD a 
prevented (%) 
Stroke b 
prevented (%) 
Total life 
years gained 
Guideline scenario 321,600 5.6 8.8 146,200 
Alternative scenario 1 321,600 3.8 6.3 110,800 
Alternative scenario 2 160,800 1.9 3.1 55,100 
Alternative scenario 3 132,800 1.6 2.6 45,200 
Alternative scenario 4 87,900 1.3 1.8 39,800 
CHD, Coronary Heart Disease: a Life-time cumulative incidence of coronary heart disease: b 
Life-time cumulative incidence of stroke 
 
DISCUSSION 
Our simulation study showed that six, respectively nine percent of the expected 
cumulative CHD and stroke incidence in the Dutch diabetes population could be 
prevented if all patients (instead of 28% in current practice) would use life-long lipid 
lowering medication. Average LE of the diabetes population would increase by 0.33 
years. The NNT in order to prevent cardiovascular disease over lifetime was 20 for 
CHD and 44 for stroke.  
Our study is not the first to model diabetes treatment. Palmer [23] evaluated the impact 
of theoretical 10% improvements in several cardiovascular risk factors. Life expectancy 
values for a typical US diabetes cohort increased by 1.0 due to improved glycemic 
control (HbA1c), 0.7 due to improved blood pressure control and 0.3 with 
improvements in cholesterol, from which the authors concluded that reducing HbA1c 
has the greatest impact on long-term health. However, although a ten percent 
reduction in HbA1c seems feasible [24], mean improvements in blood pressure are 
generally smaller [24;25]. On the other hand, average reductions in cholesterol due to 
lipid lowering treatment are generally much larger, in the range 15-20% [5]. 
Consequently, Palmer et al. underestimated the potential impact of LLT by assuming 
equal reductions in all cardiovascular risk factors.  
Other simulation studies that examined the long-term health impact of LLT in diabetes 
patients reported increases in life expectancy ranging from 0.2 years for patients with 
CHD to 5.4 years in young patients with dyslipidemia [10] , showing the large 
variation in outcome depending on population characteristics and methods used [11]. 
In addition, the CDC study [10] showed that life-long treatment reduced lifetime 
cumulative incidence for CHD but not for stroke, probably because the CDC model did 
not include an effect of statin treatment on stroke. However, despite the absence of an 
independent positive association of cholesterol with stroke mortality as found in 
observational studies, there is conclusive evidence from randomized trials that statins 
substantially reduce stroke rates [22]. 
We found that in our diabetes cohort in which the majority had no vascular disease the 
NNT in order to prevent one case of CHD over a five-year period was 36. This is 
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consistent with previous findings. Costa et al. [5] showed that the NNT in order to 
prevent a coronary event was 37 in persons (with or without diabetes) without 
cardiovascular disease, for an average follow-up of five years. A recent meta-analysis  
[26] confined to persons with diabetes reported 36 fewer people with major vascular 
events after 5 years, per 1000 patients without vascular disease at baseline, 
corresponding to a NNT of 28. This is very close to the NNT of 26 to prevent one 
cardiovascular event over five years in our study, which can be calculated by adding 
the coronary and stroke events prevented as displayed in table 1.  
 
There are several limitations with respect to the input data and assumptions used in 
our model. First, the input parameters in our model derived from well designed and 
controlled intervention studies, while for example treatment dose and adherence are 
probably lower in day-to-day realistic conditions. Although a Dutch study [27] showed 
that less than half of the patients were still taking their medication two years after 
initiating statin treatment, compliance might be better in persons with diabetes [28]. 
Our sensitivity analysis showed the impact of assuming lower treatment effect and 
compliance. Secondly, our estimates for treatment effect were based on a meta-analysis 
of trials including both persons with and without diabetes. Results of a recently 
published meta-analysis [26] confirmed that our model estimates are valid for persons 
with diabetes, because the impact of statin treatment on the incidence of major 
coronary events and strokes appeared similar for persons with and without diabetes. 
Finally, we assumed that untreated patients remained untreated, although treatment 
rates appear to increases with advancing age (table 2). If increased use of LLT in 
current practice would have been taken into account, the calculated health gains in our 
study would have been lower. On the other hand, we assumed that cholesterol levels 
did not increase with advancing age. If deterioration of cholesterol levels in untreated 
patients in the current practice scenario would have been included, the calculated 
health gains would have been larger.   
Although our study provides meaningful insight into the possible long-term effects of 
LLT, our study did not address potential drug-induced adverse events [6;29], or the 
impact of drug use on quality of life [30]. On the other hand, our model ignores 
potential beneficial effects of statin treatment on micro vascular complications [29].  
 
In conclusion, better adherence to current guidelines for LLT would substantially 
reduce the occurrence of cardiovascular complications in the Dutch diabetes 
population. With respect to future improvements, more efforts should be devoted to 
maximizing the potential for decreasing cardiovascular risk in diabetes patients. 
Strategies should be developed to increase adherence to guidelines by health care 
providers, and to increase patient compliance to pharmacological treatment as well as 
lifestyle recommendations.  
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GENERAL DISCUSSION          
The general aim of this thesis was to explore opportunities to reduce the future burden 
of diabetes and cardiovascular diabetes complications in the Dutch population through 
prevention. The three main questions addressed in this thesis were:  
1) Are weight change, alcohol consumption and smoking associated with diabetes 
incidence in a Dutch population? 
2) To what extent can preventive lifestyle interventions reduce the future incidence of 
diabetes in the Netherlands and are these interventions cost-effective? 
3) To what extent can care-related preventive interventions reduce the future incidence 
of cardiovascular complications in Dutch diabetic patients and are these interventions 
cost-effective? 
 
We used Dutch observational cohort studies to answer research question 1 and a 
computer-based simulation model, the Dutch Chronic Diseases Model (CDM) to 
answer questions 2 and 3 *.  
In the following, the three research questions are addressed. Subsequently, 
methodological issues with respect to observational studies, intervention studies, 
simulation studies and health-economic evaluations are discussed. Finally, 
implications for future research and health policy are outlined and a general 
conclusion is drawn.  
 
Are weight change, alcohol consumption and smoking associated with diabetes 
incidence in a Dutch population?  
We showed in Chapter 2 that weight change was associated with diabetes incidence in 
a Dutch population, but that this association was explained by the level of body weight 
attained after the weight change period. There was a continuous association between 5-
years weight change and diabetes incidence in the subsequent five years, if the 
association was adjusted for initial BMI (OR 1.08, 95% CI 1.04-1.13 for each kilogram of 
weight change). However, the association between weight change and diabetes 
incidence disappeared if we adjusted for attained BMI (OR 0.99, 95% CI 0.94-1.04).  
In Chapter 3, we showed that alcohol consumption was associated with diabetes 
incidence in Dutch women, but we found no evidence for a significant association 
between alcohol consumption and diabetes incidence in Dutch men. Women with an 
average alcohol consumption of 1 or 2 drinks per day (moderate drinkers) had the 
lowest risk to develop diabetes. Non-drinking women had the highest risk with a 
hazard ratio (HR) of 2.5 (95% CI 1.3-5.1) compared to moderate drinkers. The HR for   
women drinking more than 2 drinks per day was 1.9 (95% CI 0.7-5.1). We found no         
--------------------------------------------------------------------------------------------------------------------
* Due to the health care costs and quality of life weights - a value between 0 (death) and 1 (for 
perfect health) - incorporated in the model, we could calculate cost-effectiveness ratios for the 
interventions. An intervention was considered to be cost-effective if the (incremental) cost-
effectiveness ratio (ICER) was below €20,000 per quality adjusted life year (QALY; a life year 
multiplied by its quality of life weight).  
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significant associations between smoking and diabetes incidence in a Dutch 
population, but smoking more than 10 cigarettes per day tended to increase diabetes 
risk in both men and women (HR compared to non-smokers approximately 1.4 both 
for men and for women).  
 
Weight loss appears to be the main determinant for the success of lifestyle 
interventions in terms of the risk reduction for incident diabetes that is achieved 1,2. 
Weight loss can improve insulin sensitivity, thereby lowering the risk of diabetes 1. 
However, the role of weight change as an independent risk factor for diabetes and 
determinant of intervention success has not been entirely clear 3-5. Our results from 
Chapter 2 suggest that weight loss interventions affect diabetes incidence by 
influencing attained weight, but that weigh loss in itself does not contribute to diabetes 
prevention. A healthy diet and sufficient physical activity are the main tools to achieve 
and sustain weight loss. In addition improvements in diet, physical activity and fitness 
have been shown to contribute to diabetes prevention, independent of associated 
changes in body weight 6-8. Since body weight, dietary composition and physical 
activity are also risk factors for other chronic diseases, such as cardiovascular diseases 
and cancer 9-13, lifestyle interventions could contribute to the prevention of these 
diseases as well.  
There is some discussion whether the lower (cardiovascular) disease risk for moderate 
compared to non-drinkers, often found in observational studies, is entirely explained 
by a causal, protective effect of alcohol consumption, or whether this observation is 
partly due to systematic error in observational studies 14. It is suggested that the higher 
risks for unfavorable outcomes in non-drinkers can be partly explained by inclusion of 
former drinkers in the non-drinkers category, while former drinkers might have 
stopped drinking because of health problems. Since alcohol consumption has also been 
associated with unfavorable developments in cardiovascular risk factors (triglycerides, 
body weight and blood pressure 15), recommending moderate alcohol consumption to 
non-drinkers in order to reduce diabetes risk is probably not desirable. On the other 
hand, it seems obvious that heavy, irregular drinking and binge drinking should be 
discouraged in order to reduce, at least, the risk for cardiovascular disease 16;17.  
Smoking cessation will probably not reduce diabetes incidence in the Dutch population 
but, since smoking is acknowledged as an important risk factor for multiple, adverse 
health outcomes 18, it should be considered as an important target in lifestyle 
interventions. A moderate increase in the risk for diabetes for current smokers 
compared to non smokers has been reported in many studies 19. The pooled relative 
risks of 1.6 (1.4-1.8) for heavy smokers, 1.3 (1.1-1.5) for light smokers and 1.2 (1.1-1.3) 
for former smokers are consistent with a dose-response phenomenon 19. Despite this 
association, counseling for smoking cessation (alone) does not contribute to diabetes 
prevention 20,21. Smoking cessation may even increase short-term risk for diabetes, due 
to weight gain which is often observed in smokers who quit 21. Therefore, with respect 
to diabetes prevention, special attention is required for weight control in smokers who 
quit.     
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In conclusion, 5-years weight change does not affect diabetes incidence in a Dutch 
population, beyond its effect on attained weight. Alcohol consumption is associated 
with diabetes incidence in Dutch women but not in men. Smoking of at least 10 
cigarettes per day tends to increase the risk for diabetes in Dutch men and women. 
Although lifestyle advice about alcohol consumption and smoking will not contribute 
to reducing the future burden of diabetes, these behaviors should be addressed as 
integral parts of interventions to improve public health.  
 
The main results of the simulation studies in Chapters 4 to 6 that addressed research 
questions 2 and 3 are summarized in table 1. 
 
Table 1: Intervention costs, health effects and cost-effectiveness of preventive diabetes 
interventions if implemented in different target groups of the Dutch population 
Intervention 
and target 
population  
Intervention 
costs per 
participant 
Increase in 
LE per 
participant  
NNT Effect on disease 
incidence 
CER 
€/QALY 
 
Chapter 4:  
Community 
intervention for   
adults, 20-80 
year  
 
 
6 
 
0.01-0.06 
 
300-1500 # 
to prevent one 
incident case of 
diabetes in 20 
years 
 
Maximal decrease 
in diabetes 
incidence 2.4% 
with 100% 
implementation   
 
3,100-3,900 # 
Chapter 4:  
‘health care 
intervention’ for 
obese adults,  
30-70 years 
 
700 0.4-1.8  7-30 # 
to prevent one 
incident case of 
diabetes in 20 
years 
Maximum 
decrease in 
diabetes incidence 
of 1.6% with 20% 
participation  
3,900-5,500 # 
Chapter 5:  
Lifestyle 
intervention for 
adult, diabetic  
patients  
 
124-584 ‡ 
 
0.02-0.34 ‡ 
 
19-1000 ‡ 
to prevent one 
incident case of 
CVD over 
lifetime 
Maximum 
decrease of 6% in 
CVD incidence for 
participants  
9,000-39,000 ‡ 
 
Chapter 6:  
Statins for 
adult, diabetic 
patients,  
40-80 years  
371  
per year * 
0.45 14  
to prevent one 
incident case of 
CVD over 
lifetime 
Maximum 
decrease in CVD 
incidence 6-9% if 
all diabetic 
patients receive 
statins  
 
14,000* 
LE: life expectancy, CER: cost-effectiveness ratio, NNT: number needed to treat 
# Effects with assumed minimum and maximum effectiveness of the interventions 
‡ Effect range for seven interventions * Data from RIVM report Jacobs-van der Bruggen et al 22 
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To what extent can preventive lifestyle interventions reduce the future incidence of 
diabetes in the Netherlands and are these interventions cost-effective?  
In Chapter 4 we used a computer simulation model to explore the potential long-term 
health effects and cost-effectiveness of lifestyle interventions. It was shown, that a 
community-based lifestyle intervention, targeted at the Dutch general population, 
could reduce the 20-year cumulative incidence of diabetes by 0.4% to 2.4% if such 
intervention would reach all Dutch adults (table 1). It was also shown that the 20-year 
cumulative incidence of diabetes could be reduced by 0.3% to 1.6%, if one out of five 
obese Dutch adults would participate in an intensive individual-based lifestyle 
intervention. Both interventions appeared to be cost-effective with ICERs ranging from 
3,000 to 5,000 €/QALY in base-case analyses. The interventions remained cost-effective 
(with ICERs < 12,000 €/QALY) even with higher estimates for intervention costs or 
equal discounting of health effects and health care costs.  
 
Our results suggest, that large-scale implementation of both the community-based and 
the individual-based lifestyle intervention could reduce 20-years incidence of diabetes 
in the Dutch population by approximately 1% to 4%, if the effects of the interventions 
would be additive. This result is moderate compared to a previously estimated 43% 
reduction in 20-years diabetes incidence in Dutch adults, if they would all have a 
normal weight 22 , or an estimated 20% fall in diabetes incidence estimated for the UK 
population, if everybody would meet one more of five predefined healthy behavior 
goals related to BMI, diet and physical activity 23. A main reason for this moderate 
impact of lifestyle interventions on a population level, is that the population-based 
average change in lifestyle risk factors, achieved through the lifestyle interventions, is 
small due to either low effectiveness and/or a limited reach of the interventions. Body 
weight was assumed to be reduced by less than 1 kg per person through the 
community-based intervention and although effects were larger for participants of the 
intensive individual intervention (weight reduction of up to 4.5 kg), we assumed that 
‘only’ 200,000 obese Dutch adults would participate in such program.  
The impact of lifestyle interventions on a population level would increase, if the 
200,000 participants in the intensive intervention would be persons at higher baseline 
risk for diabetes, for example (obese) adults with IGT *. Another way to increase the 
population impact, could be to extend the target population, for (moderately) intensive 
lifestyle counseling, to all persons who are overweight. Both intensive lifestyle 
interventions for persons with IGT and lifestyle counseling for overweight persons 
have been shown to be cost-effective 24-28. In a recent report ‘Diabetes until 2025’ we 
estimated that implementation of a ‘realistic set of interventions’ in the Dutch 
population, including moderately intensive lifestyle counseling for overweight 
persons, could reduce diabetes incidence (from 2010 to 2025) by approximately 2.3% 
(1.2% to 3.9%) 29.               
-------------------------------------------------------------------------------------------------------------------- 
* since persons with IGT can not be identified from the CDM model, our analyses were 
‘restricted’ to persons with obesity. 
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It should be noted, that the ‘relative reduction in cumulative diabetes incidence’ does 
not capture the total health effect of the interventions. The outcome does not reflect 
that diabetes incidence in intervention participants can be delayed, and it does not 
show the potential health benefits associated with prevention and delay of other 
chronic diseases, such as cardiovascular diseases and cancers. The relative reduction in 
the annual risk to develop diabetes (often reported in trials) is always larger than the 
associated relative reduction in the cumulative incidence since, even among 
intervention participants, many persons will eventually develop diabetes. The annual 
risk to develop diabetes during the 20 year follow-up period in the China da Qing 
study was 7% for intervention participants, and 11% for controls; a relative risk 
reduction of 40% 30. Since most persons developed diabetes in those 20 years (80% of 
intervention participants and 93% of the controls), the relative reduction in cumulative 
incidence was ‘only’ 14%. However, intervention participants spent an average 3.6 
years less with diabetes compared to the controls. The total health effects of the 
interventions are better represented by improvements in quality adjusted life years 
(QALYs). In our study, the community-based intervention resulted in a modest 
projected average gain of 0.01 to 0.04 QALY per person. The projected increase of 0.3 to 
1.2 QALY, for participants of the individual-based lifestyle intervention was large, 
compared to results obtained with other lifestyle 31,32 or pharmacological 24,33 
interventions, but consistent with results from other studies that modeled similar 
interventions 24,31.  
Although the (cost)effectiveness of universal diabetes prevention appears to be more 
uncertain compared to the (cost)effectiveness of indicated prevention 31, and the 
(cost)effectiveness of indicated prevention more uncertain, if targeted at moderately 
overweight persons, compared to obese persons 34, there seems to be sufficient 
evidence that preventive lifestyle interventions are generally cost-effective in different 
target groups of the population 24-28,31,32.  
 
In conclusion, large-scale implementation of lifestyle interventions could reduce the 
future incidence of diabetes in the Netherlands by approximately 1% to 4%. Preventive 
lifestyle interventions are cost-effective in different target groups of the population.  
 
To what extent can care-related preventive interventions reduce the future incidence 
of cardiovascular complications in Dutch diabetic patients and are these 
interventions cost-effective? 
In Chapter 5 we showed that, despite a large variety in the projected long-term health 
effects of lifestyle interventions for Dutch diabetic patients, these health benefits were 
generally achieved at reasonable costs. The relative reductions in the cumulative 
lifetime incidence of cardiovascular complications, achieved through seven simulated 
interventions, ranged from 0.1% to 6.1%, for intervention participants. The cost-
effectiveness ratios ranged from 10,000 to 39,000 €/QALY (table 1).  
Chapter 6 revealed that the life-time cumulative incidence of coronary heart disease 
(CHD) and stroke could be reduced by 6% and 9% respectively, if all Dutch diabetic 
- 124 - 
patients would receive lipid lowering treatment (table 1). With more realistic 
assumptions about effectiveness and participation, the cumulative incidence of both 
CHD and stroke would decrease by approximately 2%. 
 
Although promotion of a healthy lifestyle, as a part of self-management education, is 
acknowledged as an integral part of diabetes treatment, knowledge on the 
(cost)effectiveness of lifestyle interventions for diabetes patients has been relatively 
scarce 35. We showed that there is a large variety in the efficacy and cost-effectiveness 
of available interventions (table 1). A two-year structured counseling program to 
promote physical activity 36, a six-week structured self-management education 
program called X-Pert 37 and a one-year intensive lifestyle intervention for overweight 
patients, called LOOK-AHEAD 38, obtained promising results; these interventions 
reduced lifetime CVD incidence among participants by respectively 6.1%, 5.0% and 
4.0% and they had >90% probability to be very cost-effective (ICER ≤ 20,000 €/QALY) 
even when uncertainty in intervention costs, intervention effects and long-term 
maintenance of these effects were taken into account.  
The average individual health gain of respectively 0.14, 0.09 and 0.08 QALY, obtained 
through the aforementioned interventions, is smaller than the health gain of 0.3 to 1.2 
QALY, projected for the individual-based lifestyle intervention in Chapter 4. It should 
be noted, that the assumptions about long-term maintenance of intervention effects 
such as weight loss and increased physical activity, were more conservative in the 
simulations in Chapter 5. It is noteworthy, that the increase in life-expectancy of 0.34 
years, associated with the most successful lifestyle intervention for diabetic patients, is 
not much lower than the projected increase by 0.45 years, associated with lifelong 
treatment with lipid lowering medication in the same population.  
The extent to which increased use of preventive treatments can improve future health 
depends on the amount of people eligible for a specific intervention, and the extent to 
which treatments are already applied in current care. A recent simulation study 39 
estimated that myocardial infarctions and strokes in the US population could be 
reduced by 36% and 20%, respectively, if everyone received each of 11 nationally 
recommended preventive activities for which they were eligible, if aggressive but 
feasible levels of performance and compliance of these treatments were assumed. 
Three of the interventions considered were blood glucose -, lipid lowering - and blood 
pressure lowering treatments for diabetic patients. Conform to the results in this US 
study, larger health benefits for the Dutch diabetic population can probably be 
achieved through adequate lipid-lowering and antihypertensive treatment, than 
through intensified treatment of blood glucose, partly because these interventions have 
a larger impact on CVD incidence and partly because more patients are eligible. We 
have previously shown that, with realistic treatment scenarios, lipid lowering, 
antihypertensive and blood glucose treatment can reduce the 20-year incidence of 
cardiovascular complications in the Dutch diabetic population by approximately 5%, 
5% and 1% respectively 22. The estimated cost-effectiveness ratios of these interventions 
were 14,000 €/QALY, 10,000 €/QALY and 22,000 €/QALY. The largest health benefits 
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are probably achieved in multifactor interventions in which self-management 
education (including lifestyle advise) and pharmacological treatments are combined 
29,40. We have estimated that implementation of a ‘realistic set of interventions’ in Dutch 
diabetes patients could reduce the incidence of cardiovascular complications (from 
2010 to 2025) by approximately 3.4% (0.9% to 6.5%) 29.     
 
In conclusion, there are several successful lifestyle interventions that could reduce 
lifetime incidence of cardiovascular complications, among Dutch diabetic participants, 
by up to 6%. A similar reduction could, in theory, be obtained in the whole Dutch 
diabetic population, if all patients would use lipid lowering medication. Although 
most care-related preventive interventions are cost-effective, the cost-effectiveness of 
some of the available lifestyle interventions is not so favorable and, based on current 
evidence, quite uncertain. Diabetes treatment should combine the most promising, 
cost-effective lifestyle interventions with optimal pharmacological treatment, in order 
to reduce the future incidence of cardiovascular complications in the Dutch diabetic 
population.  
 
Methodological issues 
Different kinds of studies were used in this thesis to explore opportunities for diabetes 
prevention. The results of observational cohort studies were used in Chapters 2 and 3 to 
examine associations between lifestyle risk factors and incident diabetes. Results of 
intervention studies were used to estimate (long-term) effectiveness of lifestyle- and lipid 
lowering interventions in Chapter 4, 5 and 6 and consecutively, simulation studies with 
the Chronic Diseases Model were used to explore the potential long-term health 
benefits of these interventions, if applied in the Dutch population. Health-economic 
evaluation studies were used in Chapters 4 and 5 to determine the cost-effectiveness of 
lifestyle interventions.  
 
Observational studies 
Observational studies are well suited to identify risk factors for specific outcomes. An 
observed association between a risk factor (the exposure variable) and the outcome of 
interest, indicates that the risk factor could be a target for preventive activities. If, for 
example, diabetes develops more frequently among persons with a high body weight 
than among lean persons, this suggests that weight loss interventions could be effective 
in order to prevent diabetes. There are many methodological issues to consider in 
observational studies. Some issues are especially relevant with respect to examining 
associations between lifestyle risk factors and diabetes, as done in this thesis.  
First, lifestyle habits change over time and this could influence the strength of observed 
associations, especially in studies in which baseline exposure data is associated with 
outcome data at long-term follow-up. Changes in body weight over time could explain 
why the strength of the association between BMI and diabetes appears inversely 
associated with the follow-up duration of the study 41. If possible, updated exposure 
data from repeated measurements should be used to account for these changes, for 
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example by using GEE analysis (Chapter 2). The association between BMI and diabetes 
incidence within 5 years in our analysis in Chapter 2 (OR 1.23, 95%CI 1.19-1.27) was 
indeed higher than the pooled relative risk (RR 1.18, 95%CI 1.16-1.20), derived from 
many observational studies with a median follow-up of 8 years 41. Second, the reasons 
why people change their lifestyle habits are generally unknown. If changes to a 
healthier lifestyle are made in order to reduce health related problems, this could cause 
for example, weight loss, former alcohol consumption, or former smoking, to be 
associated with a higher incidence of diabetes, instead of an expected lower risk (sick 
quitter effect). This phenomenon could explain some of our findings in Chapter 3, such 
as the high risk for diabetes observed in never drinking, formerly smoking men. 
Another potential reason for weight loss to be associated with unfavorable prognosis, 
is if weight loss is unintentional.  
The last issue relates to misclassification of exposure (for example body weight) or 
outcome (diabetic cases). Many observational studies have to rely on self-reported 
weight, which is known to be underestimated. The advantage of our study (Chapter 2) 
was that weight was repeatedly measured in participants in the Doetinchem Cohort 
Study. Similarly, many observational studies (including our studies in Chapter 2 and 3) 
have to rely on self-reported diabetes. Consequently, since many persons have 
undiagnosed diabetes, many diabetic cases are unidentified and in fact misclassified. If 
this misclassification is independent from the exposure, this will cause a dilution of the 
association of interest. However, with respect to body weight, it could be that diabetes 
is more often undiagnosed among lean persons, than among obese persons, and this 
could result in an observed association between body weight and diabetes which is 
stronger than the actual association. Although, ideally, formal diagnostic tests (blood 
glucose measurements) should be used to identify diabetic cases, this is generally not 
feasible in large observational studies.  
 
Intervention studies  
Although an association, identified from observational studies, is an important first 
step to identify targets for prevention, it is by no means sufficient. Whether a risk factor 
can be a valuable target also depends on the causality of the association and the extent 
to which the risk factor can be modified. Intervention studies, preferably randomized 
controlled trials, are needed to assess these requirements. However, intervention 
studies have limitations too. Due to the strict criteria for including participants, and the 
specified intervention protocols applied in a clinical trial setting, it is questionable 
whether results can be generalized to real-life settings. Long-term randomized trials 
require tremendous effort, patience and budgets, while evaluation of long-term effects 
is frequently hindered by (selective) drop out, and intervention activities which are 
eventually offered to the original control population as well. Therefore, most trials are 
relatively short; effects are frequently reported for intermediate outcomes such as 
lifestyle- and cardiovascular risk factors, but not for final outcomes such as disease 
incidence or mortality. In addition, essential information about long-term maintenance 
of lifestyle changes remains limited. The ability to provide relatively fast estimates of 
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long-term outcomes, while taking account of uncertainty around population 
characteristics, potential reach and (long-term) effects and costs of interventions is one 
of the main advantages of using simulation studies.   
 
Simulation studies 
A major strength of epidemiological models is that information from different sources 
can be used and combined in a consistent way. Besides information from 
observational- and intervention studies, a model can include demographic and 
epidemiological information of interest, such as population numbers, risk factor 
prevalence, disease incidence, and mortality rates. In addition, a model can include 
utility measures and disease- or age-related (health care) costs. This combination of 
data enables us to explore the (long-term) effects of multiple, sometimes theoretical 
scenario’s. For example, the long-term health impact for the Dutch population, if lipid-
lowering treatment would be given to all diabetic patients, (Chapter 6 of this thesis) 
could easily be explored with the Chronic Diseases Model, while it would otherwise be 
impossible to assess. Another advantage is that models can be used to calculate generic 
outcome measures such as life expectancy (LE) or quality adjusted life years (QALYs).  
Inevitable, there are also limitations with respect to the use of simulation models. 
Models have to rely on simplifications and assumptions. For example, in the CDM, risk 
factors are modeled in (broad) classes, and diseases are either absent or present, 
meaning that severity is not taken into account. With respect to diabetes, the CDM 
does not (yet) include micro vascular complications. Transition probabilities in the 
CDM depend on being in a specific state or not, but are independent of the time spent 
in the specific state. This means, that the risk to develop cardiovascular disease 
depends on having diabetes or not, but is independent of diabetes duration. One of the 
assumptions in the CDM is that risk factor distributions are independent, meaning for 
example that the prevalence of inactivity is assumed to be equal among persons in 
different classes of body weight. The results of simulation studies depend on the 
validity of model assumptions, as well as the quality and accuracy of input data. 
Combining information from different sources in one model, implies that the 
limitations of each source affect the outcomes. On the other hand, enforcing a model 
structure on different data sources, enables the creation of epidemiological consistency 
meaning, for example, that there is consistency between disease incidence, prevalence 
and mortality.  
Reports about simulation studies should be as clear as possible (about model structure, 
model assumptions and input data) and the impact of uncertainty of model parameters 
(such as relative risks and intervention effects) should be quantified and reported. 
Guidelines for reporting of simulation studies and methods of quantifying uncertainty 
are increasingly developed and applied 42. In this thesis, probabilistic sensitivity 
analysis was used in Chapter 5 to explore the impact of intervention costs, intervention 
effects and long-term maintenance of these effects. Three out of seven interventions 
had at least 90% probability to remain below a cost-effectiveness threshold of 20.000 
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€/QALY, while on the other hand, three interventions had more than 20% probability 
of a ICER higher than 70.000 €/QALY.  
 
Health-economic evaluation studies 
In this thesis we addressed the cost-effectiveness of lifestyle interventions in different 
target populations. All analyses were performed from a health care perspective, 
meaning that only health-related effects and health care costs were included. In the 
CDM all health care costs, including costs for diseases that are not related to the 
intervention (so-called ‘unrelated costs’), are accounted for 43,44. These unrelated costs 
are especially high in elderly people because they include, for example, costs for 
dementia. Therefore, although health care costs are initially reduced through the 
interventions, due to prevention and delay of lifestyle-related diseases, these initial 
reductions are generally outweighed by the health care costs that are made in life years 
gained. It appeared that the interventions in this thesis were generally cost-effective, 
even if these costs were included.  
Besides cost-effectiveness information, additional information for policy makers can be 
obtained from ‘value of information analyses’ and so-called ‘budget allocation models’. 
In ‘value of information analyses’ one tries to quantify how much money should be 
spent on additional research, to reduce uncertainty in some of the model parameters. A 
recent study revealed that there is some uncertainty regarding the choice between 
lifestyle intervention and standard care in overweight persons in Switzerland, and that 
the uncertainty is larger in moderately overweight persons than in obese persons 33. By 
using ‘value of information analyses‘ it was demonstrated that further research should 
focus on the effect of lifestyle interventions on (cardiovascular) risk factors and utilities 
(quality of life values), rather than intervention- and treatment costs. ‘Budget-allocation 
models’ can be used to calculate how a given budget can be optimally distributed over 
different interventions, in order for maximal health gains to be achieved, while taking 
account of specific constraints (such as the number of eligible people, expected 
participation and/or availability of facilities). A Dutch budget allocation study 45 
revealed that if budgets are either low (<€9 per person) or high (>€100 per person), 
larger health gains could be obtained by investing in cardiovascular prevention in the 
general population, than in preventive measures targeting diabetic patients, while 
moderate budgets (€9-€100 per person) were more optimally spent on interventions 
targeting diabetes patients.  
Most health economists agree that public preferences should play a role in decisions 
about the distribution of scarce resources 46. Factors that are considered to be important 
to the public in health-care resource allocation relate to characteristics of eligible 
patients (i.e. age, social role, health-related lifestyle), characteristics of the health effects 
of the interventions (start point, end point, size, duration and direction of the health 
effects) and to distributional rules 46. For example, it appears that most persons are 
willing to trade efficiency for a more equal distribution of resources 47. Although public 
preferences can be incorporated in health-economic evaluation methods, this is not 
commonly done (yet) and difficult to achieve because preferences differ between 
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people and preferences can be context-specific. Due to public preferences, decisions 
about how to invest in human health are generally not based on results from health-
economic studies alone.  
 
Implications for future research  
More evidence is required for the (cost)effectiveness of universal and selective 
prevention. Successful strategies (for specific target groups) should be identified or 
developed and besides lifestyle, there should be more emphasis on the physical and 
social environment as important determinants of health. Additional research is 
required to explore potential effective measures, such as reductions in fat or sugar in 
frequently used products, or more time for physical activity at schools. Advantages of 
such measures could be that they are structural and that they reach many people, 
including those who are generally hard to reach with individual-based interventions 
(such as persons with a low socioeconomic status).  
The efficacy and favorable cost-effectiveness of indicated prevention appear to be 
established for overweight persons and persons with IGT. Future studies should study 
participant- and intervention characteristics as determinants of the (cost)effectiveness 
of the interventions. Implementation studies are required to confirm whether results 
achieved in clinical trials can be reproduced in real-life settings 48,49 and to explore 
promoting and constraining factors for implementation 1.  
With respect to care-related prevention, it is obvious that self-management education 
(including lifestyle advice) and pharmacological treatment should be combined. 
Research should aim to compare the (cost)effectiveness of different multi-component 
treatments, as well as individual preferences, and reasons why patients and health care 
providers do not comply to recommended treatments.  
In general, future research should focus on a broad range of intervention effects, 
including effects on micro- and macro vascular diabetes complications, quality of life, 
health care costs and potential harms of the interventions (side effects of medication). 
In addition, effects of interventions on absenteeism and productivity could be included 
in future evaluations, in order to explore the (cost)effectiveness of preventive 
interventions from a societal perspective. Finally, the impact of multi-morbidity on 
quality of life values and health care costs should be established in order to improve 
the accuracy of simulation studies.  
 
Implications for health policy 
In view of the predicted increase in the future burden of diabetes and diabetes 
complications in the Netherlands, large-scale implementation of preventive diabetes 
interventions is required. The current state of knowledge justifies implementation of 
interventions, such as addressed in this thesis. Simultaneously, further research as 
proposed above should be facilitated and supported. With respect to universal 
prevention, at least information about a healthy lifestyle and the risks associated with 
unhealthy habits should be made available to all. Lifestyle counseling for high risk 
individuals (indicated prevention) could be made available through basic health care 
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insurance, while promising lifestyle counseling programs for diabetic patients (care-
related prevention) should have a structural, prominent place in future standards of 
diabetes care. Finally, continuous collection of high quality, national survey and 
registry data on (determinants of) population health and health care use should be 
enhanced, since this information is essential to monitor, predict, and prepare, for future 
developments in the Dutch population. 
 
General conclusions  
Body weight appears to be the most important, modifiable risk factor for diabetes and 
target for preventive interventions. Lifestyle interventions which focus on weight loss, 
a healthy diet and increased physical activity appear to be (cost)effective in divers 
target populations. Large-scale implementation of these interventions is justified, and 
required to reduce the future burden of diabetes and its complications. However, the 
impact on population health, achieved through these interventions, is expected to be 
moderate. Additional research is required to improve currently available interventions 
while simultaneously, opportunities for alternative approaches to diabetes prevention 
should be further explored. In diabetic patients, promising lifestyle modification 
programs should be integrated in individual-based treatment strategies, aimed to 
reduce overall cardiovascular risk. Improved diabetes treatment could reduce the 
future burden of cardiovascular diabetes complications in the Netherlands.   
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SUMMARY 
Type 2 diabetes is a chronic disease with a high prevalence, especially at advancing 
age. At the moment, diabetes (with nearly 700.000 diagnosed patients in 2007) is one of 
the most common chronic diseases in the Dutch population. Due to population ageing, 
and the high prevalence of overweight, a substantial increase in the number of people 
with diabetes is expected in the near future. For the Netherlands, it has been predicted 
that approximately 1 out of 12 persons will be diagnosed with diabetes in 2025. The 
future increase in the burden of diabetes could be reduced by (large-scale) 
implementation of interventions aimed to prevent the incidence of diabetes. However, 
a large part of the burden of diabetes can be ascribed to the cardiovascular 
complications of diabetes. These complications affect quality of life, as well as life 
expectancy of the patients. Therefore, in order to reduce the future burden of diabetes, 
it is important to prevent or delay diabetes incidence as well as the occurrence of 
cardiovascular complications in diabetes patients. 
 
The general aim of this thesis was to explore the opportunities to reduce the future 
burden of diabetes and cardiovascular diabetes complications in the Dutch population, 
through prevention. These opportunities depend on the existence of modifiable risk 
factors for diabetes and the (costs)effectiveness of currently available preventive 
interventions. In this thesis we consider the role of weight change, alcohol 
consumption and smoking as risk factors for diabetes and the (cost)effectiveness of  
interventions aimed to prevent diabetes incidence (universal-, selective and indicated 
prevention) or cardiovascular complications in diabetes patients (care-related 
prevention).  
 
The three main questions addressed in this thesis were:  
1) Are weight change, alcohol consumption and smoking associated with diabetes 
incidence in a Dutch population? (Chapters 2 and 3) 
2) To what extent can preventive lifestyle interventions reduce the future incidence of 
diabetes in the Netherlands and are these interventions cost-effective? (Chapter 4) 
3) To what extent can care-related preventive interventions reduce the future incidence 
of cardiovascular complications in Dutch diabetic patients and are these interventions 
cost-effective? (Chapters 5 and 6) 
 
We used Dutch observational cohort studies to explore the associations between 
weight change, alcohol consumption, smoking and diabetes incidence in the Dutch 
population in Chapters 2 and 3 and the RIVM Chronic Diseases Model (CDM) to study 
the potential long-term health gains and cost-effectiveness of preventive interventions 
in Chapters 4 to 6. The results, methodological issues, and implications for future 
research and health policy were discussed in Chapter 7.  
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Weight change appears to have no effect on diabetes incidence, beyond its effect on 
attained BMI.    
In chapter 2 we explored the role of weight change as a risk factor for diabetes 
incidence in a Dutch population. Conditional upon initial weight, people who gained 
more than 6 kg in five years, had an increased risk of diabetes, compared to persons 
with relatively stable weight (OR 2.4, 95%CI 1.4-4.0). If adjusted for initial BMI, 5-years 
weight change was a significant, continuous risk factor for diabetes (OR 1.08, 95% CI: 
1.04, 1.13 per kg weight change). However, it appeared that the association between 
weight change and diabetes could be explained by attained weight (the level of BMI 
attained at the end of the weight change period). There was no association between 
weight change and diabetes incidence, if the association was adjusted for attained BMI 
(OR 0.99, 95% CI 0.94, 1.04 per kg weight change). We concluded that weight change 
affects diabetes incidence because, conditional upon initial BMI, weight change 
determines attained BMI.  
 
Women who drink less than one alcohol consumption per week, have a higher risk 
for diabetes than women who drink moderately. 
The associations between alcohol consumption, smoking and diabetes incidence were 
assessed in chapter 3. We found a u-shaped association between alcohol consumption 
and diabetes incidence in Dutch women, with the lowest risk for moderate drinkers (1 
or 2 drinks per day). The HR for non-drinking, drinking less than 1 consumption per 
week, drinking 1-7 consumptions per week and drinking more than 2 consumptions 
per day were respectively 2.5 (95% CI 1.3-5.1), 2.2 (95% CI 1.1-4.3), 1.7 (95% CI 0.8-3.5) 
and 1.9 (95% CI 0.7-5.1). We found no evidence for a significant association between 
alcohol consumption and diabetes incidence in Dutch men. Smoking more than 10 
cigarettes per day tended to increase diabetes risk in both men and women, but the 
associations were not significant.  
  
Preventive lifestyle interventions can reduce the future incidence of diabetes in the 
Dutch population by approximately 1-4%.    
In Chapter 4 we explored the potential long-term health effects and cost-effectiveness 
of two types of lifestyle interventions, if implemented in the Dutch population: a 
community-based intervention, targeted at the general Dutch population, and an 
individual-based intensive intervention, targeted at obese Dutch adults. From the 
literature, we first determined the minimum and maximum effects of these 
interventions on short-term changes in body weight and physical activity. The 
maximum effect on weight for example, was a 0.7 kg reduction for the community 
intervention and a 4.5 kg reduction for the intervention for obese adults. The long-term 
effects on diabetes incidence and health care costs of these interventions were 
simulated with the CDM. These simulations revealed that the 20-year cumulative 
incidence of diabetes could be reduced by 0.5-2.4% through implementation of a 
community-based intervention, if such intervention would reach all Dutch adults, and 
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by 0.4-1.6%, if one out of five obese Dutch adults would participate in an intensive 
intervention.  
 
A community-based intervention and an intensive intervention for obese adults are 
both cost-effective. 
Intervention costs were approximately €6 per adult inhabitant in the target area for the 
community-based intervention, and €700 per participant for the intervention targeted 
at obese adults. Both interventions were projected to reduce lifetime diabetes-related 
medical costs, but total health care costs increased. The cost-effectiveness ratios ranged 
from €3,100 to €3,900 per quality adjusted life year (QALY) for the community-based 
intervention and from €3,900 to €5,500 per QALY for the intervention for obese adults. 
Both interventions remained cost-effective in the sensitivity analyses, in which higher 
intervention costs were assumed, and other discount rates were applied.  
 
In participating diabetes patients, lifestyle interventions can reduce the future 
incidence of cardiovascular complications by up to 6%.  
In Chapter 5 we assessed the potential health effects and cost-effectiveness of lifestyle 
interventions for Dutch diabetes patients. A literature search was conducted to search 
for randomized, controlled trials that assessed the effects of lifestyle interventions for 
diabetes patients. Inclusion criteria were at least 150 persons in the study, and a follow-
up of at least one year. For seven identified interventions, long-term effects on 
cardiovascular complications and health care costs were simulated with the CDM. In 
the simulations, we took account of ‘unfavorable’ long-term maintenance of short-term 
intervention effects. Based on limited available evidence we assumed, for example, that 
lifetime effect on weight would be approximately 35% of the effect achieved after one 
year of intervention. There was a large variation in effectiveness between the seven 
interventions, with reductions in cumulative lifetime incidence of cardiovascular 
complications ranging from 0.1% to 6.1%. The most effective intervention was a two 
year structured counseling program, aimed to increase physical activity in inactive 
diabetes patients. 
 
Also in diabetes patients, many lifestyle interventions appear to be cost-effective. 
There was a large variation in intervention costs, and cost-effectiveness between the 
seven interventions that were modeled. The intervention costs ranged from €124 to 
€584 per participant, and the cost-effectiveness ratios from €10,000 to €39,000 per 
QALY. The impact of uncertainty in intervention costs, intervention effects, and long-
term maintenance of effects, were quantified with probabilistic sensitivity analyses. 
These analyses revealed that 4 out of 7 interventions had a high probability to be very 
cost-effective. 
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If all Dutch diabetes patients would use lipid-lowering medication, the future 
incidence of cardiovascular complications could be reduced by approximately 7%. 
Guidelines for cardiovascular management recommend lipid lowering treatment for 
nearly all patients with diabetes. However, in current Dutch practice (in 2007) ‘only’ 
about 1 out of 3 patients received this treatment. The potential long-term health 
benefits for the Dutch diabetes population, if all patients would use lipid-lowering 
medication (statins), were modeled in Chapter 6. The simulations revealed that the life-
time cumulative incidence of coronary heart disease (CHD) and stroke could be 
reduced by six and nine percent respectively, if all Dutch diabetic patients would use 
lipid lowering medication. With more realistic assumptions about effectiveness and 
participation, the cumulative incidence of both CHD and stroke would decrease by 
approximately two percent. 
 
Large-scale implementation of preventive interventions is justified and required.  
We showed that lifestyle interventions can be cost-effective in divers target 
populations, including diabetes patients. Large-scale implementation of these 
interventions is justified, and required in order to reduce the future burden of diabetes. 
However, since the impact on population health, achieved through these interventions, 
is expected to be moderate, additional research should aim to improve currently 
available interventions. Simultaneously, opportunities for alternative approaches to the 
prevention of diabetes and its complications should be further explored.  
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SAMENVATTING          
Diabetes type 2 is een chronische ziekte die vooral op oudere leeftijd veel voorkomt. 
Anno 2010 is diabetes (met grofweg 700.000 gediagnosticeerde patiënten in 2007) zelfs 
een van de meest voorkomende chronische aandoeningen in de Nederlandse 
bevolking. Door de vergrijzing en de hoge prevalentie van overgewicht zal het 
percentage mensen met diabetes de komende decennia verder toenemen. Het RIVM 
voorspelt, dat in 2025 ongeveer 8% van de Nederlanders diabetes zal hebben. 
Preventieve maatregelen kunnen de toekomstige ziektelast van diabetes mogelijk 
beperken, doordat zij de instroom van nieuwe patiënten verminderen. Echter, ook de 
cardiovasculaire complicaties van diabetes zijn in belangrijke mate bepalend voor de 
ziektelast van diabetes. Complicaties, zoals hart- en vaatziekten, beïnvloeden zowel de 
kwaliteit van leven als de levensverwachting van mensen met diabetes. Om de 
toekomstige ziektelast van diabetes terug te dringen, is het daarom van belang om 
zowel het ontstaan van diabetes als het optreden van complicaties bij mensen met 
diabetes zoveel mogelijk uit te stellen of te voorkomen.  
In dit proefschrift onderzoeken we de mogelijkheden om de toekomstige ziektelast van 
diabetes en cardiovasculaire diabetes complicaties in Nederland terug te dringen door 
middel van preventie. Of preventie mogelijk is, hangt af van het bestaan van 
beïnvloedbare risicofactoren voor diabetes en van (kosten)effectieve preventieve 
interventies. In dit proefschrift onderzoeken we de invloed van gewichtsverandering, 
alcoholconsumptie en roken op het ontstaan van diabetes. Vervolgens onderzoeken we 
de kosteneffectiviteit van leefstijlinterventies die het ontstaan van diabetes beogen te 
voorkomen (universele, selectieve en geïndiceerde preventie). Tenslotte bestuderen we 
de (kosten)effectiviteit van interventies die tot doel hebben om cardiovasculaire 
complicaties bij mensen met diabetes te voorkomen (zorggerelateerde preventie).  
 
In dit proefschrift staan drie onderzoeksvragen centraal:  
1) Zijn gewichtsverandering, alcoholconsumptie en roken geassocieerd met diabetes 
incidentie in een Nederlandse populatie? (Hoofdstuk 2 en 3) 
2) In hoeverre kunnen preventieve leefstijlinterventies de toekomstige diabetes 
incidentie in Nederland verminderen en zijn deze interventies kosteneffectief? 
(Hoofdstuk 4) 
3) In hoeverre kunnen zorggerelateerde preventieve interventies de incidentie van 
cardiovasculaire complicaties bij mensen met diabetes in Nederland verminderen 
en zijn deze interventies kosteneffectief? (Hoofdstuk 5 en 6) 
  
Om de invloed van risicofactoren op het ontstaan van diabetes te onderzoeken, hebben 
we in hoofdstuk 2 en 3 gebruik gemaakt van gegevens van Nederlandse cohortstudies. 
In hoofdstuk 4 tot en met 6 is gebruik gemaakt van een simulatiemodel, het Chronische 
Ziekten Model (CZM), om de kosteneffectiviteit van interventies te onderzoeken. De 
resultaten, methoden en de implicaties van de bevindingen voor toekomstig onderzoek 
en gezondheidsbeleid werden bediscussieerd in hoofdstuk 7.  
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De relatie tussen gewichtsverandering en diabetesincidentie wordt geheel verklaard 
door het bereikte gewicht.  
In hoofdstuk 2 onderzochten we de rol van gewichtsverandering in een periode van 5 
jaar op het ontstaan van diabetes in de 5 jaar daarna. In analyses met correctie voor 
uitgangsgewicht, bleek dat mensen die meer dan 6 kilo waren aangekomen een veel 
grotere kans hadden om diabetes te krijgen dan mensen van wie het gewicht stabiel 
was gebleven (OR 2,4; 95%BI 1,4-4,0). Er was een continue, significant verband tussen 
gewichtsverandering en de kans op diabetes (OR 1,08; 95% BI 1,04-1,13 per kg 
gewichtsverandering). Uit aanvullende analyses bleek, dat de associatie tussen 
gewichtverandering en diabetes geheel verklaard werd door het bereikte gewicht na de 
periode van gewichtsverandering. Er was geen significante associatie tussen 
gewichtsverandering en het ontstaan van diabetes in analyses waarbij voor het effect 
van bereikt gewicht op diabetes werd gecorrigeerd (OR 0,99; 95% BI 0,94-1,04 per kg 
gewichtsverandering). We concludeerden dat gewichtsverandering invloed heeft op 
het ontstaan van diabetes omdat, uitgaande van het initiële gewicht, gewichts-
verandering het nieuwe, bereikte gewicht bepaalt.  
 
Vrouwen die minder dan een glas alcohol per dag drinken, hebben een hoger risico 
op diabetes dan vrouwen die matig drinken.  
In hoofdstuk 3 werden de associaties tussen alcohol, roken en diabetesincidentie 
onderzocht. Bij vrouwen was er sprake van een significant verband tussen 
alcoholgebruik en diabetes. Het laagste risico hadden vrouwen met een gemiddeld 
alcoholgebruik van 1 tot 2 consumpties per dag. De hazard ratio’s (HR) voor diabetes 
voor vrouwen met ‘0 consumpties per jaar’, ‘minder dan 1 consumptie per week’, ‘1-7 
consumpties per week’, en ‘meer dan 2 consumpties per dag’ waren respectievelijk 2,5 
(95% BI 1,3-5,1), 2,2 (95% BI 1,1-4,3), 1,7 (95% BI 0,8-3,5) en 1,9 (95% BI 0,7-5,1). Bij 
mannen vonden we geen bewijs voor een significante associatie tussen 
alcoholconsumptie en de incidentie van diabetes. Nederlandse mannen en vrouwen 
die meer rookten dan 10 sigaretten per dag, hadden een hoger risico op diabetes dan 
mannen en vrouwen die nooit rookten. Het effect van roken op diabetesincidentie was 
in deze studie echter niet statistisch significant.  
 
Preventieve leefstijlinterventies kunnen de toekomstige diabetesincidentie in 
Nederland met 1 tot 4% verminderen.  
In hoofdstuk 4 onderzochten we de mogelijk te behalen gezondheidswinst voor de 
Nederlandse populatie bij grootschalige implementatie van twee leefstijlinterventies: 
een wijkgerichte leefstijlbevorderende interventie voor de algemene populatie 
(wijkinterventie) en een intensieve leefstijlinterventie voor volwassenen met ernstig 
overgewicht. Op basis van literatuur werd voor beide interventies het minimaal en 
maximaal te verwachten kortetermijn effect op gewicht en lichamelijke activiteit 
bepaald. Het maximale effect op gewicht bijvoorbeeld was 0,7 kg voor de 
wijkinterventie en 4,5 kg voor de interventie voor volwassenen met obesitas. De 
langetermijn effecten van beide interventies werden gesimuleerd met het CZM. Uit de 
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simulaties bleek dat implementatie van de wijkinterventie in heel Nederland (bij 100% 
bereik) 0,5-2,4% van de verwachte diabetesincidentie in 20 jaar kan voorkomen. 
Deelname van 1 op de 5 Nederlandse volwassenen met ernstig overgewicht aan de 
intensieve leefstijlinterventie zou 0,4-1,6% van de verwachte diabetesincidentie 
voorkomen.  
 
Een wijkgerichte interventie en een intensieve leefstijlinterventie voor volwassenen 
met obesitas zijn beiden kosteneffectief. 
Het uitvoeren van de wijkgerichte interventie kost ongeveer €6 per volwassen 
inwoner. De intensieve interventie voor mensen met obesitas kost ongeveer €700 per 
deelnemer. Volgens de projecties zouden met beide interventies de 
diabetesgerelateerde medische kosten worden teruggedrongen, maar de totale 
medische kosten zouden toenemen. De interventies waren beiden kosteneffectief met 
kosteneffectiviteitsratio’s variërend van €3.100 tot €3.900 per (voor kwaliteit 
gecorrigeerd) levensjaar (QALY) voor de wijkinterventie en van €3.900 tot €5.500 per 
QALY voor de interventie voor volwassenen met obesitas. Beide interventies bleven 
kosteneffectief in sensitiviteitsanalyses waarin hogere interventiekosten werden 
verondersteld.  
 
Deelname aan leefstijlinterventies kan de kans op cardiovasculaire complicaties bij 
mensen met diabetes met 6% verminderen.  
In hoofdstuk 5 onderzochten we de mogelijke gezondheidswinst en de kosten-
effectiviteit van leefstijlinterventies voor mensen met diabetes. In de literatuur zochten 
we recente gerandomiseerde, gecontroleerde studies naar de effectiviteit van 
leefstijlinterventies voor mensen met diabetes. Deze interventies moesten voldoen aan 
een aantal criteria zoals minimaal 150 deelnemers en een minimale follow-up duur van 
een jaar. Voor zeven geselecteerde interventies werden de langetermijneffecten op 
cardiovasculaire complicaties en medische kosten gesimuleerd met het CZM. Hierbij 
hielden we expliciet rekening met terugval in leefstijlveranderingen. Op basis van 
(beperkt beschikbare) gegevens van langdurige studies werd bijvoorbeeld aangenomen 
dat van het bereikte effect op gewicht na 1 jaar ongeveer 35% behouden blijft op lange 
termijn. Er was veel verschil in effectiviteit tussen de zeven interventies. De reductie 
van het risico op cardiovasculaire complicaties varieerde van 0,1% tot 6,1%. De meest 
effectieve interventie was een programma waarin artsen gedurende twee jaar op een 
gestructureerde manier probeerden om de lichamelijke activiteit van inactieve 
diabetespatiënten te verhogen. 
 
Ook bij mensen met diabetes zijn veel leefstijlinterventies kosteneffectief.  
De interventiekosten en de kosteneffectiviteitsratio’s varieerden sterk tussen de zeven 
geselecteerde interventies. De kosten varieerden van €124 tot €584 per deelnemer en de 
kosteneffectiviteitsratio’s van €10.000 tot €39.000 per QALY. De invloed van variatie in 
interventiekosten, interventie effecten en de mate van behoud van effecten op 
langetermijn op de modeluitkomsten werd gekwantificeerd met probabilistische 
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sensitiviteitsanalyses. Uit deze analyses bleek, dat 4 van de 7 interventies zeer 
waarschijnlijk kosteneffectief zullen zijn.  
 
Meer gebruik van cholesterolverlagende medicatie zou maximaal 7% van de 
cardiovasculaire complicaties kunnen voorkomen.  
Richtlijnen voor cardiovasculair risicomanagement bevelen aan om statines voor te 
schrijven aan nagenoeg alle mensen met diabetes. Echter, in de Nederlandse praktijk 
(2007) gebruikt ‘slechts’ een op de drie diabetespatiënten deze cholesterolverlagende 
medicatie. In hoofdstuk 6 onderzochten we de mogelijke gezondheidswinst voor de 
Nederlandse diabetespopulatie als alle patiënten cholesterolverlagende medicatie 
(statines) zouden krijgen. Uit de modelsimulaties bleek, dat medicatie voor alle 
patiënten, in vergelijking tot behandeling volgens de huidige praktijk, maximaal 6% 
van de te verwachten cumulatieve incidentie van coronaire hartziekten en 9% van de 
cerebrovasculaire aandoeningen bij de Nederlandse diabetespopulatie zou kunnen 
voorkomen. Bij een scenario met realistischere veronderstellingen over de effectiviteit 
van de medicatie en uitbreiding van medicijngebruik, zou ongeveer 2% van de 
cardiovasculaire complicaties kunnen worden voorkomen.  
 
Grootschalige inzet van preventieve maatregelen is gerechtvaardigd en nodig.  
Leefstijlinterventies blijken, zowel voor mensen met als voor mensen zonder diabetes, 
kosteneffectief te zijn. Grootschalige inzet van leefstijladvisering is gerechtvaardigd en 
noodzakelijk om de toekomstige ziektelast van diabetes te beperken. Echter, de invloed 
van deze interventies op de volksgezondheid is relatief beperkt. Er zal gezocht moeten 
worden naar manieren om de mogelijkheden voor de preventie van diabetes en 
diabetescomplicaties verder uit te breiden en te verbeteren.  
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DANKWOORD  
Het is zover, mijn proefschrift is klaar  !! Een proefschrift schrijven, doe je natuurlijk 
niet alleen. Op deze plaats wil ik daarom graag van de mogelijkheid gebruik maken 
om iedereen te bedanken die, op wat voor manier dan ook, betrokken is geweest bij het 
tot stand komen van dit boekje. Een aantal mensen wil ik daarbij speciaal bedanken.   
 
Caroline, ik ben je echt heel dankbaar voor de mogelijkheden die je voor mij hebt 
gecreëerd en natuurlijk ook voor je steun en inhoudelijke bijdrage aan dit proefschrift. 
Toen ik in 2003 aangaf dat ik meer geïnteresseerd was in ‘diabetesepidemiologie’ dan 
in ‘organisatie van zorg’ en dat ik best wat meer van het Chronische Ziekten Model 
zou willen weten, had ik niet gedacht dat dit het resultaat zou zijn. Daar waar ik me 
vooral richtte op de cijfers, keek jij naar de vertaling van de cijfers naar betere preventie 
en zorg voor mensen met diabetes. Natuurlijk is dat waar het om gaat! Dat ik mijn 
laatste half jaar op het RIVM fulltime aan mijn proefschrift heb kunnen werken was 
een ongekende luxe, waarvoor ik jou (en Jet) enorm dankbaar ben.    
Pieter, met jouw kennis op het gebied van de gezondheidseconomie en het Chronisch 
Ziekten Model en jouw inzet was je zeer waardevol in mijn ‘begeleidingsteam’. Je was 
consequent de eerste die reageerde op mijn concepten, waarvoor dank. Ik mis je humor 
en de discussies die je graag bij Jeroen en mij op de kamer voerde, over wat dan ook. 
Jullie hadden overal verstand van en overal een duidelijke mening over en ik heb veel 
van jullie geleerd (ook over voetbal..).  
Edith, toen het proefschrift al aardig vorm begon te krijgen, moesten we nog op zoek 
naar een promotor. Ik ben blij dat jij de uitdaging aandurfde en dat ik van jou, haast 
onuitputtelijke, inhoudelijke en methodologische kennis gebruik heb kunnen maken. Je 
was altijd enthousiast, je commentaar was opbouwend kritisch. Ik vind het leerzaam 
en prettig om met jou te kunnen samenwerken. Je lessen en presentaties zijn altijd zeer 
inspirerend en een voorbeeld voor velen.  
Beste Jeroen en Annemieke, bedankt dat jullie mijn paranimfen willen zijn!  
Jeroen, we hebben een hele tijd een kamer en daardoor een behoorlijk aantal 
gebeurtenissen en ervaringen met elkaar gedeeld. Ook inhoudelijk konden we elkaar 
soms helpen. Zo ben je bijvoorbeeld coauteur bij een van de artikelen in dit boekje. 
Bedankt voor alles, je was een gezellige, attente, eerlijke en zeer sociale collega. Ik wens 
jou en je familie veel succes met alles en ik hoop dat we contact houden.  
Beste Annemieke, met uitzondering van het delen van een kamer, geldt hetzelfde voor 
jou. Daarnaast ga ik de EDEG bijeenkomsten missen en daarvan dan met name…..effe 
lekker swingen. We konden daar beiden echt even van genieten.  
Ook alle andere RIVM collega’s (en speciaal ook Rudolf als het grote brein achter het 
CZM) wil ik bedanken voor hun bijdrage aan dit proefschrift, maar vooral aan negen 
jaar met veel plezier werken op het RIVM. Ik denk graag terug aan een leerzame, 
gezellige en sportieve tijd waarin we samen leuke maar ook verdrietige dingen hebben 
meegemaakt. Inmiddels voel ik me al heel aardig thuis bij de GGD. Ik hoop dat ik 
samen met mijn nieuwe collega’s een fijne tijd tegemoet ga en ik heb daar alle 
vertrouwen in!   
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Helmie, Wim, Mark en Marjan, wij genieten nog steeds van onze afspraakjes. Het 
tennissen en uitgebreid koken hebben tijdelijk plaatsgemaakt voor speeltuinbezoekjes 
en kindvriendelijke maaltijden, maar het is prachtig om onze kinderen te kunnen zien 
opgroeien. We hebben heel wat lief, leed, vakanties en jaarwisselingen gedeeld en ik 
hoop dat we dat nog lang blijven doen.   
Marc en Cindy, Rana en Christine, Gielion en Lieke, Jurgen en Ilona, Rene en Karen, 
Bart en Kirsten. De activiteiten tijdens onze uitjes zijn, door de komst van 17 kinderen 
en een hond, in de loop van de tijd ook enigszins veranderd maar de lol is er zeker niet 
minder om.  
 
Beste (schoon)papa, zwagers en schoonzussen, dank voor jullie steun en belangstelling. 
Het is jammer dat ma deze mijlpaal (en vele andere, minstens zo belangrijke life-events 
van de familie) niet heeft kunnen meemaken.  
Zussie Danielle, tja wat zou ik moeten zonder een grote zus. Ik heb vaak je voorbeeld 
gevolgd, onder andere in mijn studiekeuzes. Ik hoop dat wij, samen met onze mannen, 
nog heel veel en heel lang samen leuke dingen blijven doen.  
Lieve papa en mama, dank voor de ruimte, steun en liefde die jullie Danielle en mij 
altijd gegeven hebben. Jullie hebben mijn promotie-avonturen, trots en met 
belangstelling gevolgd. De Nederlandse samenvatting hebben jullie zelfs kritisch 
gelezen en waar nodig verbeterd. Dank voor alles en ik hoop dat we nog lang samen 
van het leven (en onze reguliere vakanties in Zeeland), kunnen genieten.   
 
Mijn lieve mannen! 
Mika en Lasse, het zou onzin zijn om te zeggen dat dit boekje er zonder jullie steun 
nooit was gekomen (waarschijnlijk zelfs sneller). Toch had ik geen dag samen met jullie 
willen missen, jullie zijn mijn kanjers! Mars, eindelijk kunnen we op ‘gelijk niveau’ 
verder en eindelijk heb ik een goede gelegenheid om te reageren op jouw dankwoord 
uit 1999...........jij ook bedankt voor al je liefde, steun en geduld, we zijn een goed team! 
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